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Abstract 
  
 The differentiation of multipotent naïve T cells is influenced by the microenvironment.  
Cytokines, costimulatory proteins and other biological factors can tune this differentiation 
process, influencing cell fate.  Controlling naïve T cell differentiation can guide the type of 
immune response elicited since each T cell subset has a specific function in the immune system.  
In this dissertation, I examine the participation of costimulatory molecules expressed on the 
surface of naïve CD4+ T cells in differentiation of these cells.  I demonstrate that stimulation 
through the TCR and CTLA-4 directs naïve CD4+ T cell differentiation to regulatory T cells in 
the absence of exogenous cytokines.  I evaluate how combined stimuli influence differentiation 
and function in T cells.  Combined stimulation through CTLA-4 and CD28 (CD3+CD28+CTLA-
4) results in distinct functional outcomes from combined stimulation through CTLA-4 and 
ICAM-1 (CD3+ICAM-1+CTLA-4) or alternatively, ICAM-1 and CD28 (CD3+CD28+ICAM-1).  
Differentiation to Th1, Th2 or Treg cells has been evaluated in our previous studies.   In this 
dissertation, I extend these studies by examining whether costimulation in the absence of 
exogenous cytokines can support Th17 differentiation.  I found that costimulation through 
ICAM-1, CD28, LFA-1, or CTLA-4 did not activate naïve CD4+ T cells to differentiate to Th17 
cells.  I also evaluated how the low affinity IgE receptor, CD23, expressed on T cells participates 
in naïve T cell differentiation and mature T cell function.  CD23 functions as a negative regulator 
of Th2 responses by inhibiting differentiation of naïve T cells to Th2 cells and enhancing 
activation of Th1 cells in mature T cells.   Next, I examined how lipoproteins relevant to 
atherosclerosis may guide differentiation of naïve CD4+ T cells.  Consistent with their known 
roles in promoting or inhibiting atherosclerosis, oxLDL activates differentiation to Th1 cells 
	   iv	  
whereas HDL inhibits T cell proliferation and viability.  Different responses by naïve T cells to 
these lipoproteins may have direct implications in how atherosclerosis is exacerbated or 
attenuated during disease.  Finally, I explore whether autoimmunity is involved in a mouse 
model of emphysema.  I demonstrate that T cells adoptively transferred emphysema to naïve, 
immunodeficient mice, supporting a role for autoimmunity in an elastase-induced model.  
Peptide therapy targeting the interactions between ICAM-1 and LFA-1 was able to reduce 
severity of emphysema as well.   
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Overview of adaptive immune response and T cells 
The immune system can be divided into two main branches: the innate immune response 
and the adaptive immune response.  The innate immune response elicits a quick, robust response 
and mostly recognizes pathogens nonspecifically.  The adaptive immune system provides 
memory and can distinguish between non-self and self-antigens with high specificity.  Adaptive 
immune cells include lymphocytes (T and B cells) and APCs (antigen presenting cells).  
Lymphocytes undergo gene rearrangement resulting in diverse repertoire of distinct BCR (B cell 
receptor) or TCR (T cell receptor) specificities to facilitate immune surveillance and clearance  
of pathogens.  B cells produce antibodies which assist in targeting foreign antigens for clearance 
by complement or other immune cells such as neutrophils and macrophages.  T cells, unlike B 
cells, require cognate antigen (Ag) to be presented in the context of MHC (major 
histocompatibility complex) on APCs (antigen presenting cells) to activate.  Dendritic cells and 
activated macrophages and B cells can serve as APCs for T cells.  
 
CD4+ and CD8+ T cells 
T cells can be divided into either CD4+ T cells (helper T cells) or CD8+ T cells 
(cytotoxic T cells) based on the type of MHC molecule that they engage.  CD8+ T cells are 
MHC I-dependent and can interact with nearly all somatic cells.  CD8+ T cells target and kill 
infected or altered cells (such as damaged or tumor cells).  CD4+ T cells engage MHC II and 
therefore, are primarily limited to interactions with APCs.  CD4+ T cells help orchestrate the 
immune response, activating several other types of immune cells such as CD8+ T cells, B cells, 
macrophages, etc. depending on the response necessary to protect the host.   
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T helper subsets  
Several types of CD4+ T cells subsets have been defined such as: T helper 1 (Th1), T 
helper 2 (Th2), T helper 17 (Th17), and regulatory T cells (Treg cells), each responsible for 
regulating a specific area of the immune system by different effector functions.  See Fig. 1.1 for 
brief description of the function of each subset in the immune response (black text) and the 
associated pathology associated with each subset when misdirected (red text).  The balance of 
these subsets is important for protection against infection, cancer, allergies and autoimmunity.  
Therefore, understanding how these cells differentiate into the various subsets is important.   
 
Naïve CD4+ T cell differentiation 
Naïve T cells represent a resting and less differentiated T cell subset that has recently 
emigrated from the thymus.  Naïve cells circulate through the blood and secondary lymphoid 
organs in search for cognate antigen.  If a naïve T cell does not find its specific antigen, it will 
undergo apoptosis in 6 weeks.  If cognate antigen is appropriately presented by an APC, the 
naïve T cell will activate, clonally expand and differentiate into both effector and memory T 
cells.  Effector T cells are highly activated, differentiated T cells that live for a short time, 
secreting cytokines, chemokines, and other factors to elicit a primary immune response.  They 
typically live for a week or so, leaving behind memory T cells which can live for many years.  
See Fig. 1.2 for model of naïve T cell differentiation to effector and memory T cells during a 
primary immune response.  Memory T cells may differentiate indirectly through effector T cells 
or directly from naïve T cell populations and can remain in a resting state searching for cognate 
antigen for decades.  Depending on expression of migration proteins, CD62L and CCR7,  
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Fig. 1.1 
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Figure 1.1. Naïve CD4+ T cells can differentiate into various T helper subsets.  Th1 cells 
control the cell-mediated immune response which is important for controlling intracellular 
pathogens and cancer cells.  Th2 cells mediate the humoral immune response during infection 
with various pathogens: viruses, bacteria and parasites.  Th17 cells activate inflammatory 
responses and are particularly important in defense against pathogens in the mucosa.  Treg cells 
help regulate the other immune cells to protect against autoimmunity and inappropriate immune 
responses.  Normal functions of each subset are indicated by black text.  Misdirected or 
inappropriate function of each subset can lead to various diseases indicated by red text.   
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Fig. 1.2 
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Figure 1.2.  Model of activation and differentiation of naïve CD4+ T cells to effector and 
memory T cells during a primary immune response.  Naïve CD4+ T cells will activate, 
clonally expand, and differentiate into effector and memory T cells in response to cognate 
antigen presented on MHC II of an APC.  Naïve T cells that do not encounter cognate antigen 
eventually die by apoptosis.  Effector T cells also die by apoptosis after carrying out their 
specific functions during the immune response.  Memory T cells live for many years and respond 
more quickly and strongly during a secondary immune response than naïve T cells if antigen is 
encountered again.   
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memory T cells may circulate through the secondary lymphoid tissues (central memory) or home 
to specific tissues (effector memory) (1).  If a memory T cell encounters cognate antigen, a more 
robust, quicker immune response will be elicited, conferring an antigenic “memory” response to 
the host.  
 
Factors guiding naïve T cell differentiation within the microenvironment 
Signaling through the TCR is sufficient to activate and induce proliferation of memory T 
cells.  Naïve T cells, however, must receive signals through the TCR (signal 1) and a 
costimulatory molecule (signal 2) to differentiate and avoid anergy induction or death (2-5) as 
modeled in Fig. 1.3.  Many different costimulatory molecules can induce this second signal, but 
only one second signal is required in conjunction with the TCR signal.  The microenvironment of 
an activating naïve cell may tune differentiation to a specific T helper subset such as Th1 or Th2 
cells.  Cytokines are well recognized as an essential part of tuning naïve T cell differentiation.  
The participation of costimulatory proteins has not been as well characterized.  Data from the 
Benedict laboratory suggests that costimulatory proteins also tune differentiation, influencing 
cell fate.  We have demonstrated that depending on the type of costimulation received by a naïve 
T cell, differentiation may be directed to Th1, Th2, or Treg cells in the absence of exogenous 
cytokines (6-8).  The results from our previous studies comparing the participation of CD28, 
ICAM-1, and LFA-1 in T cell differentiation are summarized in Table 1.1 and discussed below 
in each description of these costimulatory molecules.  
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Fig. 1.3 
    Signal 1 (TCR/CD3) + Signal 2 (LFA-1, CD28, or ICAM-1) = Differentiation 
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Fig. 1.3.  Model of naïve T cell and APC interaction and signaling during activation.  In 
naïve T cells, signaling through the TCR (signal 1) and a costimulatory molecule (signal 2) is 
required for full activation and differentiation.  LFA-1, CD28, or ICAM-1 interact with their 
counter receptors on the APC to transmit signal 2.  
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Table 1.1 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CD3+CD28 CD3+ICAM-1 CD3+LFA-1 
Proliferation 
 ✔ ✔ ✔ 
Protection from 
apoptosis 
 
✔ ✔ ✕  
Memory T cell  
Differentiation 
 
✔ ✔ ✕ 
Effector T cell  
Differentiation 
 
✔ ✔ ✔ 
Differentiation 
 to Th1 cells 
 
✔ ✔ ✔ 
Differentiation 
to Th2 cells 
 
✔ ✕ ✕ 
Differentiation 
to Treg cells 
 
✕ ✔ ✕ 
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Table 1.1.  Summarizes the findings from our lab comparing costimulation through CD28, 
ICAM-1 or LFA-1 in the absence of exogenous cytokines.  Drs. Jacob Kohlmeier, Scott 
Tibbetts, Chintana Chirathaworn, Kelli Williams and Abby Dotson have contributed to these 
observations.   
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Review of some of the 15 known costimulatory proteins 
CD28 
The best-characterized costimulatory molecule is CD28, which promotes T cell 
proliferation and production of IL-2, an important cytokine for T cell activation and 
proliferation.  CD28 is highly expressed on most T cells, and as a homodimer interacts with one 
of two counter receptors: CD80 or CD86 (B7-1 and B7-2, respectively) (9-11).  Signaling 
through CD28 activates PI-3K, JNK, NFAT and NFκB leading to expression of genes that 
promote cell survival, proliferation, and IL-2 production (12-15).  In our studies, costimulation 
through CD28 supported the generation of effector and memory T cells with either Th1 or Th2 
function but not suppressive function (Treg cells) (6, 7) (Table 1.1).   
 
LFA-1 (Leukocyte function-associated antigen 1) 
 LFA-1, a β2 integrin, functions as an adhesion molecule supporting extravasation of 
leukocytes into tissues and promoting the stable interaction between a T cell and APC during 
activation.  LFA-1 also functions as a costimulatory molecule and activates the MAPK and JNK 
pathways inducing T cell activation, IL-2 production, and Th1 differentiation (16-19).  LFA-1 is 
a heterodimer that consists of two subunits: CD11a and CD18, and its expression is limited to 
leukocytes (white blood cells).  Ligands of LFA-1 include the intercellular adhesion molecules: 
ICAM-1, ICAM-2, and ICAM-3.  Costimulation through LFA-1 in the absence of exogenous 
cytokines induces differentiation to effector but not memory T cells with a Th1 but not Th2 or 
Treg phenotype (7) (Table 1.1). 
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ICAM-1 (Intercellular adhesion molecule 1) 
 ICAM-1 is widely expressed on many cells including endothelial and epithelial cells, 
monocytes, leukocytes and low levels on naïve and resting T cells (20, 21).  Expression of 
ICAM-1 is upregulated following T cell activation and can also function as a costimulatory 
molecule for T cells in addition to its many roles as an adhesion protein (6-8, 21, 22).  The 
integrins, LFA-1, MAC-1, and gp150/95, and CD43 interact with ICAM-1.  The signaling events 
activated by costimulation through ICAM-1 are still being characterized, but stimulation through 
ICAM-1 leads to activation of PKC, MAPK, and various other kinases (23-25).  Efforts to define 
the signaling complex and pathway of ICAM-1 our ongoing in our laboratory.  Thus far, the 
Benedict laboratory has determined that cdc2 kinase and MAPK are constitutively associated 
with the cytoplasmic tail of ICAM-1 and following crosslinking of ICAM-1, several proteins 
become quickly associated with ICAM-1: ZAP-70, Fyn, Lck, TCRβ and CD3ζ chains and then 
dissociate 10 minutes later (26), unpublished data).  Costimulation of naïve CD4+ T cells 
through ICAM-1 stimulates differentiation to effector and memory T cells and Th1 and Treg 
cells but not Th2 cells (7, 8) (Table 1.1).  
 
CTLA-4 (Cytotoxic T lymphocyte antigen 4) 
CTLA-4 is best known as a negative regulator of T cell activation since deletion of the 
ctla4 gene causes a fatal lymphoproliferative disease in mice (27).  CTLA-4 regulates T cell 
function by suppressing proliferation and the production of IL-2 and opposing the stimulatory 
actions of CD28 (28-31).  CTLA-4 binds the same counter receptors, CD80 and CD86, and 
shares similar structure to CD28 (32, 33).  Competition for these counter receptors is one 
proposed theory for CTLA-4 suppression since it binds the B7 ligands with higher affinity than 
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CD28 (34, 35).  CTLA-4 may also capture CD80 or CD86 from APCs by trans-endocytosis into 
the T cell for degradation, limiting accessibility to these ligands by CD28 (36).  Although early 
studies indicated an inhibitory function for CTLA-4 by transducing inhibitory signals directly 
into the T cell expressing CTLA-4, most functions of CTLA-4 are thought to be indirect and 
mediated by CTLA-4-expressing cells such as Treg cells (reviewed in 37).  CTLA-4 is not 
expressed on resting T cells but can be detected 48 hours following activation (38).   
CTLA-4 has been associated with function, maintenance and generation of regulatory T 
cells.  Treg cells constitutively express CTLA-4, and CTLA-4 is important for the suppressive 
function of Treg cells and expression of the Treg transcription factor, Foxp3 (39-45).  Foxp3 
suppresses many genes associated with T cell activation including the genes that encode IL-2, 
JAK2 and ZAP-70 (46).  Strong expression of Foxp3 by T cells is associated with suppressive 
function (47).  Recently, participation of CTLA-4 in the differentiation of murine naïve CD4+ T 
cells has been demonstrated by stimulation through CD3+CD28+CTLA-4 in the presence of 
exogenous IL-2 and TGF-β (48) or by incubation with LPS-treated APCs and co-ligation of 
CTLA-4 into the TCR complex using a bispecific protein that binds MHC on the APC and 
CTLA-4 on the T cell (49).   
 
Dissertation: Participation of costimulatory molecules in naïve CD4+ T cell differentiation 
(Chapters 1-3) 
One primary goal of this dissertation work was to examine how costimulation through 
CTLA-4 guides differentiation of human naïve CD4+ T cells in the absence of any other factors.  
This is addressed in Chapter 2 of the dissertation.  Also, in Chapter 2, we examine the role of 
CTLA-4 as an additional stimulus combined with costimulation through either ICAM-1 or CD28 
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and how signaling a naïve T cell through more than one costimulatory molecule influences 
differentiation. In Chapter 3, we examine the ability of CD28, LFA-1 and ICAM-1 to activate 
differentiation of human naïve T cells to Th17 cells, a helper T subset, associated with directing 
the inflammatory response.   
 
Dissertation: Participation of other biological factors in naïve T cell differentiation 
(Chapters 4 & 5) 
 In addition to our overall goal to evaluate the participation of each costimulatory 
molecule in T cell activation and differentiation individually, we also seek to understand how 
other receptors or biological factors may guide cell fate.  T cells express many other receptors on  
their surface.  If one of these receptors happens to be engaged during activation and transmits 
signals into the T cells, this may influence differentiation.  In Chapter 4, we examine the 
participation of the low affinity receptor for IgE, CD23, in naïve T cell differentiation and 
mature T cell activation. 
Differentiation of naïve T cells typically occurs in secondary lymphoid organs.  However, 
under certain chronic inflammatory conditions, naïve T cells can home to tissues and undergo 
activation and differentiation in extra-lymphoid tissues (50-52).  In these situations, other 
biological factors that are normally not present in the microenvironment of a lymph node or 
spleen may also participate in tuning differentiation of naïve T cells.  This is the premise of 
Chapter 5 where we examine the role of lipoproteins in naïve CD4+ T cell activation and 
differentiation.   
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CD23, the low affinity IgE Receptor 
 CD23 is primarily associated with regulating IgE synthesis and B cell responses during 
an allergic or parasitic response (53-55).  Many cells including activated T cells express CD23 
(56-58).  However, the function of CD23 on T cells has not been examined.  The goal of Chapter 
4 is to determine how stimulation through CD23 may regulate T cell differentiation and function 
in naïve CD4+ T cells and mature (CD45RO+) T cells.  
 
Lipoproteins in atherosclerosis and T cell responses 
 The lipoproteins, HDL (high density lipoprotein) and LDL (low density lipoprotein), 
exert opposing effects on the development and progression of atherosclerosis.  LDL crosses the 
endothelium and becomes oxidized, forming oxLDL (oxidized LDL).  This modified form of 
LDL is highly atherogenic and promotes the activation of platelets, endothelial cells, and 
macrophages (59-61).  This leads to a robust inflammatory response and recruitment of other 
cells such as T cells, further exacerbating inflammation and progression of atherosclerotic 
plaque.  HDL opposes many of these processes by inhibiting activation of platelets, 
macrophages, and endothelial cells, removing cholesterol from plaque, and inhibiting the 
oxidation of LDL (62-66).  We have previously published the differential effects of lipoproteins 
on mixed T cell populations (naïve and mature effector and memory CD4+ and CD8+ T cells) in 
the context of either ICAM-1 or LFA-1 costimulation (67).  We expand this investigation to 
purified naïve CD4+ T cells comparing costimulation through CD28, ICAM-1 or CTLA-4 in 
Chapter 5.   
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Dissertation: Targeting costimulatory proteins for therapy (Chapter 6) 
 The immune system protects against pathogens and cancer and when misregulated can 
lead to autoimmunity or hypersensitivity (allergy).  The normal protective immune response can 
also be harmful when elicited against a transplanted tissue or organ.  T cells are the primary 
regulators of these immune responses.  We seek to understand the molecular mechanisms 
guiding differentiation and function of T cells so that this knowledge can be used to develop 
effective and safe therapies to modulate the immune system to treat disease.  By understanding 
the costimulatory proteins and other biological factors that guide T helper function and 
differentiation, we may be able to manipulate these processes in vivo for therapy.  Our studies on 
the participation of ICAM-1 as a costimulatory molecule have led to the development of 
inhibitory peptides targeting ICAM-1:LFA-1 interaction (68-70).  Each cyclic peptide consists of 
10 amino acids; one binds to LFA-1 (cIE-L) and the other to ICAM-1 (cLAB-L), inhibiting T 
cell function and adhesion in vitro (68, 69).  The peptides block the transduction of the second 
signal (generated by either ICAM-1 or LFA-1 on the T cell); without this second signal, naïve T 
cells become anergic or die (See Fig. 1.4).  The combined use of these peptides attenuates 
murine models of autoimmunity, arthritis and diabetes (unpublished data, 71), by reducing 
leukocyte infiltration and suppressing antigen-specific responses by autoreactive T cells.  We can 
treat autoimmune diseases in mice by inhibiting autoantigen-specific T cell responses through 
the use of this peptide therapy.   
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Fig. 1.4 
    Without peptide therapy 
 
 
 
 
 
 
 
 
 
 
              Peptide therapy blocks second signal 
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Figure 1.4. Peptides (c-IE-L and c-LAB-L) block signal 2 which leads to anergy or 
apoptosis of autoreactive T cells.  The combined use of peptides, cIE-L and cLAB-L, inhibits 
the ability of ICAM-1 and LFA-1 to signal into the T cell expressing them, resulting in anergy or 
death of that cell.  
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Emphysema in COPD 
 Emphysema represents one of the two major forms of chronic obstructive pulmonary 
disease (COPD).  The other form is chronic bronchitis and not examined here.  Destruction of the 
alveolar epithelia leads to enlarged airspaces and consequently, less efficient gas exchange 
making it more difficult to breathe.  In patients with COPD, pulmonary inflammation and 
destruction continue even after smoking cessation and long after the noxious substances from 
cigarette smoke have been eliminated (72-74).  This is suggestive of an autoimmune response 
against self-antigens.  COPD has not been established as an autoimmune disease, but recent 
evidence supports a role for T cells in driving autoimmunity in this disease.  CD4+ T cell clones 
from patients with emphysema produce IL-6 (Th2 cytokine) and IFN-γ (Th1 cytokine) in 
response to specific elastin peptide sequences, and the presence of these autoreactive T cells 
correlates with disease severity (75, 76).  CD3+ T cells from mice with smoke-induced 
emphysema transfer disease to naïve mice (77, 78).  In Chapter 6, we evaluate the ability of T 
cells from an elastase-induced model of emphysema to transfer disease to immunodeficient mice 
and the efficacy of peptide therapy on disease severity.  
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Chapter 2 
 Role of CTLA-4 in T cell differentiaton 
 
Part I: 
Costimulation through CTLA-4 induced differentiation of human naïve CD4+ T to 
regulatory T cells 
 
Part II: 
CTLA-4 enhanced naïve CD4+ T cell differentiation to memory or regulatory cells 
depending on the choice of costimulatory protein engaged during differentiation 
 
Part III: 
Costimulation through CTLA-4 did not induce differentiation of CD4+ T cells to 
regulatory T cells in mice 
 
 
 
 
	   34	  
Introduction 
CTLA-4 (cytotoxic T lymphocyte antigen-4), a member of the CD28 family of receptors, 
functions overall as a negative regulator of T cell activation in contrast to CD28 which induces T 
cell activation.  Defining the precise mechanisms of T cell regulation by CTLA-4 has been 
challenging because CTLA-4 shares the same counter receptors, CD80 and CD86, with CD28.  
Multiple functions have been proposed, but there is still no consensus of how CTLA-4 functions  
in vivo.  Most studies investigating the function of CTLA-4 have been performed in mice.  
Differences between human and mouse immunology and the complexities of studying CTLA-4 
function prompted us to investigate how CTLA-4 costimulation would influence differentiation 
of human naïve CD4+ T cells.   
 
CD28 and CTLA-4 share the same counter receptors but have different roles in the immune 
response 
Naïve T cells that have recently exited the thymus, require signals from both the TCR 
(CD3) interacting with the antigen:MHC complex (signal 1) and a costimulatory molecule 
interacting with its counter receptor (signal 2) for activation and protection against anergy (1-3).  
The best characterized costimulatory molecule is CD28, which promotes T cell proliferation and 
production of IL-2 (4-7) by engaging either B7-1 or B7-2 (CD80 or CD86, respectively) (8).  
CD80 and CD86 also interact with CTLA-4 which shares a similar structure to CD28 but differs 
considerably in function (9, 10).  CTLA-4 has a much higher affinity for these counter receptors 
than CD28 (11, 12).  However, CD28 is expressed by resting and activated T cells in contrast to 
CTLA-4 which is not expressed on the surface of resting T cells (excluding Treg cells) but is 
upregulated following activation (13). 
	   35	  
 CTLA-4, a negative regulator of T cell activation, suppresses T cell proliferation, cell 
cycle progression, and production of IL-2 (14-17).  Hypothesized mechanisms of CTLA-4 
suppression included direct inhibitory signaling (15, 16), limiting access of CD28 to B7 ligands 
(CD80 and CD86) either through sequestration (18) or transendocytosis of the counter receptors 
from the surface of APCs (antigen presenting cells) (19).  However, some evidence supports a 
positive effect on T cell proliferation by CTLA-4, opposing theories of CTLA-4 strictly as an 
inhibitory molecule (13, 20).  Ultimately, the function of CTLA-4 was affirmed inhibitory since 
CTLA-4 knockout mice develop a fatal lymphoproliferative disorder (21), but this observation 
was made before the role and function of regulatory T cells (Treg cells) was well defined.  Mice 
deficient in Foxp3, the transcription factor associated with Treg cells, develop a similar 
lymphoproliferative disease (22) to mice deficient in CTLA-4, suggesting a role for CTLA-4 in 
regulatory T cell function or development. 
 
CTLA-4 is important for the function of Treg cells and may play a role in Treg development or 
differentiation 
Although there has been some controversy over the role of CTLA-4 in Treg function in 
the past, it is becoming more widely accepted that CTLA-4 is vital for the suppressive function 
of Treg cells and possibly development.  Suppressive function of Treg cells is largely dependent 
on constitutive expression of CTLA-4 (23-28).  Deletion of CTLA-4 in Treg cells results in the 
loss of their suppressive function and the development of systemic lymphoproliferation (29), 
similar to what is observed in either Foxp3 or CTLA-4 deficient mice.  Blocking CTLA-4 on 
Treg cells in vitro and in vivo eliminates their inhibitory activity (30-32).  Furthermore, induced 
expression of CTLA-4 in T cells confers suppressive function (33).  Currently, the thought is that 
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CTLA-4 mostly functions as an indirect regulator of T cell activation by inhibiting APC 
function, rather than transmitting direct inhibitory signaling into the T cell where it is expressed 
(34-36).   
CTLA-4 may also play an important role in Treg differentiation.  CTLA-4 promotes both 
in vitro and in vivo induction of Foxp3, the major transcription factor of Treg cells, and is 
required for TGF-β-dependent induction of Foxp3 (37, 38).  Engagement of CTLA-4 in the 
presence of IL-2 and TGF-β or co-ligation of both the TCR and CTLA-4 through a bispecific 
protein induces differentiation of naïve T cells to adaptive CD4+CD25+ regulatory T cells (Treg 
cells) in mice (38, 39).  Whether CTLA-4 costimulation can induce human naïve CD4+ T cell 
differentiation to Treg cells and do so independently of exogenous cytokines remains to be 
determined.  
 
In vitro model of differentiation to determine how CTLA-4 participates in the differentiation of 
human naïve CD4+ T cells  
Defining the precise role of CTLA-4 in T cell differentiation is challenging because 
CTLA-4 and CD28 share the same counter receptors.  Therefore, we used a reductionist 
approach as we previously described (40, 41) in which immobilized antibodies specific for the 
TCR and a costimulatory molecule model the activation of naïve T cells.  Using this system, we 
have shown that the choice of costimulatory molecule differentially influences human naïve 
CD4+ T cell differentiation (40, 41).  We have shown that costimulation through CD28 induces 
differentiation to Th1 and Th2 cells but not Treg cells while costimulation through ICAM-1 
promotes differentiation to Th1 and Treg cells not Th2 (40, 41).  We used this in vitro system to 
investigate the effects of stimulation through CTLA-4 on human naïve CD4+ T cell 
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differentiation in the absence of exogenous cytokines.  We hypothesized that stimulation through 
CTLA-4 would support generation of Treg cells.  Consistent with previous work in mice (39, 
40), CTLA-4 and TCR (CD3) engagement of human naïve CD4+ T cells induced differentiation 
to CD4+CD25+Foxp3hi (Treg) cells capable of secreting IL-10, a suppressive cytokine secreted 
by Treg cells.  Unique to other studies, we show that CTLA-4 costimulation induced Treg 
differentiation in human cells without the need for exogenous cytokines (See model of proposed 
CTLA-4 function as a costimulatory molecule in Fig. 2.1-2.2).  In part I, we investigated the role 
of CTLA-4 as a costimulatory molecule (CD3+CTLA-4).  In part II, the participation of CTLA-4 
in conjunction with either CD28 or ICAM-1 costimulation was addressed (CD3+CD28+CTLA-4 
and CD3+ICAM-1+CTLA-4) to determine how differentiation is modulated by stimulation 
through multiple costimulatory proteins.  In part III, we examined whether costimulation through 
CTLA-4 could induce differentiation of murine CD4+ T cells to regulatory T cells.   
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Fig. 2.1 
 
 
 
 
 
 
 
Fig. 2.2 
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Figures 2.1-2.2. Model of our hypothesis for a two-step process by which CTLA-4 functions 
as a negative regulator of T cell responses by inducing Treg differentiation. Fig. 2.1. Step 1: 
CTLA-4 functions intrinsically by transmitting signals to induce activation and differentiation of 
human naïve CD4+ T cells to regulatory T cells (Treg cells).  Fig. 2.2. Step 2: CTLA-4 functions 
as a negative T cell regulator by generating a Treg population that suppresses T cell activation 
through various mechanisms.   
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Materials and Methods 
Antibodies and reagents 
Antibodies used to stain cells for flow cytometry were: anti-CD11a-FITC (BD 
Biosciences, San Jose, CA), anti-CD27-PE (Invitrogen, Carlsbad, CA), anti-CD27-PECy5 
(eBioscience, San Diego, CA), anti-CD45RO-APC (Invitrogen), anti-CD45RO-Tri Color 
(Invitrogen), anti-Foxp3-PE (Miltenyi Biotec, Auburn, CA), and anti-CD25-Tri Color 
(Invitrogen).  eBioscience Foxp3 buffers and protocol were used for intracellular staining of 
Foxp3.  Cells were stained with 2.5 µM 5-(and-6)-carboxyfluorescein diacetate, succinimidyl 
ester (CFSE, Invitrogen) on day 0 of stimulation for proliferation assays and stained on day 7 
with 7-AAD (7-aminoactinomycin D, BD Biosciences) and Annexin V-PE (BD Biosciences) for 
cell death analysis.  Flow cytometry was performed using an Accuri C6 (BD Accuri Cytometers, 
Ann Arbor, MI) and data analysis using CFlow (Accuri).  Antibodies used for cytokine blocking 
were anti-IL-2 (5334; R&D Systems, Minneapolis, MN) and anti-TGF-β1 (9016; R&D Systems) 
with mouse IgG1 (eBioscience) as the isotype control.  Clones and concentrations of stimulating 
antibodies used in the mouse studies are listed under Murine CD4+ T cell stimulation (see 
below). 
 
Human Subjects 
Peripheral blood (240 ml into heparin) was obtained after informed consent from healthy 
adult volunteers of both genders, ages 20-30 years, who had been free of infection for 14 days 
and did not have immune disorders.  Procedures were approved by the University of Kansas 
Institutional Review Board.   
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Human naïve CD4+ T cell purification 
Human naïve CD4+ T cells were isolated from peripheral blood of healthy adult 
volunteers.  Ficoll-Paque PLUS (GE Healthcare, Piscataway, NJ) density gradient centrifugation 
yielded peripheral blood mononuclear cells (PBMCs), and then naïve T cells were negatively 
selected using the Human Naïve CD4+ T Cell Enrichment Kit from STEMCELL Technologies 
(Vancouver, BC) as previously described (40).  Naïve T cells were defined as 
CD4+CD45RA+CD45RO(-)CD11alo CD27+CCR7+CD62L+.  Routinely, >98% CD45RO(-
)CD11aloCD27+ naïve CD4+ T cell purity was obtained.  Yields varied with human subjects but 
typically averaged 20 million naïve CD4+ T cells from 240 ml peripheral blood.  Cells were 
cultured immediately in complete RPMI 1640 (Mediatech, Herndon, VA) supplemented with 
10% FBS (Atlanta Biologicals, Lawrenceville, GA), 2 mM L-glutamine (Invitrogen), 50 units/ml 
penicillin, and 50 µg/ml streptomycin (P/S, Invitrogen) at 37°C, 5% CO2.   
 
Human Naïve CD4+ T cell stimulation 
Human naïve CD4+ naïve T cells were stimulated through plate-bound antibodies as we 
have previously described (40).  Each antibody was titrated to the lowest concentration that gave 
maximum T cell proliferation: anti-CD3 (OKT3) used at 1 µg/ml (eBioscience), anti-CD28 
(ANC28.1/5D10) used at 2-3 µg/ml (Ancell, Bayport, MN), anti-ICAM-1 (R6.5) used at 10 
µg/ml (BioXcell, West Lebanon, NH), and anti-CTLA-4 (BN13) used at 20 µg/ml (BD 
Biosciences or BioXcell).  Stimulating antibodies in PBS were adhered to flat-bottom, 96-well 
plates for 2-3 hours at 37°C.  Plates were washed three times with PBS to remove unbound 
antibody.  Naïve CD4+ T cells were plated at 1.5 x106 cells/ml in 200 µL complete RPMI 1640 
and stimulated 7-14 days using: anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-
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CTLA-4, anti-CD3+anti-CD28+anti-CTLA-4, anti-CD3+anti-ICAM-1+anti-CTLA-4, or anti-
CD3.  In selected experiments where indicated either exogenous cytokines or blocking cytokine 
antibodies were added at the start of stimulation.  Recombinant human cytokine TGF-β1 (R&D 
Systems, Minneapolis, MN) was used at 10 ng/ml and IL-2 (Boehringer Mannheim, Germany) at 
10 U/ml.  To block endogenous cytokines, anti-IL-2 (R&D Systems), anti-IL-10 (R&D Systems) 
or isotype control (mouse IgG1 for anti-IL-2 or ratIgG1 for anti-IL-10) was added at 20 µg/ml on 
day 0.  
 
Mice and cells 
 10-week-old female C57Bl/6 mice (n =3) were used in part III.  The University of Kansas 
Institutional Animal Review Board approved all animal experiments.  Spleens were harvested, 
minced and pressed through a sterile 70 µm nylon mesh cell strainer.  Splenocytes were 
incubated at room temperature for 5 minutes in ACK lysis buffer (0.15 M NH4Cl, 10 mM 
KHCO3, 0.1 mM Na2EDTA, pH 7.2) to remove erythrocytes.  CD4+ T cells were negatively 
selected using the Mouse CD4+ T Cell Enrichment Kit from STEMCELL Technologies and 
were routinely ≥98% pure. 
 
Murine CD4+ T cell stimulation 
Murine CD4+ naïve T cells were stimulated through plate-bound antibodies as we have 
previously described (40).  Each antibody was titrated to the lowest concentration that gave 
maximum T cell proliferation: anti-CD3 (500A2, BD Biosciences) used at 0.5 µg/ml, anti-CD28 
(37.51, BD Biosciences) used at 2.5 µg/ml , anti-ICAM-1 (KAT-1, eBioscience) or anti-ICAM-1 
(YN1/1.7.4, eBioscience) used at 10 µg/ml, and anti-human CTLA-4 (BN13, BD Biosciences or 
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BioXcell) or anti-murine CTLA-4 (9H10, BioLegend) used at 20 µg/ml.   Stimulating antibodies 
were plated as described above for naïve CD4+ T cell stimulations.  Murine CD4+ T cells were 
plated at 1.5 x106 cells/ml and stimulated 5 days using: anti-CD3, anti-CD3+anti-CD28, anti-
CD3+anti-ICAM-1 (KAT-1), anti-CD3+anti-ICAM-1 (YN1.1.7.4), anti-CD3+anti-msCTLA-4 
(9H10), anti-CD3+anti-huCTLA-4 (BN13), anti-CD3+anti-CD28+anti-msCTLA-4, anti-
CD3+anti-CD28+anti-huCTLA-4, anti-CD3+anti-ICAM-1(KAT)+anti-msCTLA-4, anti-
CD3+anti-ICAM-1(KAT)+anti-huCTLA-4, anti-CD3+anti-ICAM-1(YN1)+anti-msCTLA-4, or 
anti-CD3+anti-ICAM-1(YN1)+anti-huCTLA-4.  Exogenous rh-IL-2 and rhTGF-β1 were added 
to select cultures stimulated through CD3+CD28 to serve as a positive control for Treg 
differentiation.  Recombinant human cytokine TGF-β1 (R&D Systems) was used at 10 ng/ml 
and IL-2 (Boehringer Mannheim) at 10 U/ml.  
 
ELISA 
Supernatant fluid from stimulated cells was collected at day 7 or 10 for analysis of IL-2 
and IL-10 production using the Ready-Set-Go! ELISA kits and protocol (eBioscience).  
Supernates from day 7 were collected to determine the production of TGF-β1 or soluble CD25 
using Quantikine ELISA kits from R&D Systems.  Plates were read at 450 nm using the EL311 
Microplate Autoreader (Bio-Tek Instruments, Inc., Winooski, VT).   
 
Statistical Analysis 
The one-way, paired student’s t-test was used to determine statistical differences unless 
otherwise indicated.  All statistical analysis was performed using GraphPad Prism (GraphPad 
Software Inc., La Jolla, CA).  
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Results 
Part I 
Costimulation through CTLA-4 activated differentiation of human naïve CD4+ T cells to 
regulatory T cells 
We observed previously that in the absence of exogenous cytokines, costimulation of 
human naïve CD4+ T cells through CD3+ICAM-1 induces differentiation to Treg cells in 
contrast to CD3+CD28 (41).  CTLA-4 has been implicated in the maintenance of Treg function 
and the induction of Foxp3 expression in mice (30, 37, 42).  Ligation of CTLA-4 in the presence 
of other stimuli has induced Treg differentiation in murine naïve T cells (38, 39).  Therefore, we 
investigated whether stimulation of human naïve CD4+ T cells through the TCR (CD3) and 
CTLA-4 would promote differentiation to Treg cells.  Treg cells can be identified by expression 
of CD25 (alpha subunit of the IL-2 receptor) and Foxp3 (Treg transcription factor).  Naive CD4+ 
T cells stimulated for 7 or 10 days were assessed for the coexpression of these Treg markers: 
CD25 and Foxp3.  Consonant with our previous work (41), ICAM-1 costimulation guided naïve 
T cell differentiation to cells with a Treg phenotype (CD25+Foxp3hi) (Fig. 2.3-2.4).  As 
published previously (41, 43), stimulation through CD3 or CD3+CD28 did not induce 
differentiation to a Treg (CD25+Foxp3hi) population (Fig. 2.3-2.4).  Stimulation of human naïve 
CD4+ T cells through CD3+CTLA-4 induced differentiation to a Treg population similar in 
manner to CD3+ICAM-1 (Fig. 2.3-2.4). 
One mechanism by which Treg cells inhibit other T cells is through the secretion of 
suppressive cytokines, TGF-β and IL-10.  IL-10 can limit the production of IL-2, thereby 
suppressing T cell activation (44, 45).  These cytokines also participate in Treg differentiation  
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Fig. 2.3 
 
 
 
 
 
 
 
 
 
Fig. 2.4 
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Fig. 2.5 
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Figures 2.3-2.5.  Costimulation through CTLA-4 induced differentiation of human naïve 
CD4+ T cells to regulatory T cells.  Human naïve CD4+ T cells stimulated for 7 or 10 days 
with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-CTLA-4 or anti-CD3 were 
stained for CD25 and strong Foxp3 and analyzed by flow cytometry.   Regulatory T cells (Treg 
cells) are defined as CD4+CD25+Foxp3hi.  Supernates were collected for analysis of IL10 
production by ELISA.  Fig. 2.3, Upper right quadrant identifies regulatory T cell population with 
cell numbers indicated.  Fig. 2.4, average number of CD4+CD25+Foxp3hi T cells ± SEM at days 
7 or 10. Representative of fifteen (CD3+CD28; CD3+ICAM-1) or thirteen (CD3+CTLA-4; 
CD3) experiments.  Fig. 2.5, Average production of IL-10 pg/ml ± SEM at days 7 or 10.  
Representative of two (CD3+CD28) or nine (CD3+ICAM-1; CD3+CTLA-4; CD3) experiments. 
* p < 0.05, ** p < 0.01 
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(46-48).  TGF-β and IL-10 production was measured to determine whether Treg phenotype 
(expression of CD25 and strong Foxp3) was accompanied with Treg function.  Supernates from 
the various stimuli were collected on day 7 or day 10 for analysis by ELISA.  Consistent with 
our previous work (41), stimulation through CD3+CD28 yielded minimal IL-10 (19 ± 2 pg/ml) 
whereas CD3+ICAM-1 generated substantial IL-10 secretion (746 ± 328 pg/ml) (Fig. 2.5).  High 
levels of IL-10 were also produced by cells costimulated through CD3+CTLA-4 (321 ± 157 
pg/ml) and did not statistically differ from CD3+ICAM-1 (Fig. 2.5; p = 0.06).  As expected, we 
detected negligible amounts of IL-10 (14 ± 9 pg/ml) by cells stimulated through only the TCR 
(CD3).  Thus, in this system, the appearance of a Treg phenotype was accompanied by secretion 
of IL-10, supporting a role for CTLA-4 in guiding differentiation of human naïve T cells to Treg 
cells.   
TGF-β production was also measured but was not a reliable indicator of Treg function in 
this in vitro system as we previously reported (41).  Although CD28 costimulation failed to 
support Treg differentiation, cells costimulated through CD28 secreted high levels of TGF-β 
similar to costimulation through ICAM-1 or CTLA-4 (data not shown).  
 
CTLA-4 costimulation of naïve CD4+ T cells generated effector and memory T cell populations  
 In addition to the Treg population induced by CTLA-4, we observed a CD25+ Foxp3lo 
population at days 7 and 10, suggesting that costimulation through CTLA-4 may also induce 
differentiation of naïve T cells to classically defined memory and effector T cells (49).  
Consistent with our previous work (40), human naïve CD4+ T cells stimulated for 7 or 14 days 
through either CD3+CD28 or CD3+ICAM-1 differentiated to both effector [CD45RA(-)RO+, 
CD11ahi, CD27hi] (upper right quadrants in Fig. 2.6, 7 days and Fig. 2.9, 14 days summarized in 
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Fig. 2.7, 7 days and Fig. 2.10, 14 days) and memory [CD45RA(-)RO+CD11ahiCD27lo] (lower 
right quadrants in Fig. 2.6, 7 days and Fig. 2.9, 14 days summarized in Fig. 2.8, 7 days and Fig. 
2.11, 14 days).  Stimulation through CD3+CTLA-4 promoted differentiation to both effector and 
memory T cells that was comparable to ICAM-1 costimulation on day 7 (p = 0.13) but 
significantly higher than stimulation through CD3 (p < 0.05) and lower than CD3+CD28 (p < 
0.01) (Fig. 2.6-2.8).  As we have previously observed (40, 41), costimulation through CD28 
demonstrates faster kinetics of activation than ICAM-1.  The greater number of effector and 
memory T cells generated by stimulation through CD28 on day 7 (Fig. 2.7-2.8) is consistent with 
these studies, and by day 14, costimulation through ICAM-1 or CTLA-4 have attained 
comparable levels of differentiation to CD28 (Fig 2.10-2.11).  
 
Costimulation through CTLA-4 supported the generation of central memory T cells 
 Memory T cells [CD45RO+CD45RA(-)CD11ahiCD27lo] can be classified into two major 
subtypes: effector memory or central memory, which differ in their activation states and homing 
patterns (50).  Central memory T cells express CCR7 and CD62L allowing them to home to 
secondary lymphoid organs such as lymph nodes in contrast to effector memory cells that 
express lower levels of CCR7 and CD62L and wander widely through the body (51).  We 
compared the ability of CTLA-4 to generate central memory T cells to CD28 and ICAM-1 by 
staining for CD27, CD62L and CD45RO on days 7 and 14 (Fig. 2.12-2.13).  Costimulation 
through CTLA-4 supported a slightly elevated frequency of central memory T cells 
(CD45RO+CD27(-)CD62Lhi) compared to CD28 (p < 0.01, 7 days; p < 0.05, 14 days) but did 
not differ from ICAM-1 (p = 0.06, 7 days; p = 0.48, 14 days).  Although statistically different,  
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Fig. 2.6 
 
 
 
 
 
 
 
 
 
Fig. 2.7      Fig. 2.8 
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Fig. 2.9 
 
 
 
 
 
 
 
 
Fig. 2.10      Fig. 2.11 
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Figures 2.6-2.11.  Costimulation through CTLA-4 supported differentiation of human 
naïve CD4+ T cells to effector and memory T cells.  Human naïve CD4+ T cells stimulated for 
7 or 14 days with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-CTLA-4 or anti-
CD3 were stained for expression of CD11a, CD27 and CD45RO and analyzed by flow 
cytometry.  Representative of fourteen (CD3+CD28), thirteen (CD3+ICAM-1), or twelve 
(CD3+CTLA-4; CD3) experiments.  Fig. 2.6 and 2.9. representative figure of the number of 
CD4+CD45RO+CD11a+CD27hi T cells (effector T cells, upper right quadrant) and 
CD4+CD45RO+CD11a+CD27lo T cells (memory T cells, lower right quadrant) on day 7 (Fig. 
2.6) or day 14 (Fig. 2.9).  Fig. 2.7 and 2.10, average number of effector T cells ± SEM on day 7 
(Fig. 2.7) or day 14 (Fig. 2.10).  Fig. 2.8 and 2.11, average number of memory T cells ± SEM at 
day 7 (Fig. 2.8) or day 14 (Fig. 2.11). 
* p < 0.05, ** p < 0.01 
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Fig. 2.12 
 
 
 
 
 
 
 
 
Fig. 2.13 
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Figures 2.12-2.13.  Costimulation through CTLA-4 supported central memory T cells. 
Human naïve CD4+ T cells stimulated for 7 or 14 days with anti-CD3+anti-CD28, anti-
CD3+anti-ICAM-1, or anti-CD3+anti-CTLA-4 were stained for CD45RO, CD27 and CD62L 
expression and analyzed by flow cytometry.  Central memory T cells were defined as 
[CD4+CD45RO+CD27(-)+CD62L+].  Representative of four (CD3+CD28) or three 
(CD3+ICAM-1 and CD3+CTLA-4) experiments.  Fig. 2.12, Average percentage of central 
memory T cells ± SEM on day 7.  Fig. 2.13, Average percentage of central memory T cells ± 
SEM on day 14.   
* p < 0.05, ** p < 0.01 
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the changes in percentage of central memory T cells are modest and may not support a 
biologically relevant difference among the three costimulatory proteins. 
 
Costimulation through CTLA-4 promoted human naïve CD4+ T cell proliferation without 
impairing cell viability 
Cell proliferation is an integral part of the differentiation process.  CTLA-4 inhibits 
proliferation of mixed murine T cell populations consisting of CD8+ and CD4+ memory, 
effector, and naïve T cells at 72 hours of in vitro stimulation (14-17).  Other studies support a 
positive role for CTLA-4 in T cell proliferation (13, 20, 52).  We hypothesized that costimulation 
through CTLA-4 would support proliferation of naïve T cells.  In contrast to work of others (14-
17), we studied proliferation of purified human naïve CD4+ T cells (representative data in Fig. 
2.14, summarized in Fig. 2.15-2.17).  Costimulation through CD3+CTLA-4 induced 
proliferation on days 7, 10, and 12 in contrast to stimulation through the TCR (CD3).  CTLA-4 
failed to induce the same robust proliferation observed with CD28 or ICAM-1 by day 7 (Fig. 
2.15), however, by days 10 (Fig. 2.16) or 12 (Fig. 2.17), proliferation generated by CTLA-4 
costimulation was indistinguishable from ICAM-1 or CD28. 
 Our lab observed (40) that CD28 or ICAM-1 costimulation supports T cell proliferation 
while protecting against cell death but LFA-1 induces strong proliferation accompanied by 
considerable cell death and only modest differentiation.  Here (representative data in Fig. 2.18, 
summarized in Fig. 2.19), stimulation through CD3+CTLA-4 did not increase cell death beyond 
that caused by CD28 and ICAM-1.  Thus, stimulation through CD3+CTLA-4 promoted both 
differentiation and proliferation of human naïve CD4+ T cells in much the same manner as either 
CD28 or ICAM-1. 
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Fig. 2.14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   57	  
Fig. 2.15 
        Day 7 
 
 
 
 
 
 
Fig. 2.16 
       Day 10 
     
 
 
 
 
 
 
Fig. 2.17 
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Figures 2.14-2.17. Costimulation through CTLA-4 supported proliferation of naïve CD4+ T 
cells.  Human naïve CD4+ T cells were stained with 2.5 µM CFSE on day 0 and stimulated for 7, 
10 or 12 days using anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-CTLA-4 or 
anti-CD3.  CFSE dilution was analyzed by flow cytometry.  Fig. 2.14, Proliferation on days 7 
(upper panels), 10 (middle panels), and 12 (lower panels).  The percentage of divided cells is 
indicated in each histogram plot.  Fig. 2.15, Average percentage of total divided T cells ± SEM 
at day 7.  Representative of 6 experiments.  Fig. 2.16, Average percentage of total divided T cells 
± SEM at day 10. Representative of 4 experiments.  Fig. 2.17, Average percentage of total 
divided T cells ± SEM at day 12.  Representative of 4 experiments.  
* p < 0.05, ** p < 0.01 
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Fig. 2.18 
 
 
 
 
 
 
 
 
 
 
Fig. 2.19 
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Figures 2.18-2.19.  Costimulation through CTLA-4 promoted proliferation and 
differentiation of naïve T cells without affecting cell survival.  Human naïve CD4+ T cells 
were stimulated for 7 days using anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-
CTLA-4 or anti-CD3.  Cells were stained for Annexin V and 7-AAD and analyzed by flow 
cytometry.  Dead cells were indicated by expression of both Annexin V and 7-AAD.  
Representative of nine separate experiments.  Fig. 2.18, Upper right quadrant of each plot 
identifies the percentage of Annexin V+7AAD+ cells.  Fig. 2.19, Average percentage of 
Annexin V+7AAD+ cells ± SEM on day 7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   61	  
Costimulation through CTLA-4 favored differentiation to Treg cells 
  Although costimulation through CTLA-4 resulted in less proliferation on day 7 than 
either CD28 or ICAM-1, CTLA-4 generated numerous Treg cells.  This suggests that CTLA-4 
may favor differentiation to Treg cells rather than inducing widespread T cell activation, a 
function that would be consistent with its role as a negative regulator.  We examined the relative 
percentage of Treg cells in the divided and CD25+ (Treg and activated cells) populations to 
determine whether costimulation through CTLA-4 induces a larger representative Treg 
population compared to ICAM-1 (Fig. 2.20-2.25).  Although costimulation through CTLA-4 
generated a larger CD25+ population than stimulation through only the TCR (CD3) (p < 0.01) 
(representative data in Fig. 2.20, summarized in Fig. 2.21, p < 0.01), this CD25+ population was 
much smaller than the CD25+ populations observed with CD3+CD28 (p < 0.05) or CD3+ICAM-
1 (p < 0.001).  This indicates that CTLA-4 does not induce the same degree of activation as the 
other two stimuli.  If we examine the fraction of the CD25+ T cell population that are Treg cells, 
the Treg population represented on average 23%, 13%, and 1% of the CD25+ T cells induced by 
stimulation through CD3+CTLA-4, CD3+ICAM-1, and CD3+CD28, respectively (Fig. 2.22).  
Thus, stimulation through CTLA-4 favored differentiation to Treg cells greater than ICAM-1 by 
inducing less activation but greater percentages of Treg cells. 
Costimulation through CTLA-4 induced overall less T cell proliferation than ICAM-1 or 
CD28 on day 7 but appeared to favor proliferation of Treg cells (Fig. 2.23-2.25).  We examined 
the percentage of Treg cells with the T cell population that divided to evaluate whether CTLA-4 
favored proliferation of Treg cells (Fig. 2.25).  Stimulation through CD3 did not activate 
proliferation as expected.  Costimulation through CD28 induced robust proliferation but no  
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Fig. 2.20 
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Figures 2.20-2.22.  Costimulation through CTLA-4 induced less T cell activation than 
ICAM-1 or CD28 and favored differentiation to Treg cells.  Human naïve CD4+ T cells 
stimulated for 7 days with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-CTLA-
4 or anti-CD3 were stained for CD25 and strong Foxp3 expression and analyzed by flow 
cytometry.  Representative of fifteen (CD3+CD28; CD3+ICAM-1) or thirteen (CD3+CTLA-4; 
CD3) separate experiments.  Fig. 2.20, Histogram plots identify the CD4+CD25+ T cell 
population with cells numbers indicated.  Fig. 2.21, Average number of total CD4+CD25+ T 
cells ± SEM on day 7 (gated on total population). Fig. 2.22, Average percentage ± SEM of total 
CD4+ CD25+ T cells that also strongly express Foxp3 (gated on CD25+ population only).  
* p < 0.05, ** p < 0.01, *** p < 0.001. 
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Fig. 2.23 
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Figures 2.23-2.25. Costimulation through CTLA-4 induced overall less T cell proliferation 
than ICAM-1 or CD28 and favored proliferation of Treg cells.  Human naïve CD4+ T cells 
were stained with 2.5 µM CFSE at day 0 and stimulated for 7 days through anti-CD3+anti-
CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-CTLA-4 or anti-CD3.  Cells were stained for 
CD25 and strong Foxp3 (Fig. 2.23 and Fig. 2.25) on day 7 and analyzed for CFSE dilution and 
expression of Treg markers by flow cytometry.  Representative of 10 experiments (Fig. 2.24) or 
3 experiments (Fig. 2.23 and Fig. 2.25).  Fig. 2.23, Upper left quadrant identifies the 
CD4+CD25+Foxp3hi cells that had divided, with percentages indicating the percentage of Treg 
cells within the divided population.  Fig. 2.24, Average number of divided T cells ± SEM.  Fig. 
2.25, Average percentage of CD4+ CD25+ Foxp3hi T cells (Treg cells) ± SEM within the 
population of divided cells.  
* p < 0.05, ** p < 0.01, *** p < 0.001. 
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Treg differentiation (Fig. 2.23-2.25).  ICAM-1 also activated a greater proliferative response 
compared to CTLA-4 (Fig. 2.24); however, costimulation through CTLA-4 favored proliferation 
to Treg cells. 
Although costimulation through CTLA-4 supported production of IL-10 (a suppressive 
cytokine secreted by Treg cells) (Fig. 2.5), it did not support substantial production of IL-2 as 
seen with CD28 or ICAM-1 costimulations (Fig. 2.26).  Costimulation through CTLA-4 
modestly increased IL-2 production from 34 ± 9 pg/ml (CD3) to 103 ± 51 pg/ml (CD3+CTLA-
4).  IL-2 supports general T cell activation and proliferation and is an index of Th1 function in 
conjunction with IFN-γ.  Therefore, we also tested whether costimulation through CTLA-4 
induced production of IFN-γ on day 7.  Average production of  IFN-γ  induced by costimulation 
through CTLA-4 (174 pg/ml) was slightly lower than CD28 (273 pg/ml) or ICAM-1 (285 
pg/ml), but CTLA-4 failed to induce any IFN-γ in 67% of the experiments (not shown).  CTLA-
4, therefore, did not appear to support Th1 function based on the low production of IL-2 and 
inability to consistently induce IFN-γ production.  These data suggest that CTLA-4 induces 
differentiation and proliferation of naïve CD4+ T cells but strongly favors differentiation to Treg 
cells, a role that would be consistent with its status as an inhibitory protein.   
 
Differentiation of naïve T cells to Treg cells by CTLA-4 was dependent on a low level of 
endogenous IL-2 
 In our previous study (41), costimulation through ICAM-1 guided naïve CD4+ T cell 
differentiation to Treg cells by an IL-2-dependent mechanism.  In the present study, CTLA-4  
costimulation yielded 10-fold lower levels of IL-2 production (103 ± 51 pg/ml) in contrast to 
ICAM-1 costimulation (1,122 ± 417 pg/ml) suggesting a possible mechanistic difference in 
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Fig. 2.26   
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Fig. 2.26.  Costimulation through CTLA-4 induced low levels of IL-2 production. Human 
naïve CD4+ T cells were stimulated for 7 days with anti-CD3+anti-CD28, anti-CD3+anti-
ICAM-1, anti-CD3+anti-CTLA-4 or anti-CD3.  On day 7, supernate was collected for analysis 
by ELISA.  Fig. 2.26, Average production of IL-2 pg/ml ± SEM.  Representative of four 
experiments (CD3+CD28) or five experiments (CD3+ICAM-1, CD3+CTLA-4, CD3).  Fig. 2.27, 
Average production of IFN-γ pg/ml ± SEM.  Representative of four experiments (CD3+CD28), 
five experiments (CD3+ICAM-1), or three experiments (CD3+CTLA-4). 
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induction of Treg differentiation between the two stimuli.  We tested whether induction of Treg 
differentiation by CTLA-4 required endogenous IL-2 (Fig. 2.27-2.28).  An isotype control or 
blocking antibody against IL-2 or IL-10 were added at the start of stimulations, and the number 
of CD4+CD25+Foxp3hi T cells (Treg cells) was assessed by flow cytometry on day 7.  Blocking 
IL-2 inhibited differentiation to Treg cells by ICAM-1 and CTLA-4 (representative figures in 
Fig. 2.27, summarized in Fig. 2.28).  In vivo studies indicate that Treg cells require IL-2 for 
maintenance and survival (53, 54) consistent with our findings here. 
TGF-β induces differentiation of naïve T cells to Treg cells that is further supported by 
IL-2 addition (41, 55, 56).  In Dr. Kelli Williams’s dissertation (58), the addition of exogenous 
IL-2 and TGF-β enhanced differentiation of naïve T cells to Treg cells by ICAM-1 
costimulation.  Here, we compared the effect of adding exogenous IL-2, TGF-β, or both IL-2 and 
TGF-β on Treg differentiation induced by ICAM-1 and CTLA-4.  Adding exogenous IL-2, TGF-
β, or both IL-2 and TGF-β showed an overall trend of increasing the number of Treg cells 
generated through CD3+ICAM-1 (Fig. 2.29-2.30).  Addition of TGF-β or TGF-β+IL-2 
augmented differentiation to Treg cells 2.5- or 2-fold, respectively, by CTLA-4 (Fig. 2.29-2.30).  
Exogenous IL-2 consistently had little effect on Treg induction by CTLA-4 in contrast to 
costimulation through ICAM-1, which may suggest different mechanistic pathways by which 
ICAM-1 and CTLA-4 induce Treg differentiation.  Overall, differentiation to Treg cells by 
costimulation through CTLA-4 was dependent on low levels of endogenous IL-2 and was 
enhanced by addition of exogenous TGF-β but not IL-2.  
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Fig. 2.27 
 
 
 
 
 
 
 
 
 
 
Fig. 2.28 
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Figures 2.27-2.28.  Differentiation of naïve T cells to Treg cells by CTLA-4 was dependent 
on a low level of endogenous IL-2.  Human naïve CD4+ T cells were stimulated for 7 days with 
anti-CD3+anti-ICAM-1 or anti-CD3+anti-CTLA-4.  Isotype controls, anti-IL-2 antibody, or  
anti-IL-10 antibody were added to medium at the start of stimulations as indicated.  On day 7, T 
cells stained for CD25 and Foxp3 were analyzed by flow cytometry.  Treg cells were defined as 
CD4+CD25+Foxp3hi.  Representative of 4 experiments.  Fig. 2.27, Upper right quadrant 
identifies the Treg population with cell numbers indicated.  Fig. 2.28, Average number of Treg 
cells ± SEM with added isotype control, anti-IL-2, or anti-IL-10.   
* p < 0.05 
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Fig. 2.29 
 
 
 
 
 
 
 
 
 
 
Fig. 2.30 
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Figures 2.29-2.30.  Differentiaton to Treg cells by CTLA-4 costimulation was enhanced by 
exogenous TGF-β  but not IL-2.  Human naïve CD4+ T cells were stimulated for 7 days with 
anti-CD3+anti-ICAM-1 or anti-CD3+anti-CTLA-4.  Recombinant human IL-2 (rhIL-2), 
recombinant human TGF-β (rhTGF-β), or the combination of rhIL-2 and rhTGF-β were added to 
medium at the start of stimulations as indicated.  On day 7, T cells stained for CD25 and Foxp3 
were analyzed by flow cytometry.  Treg cells were defined as CD4+CD25+Foxp3hi.  
Representative of 4 experiments.  Fig. 2.29, Upper right quadrant identifies the Treg population 
with cell numbers indicated.  Fig. 2.30, Average number of Treg cells ± SEM with added 
medium (NONE), rhIL-2, rhTGF-β, or combination of rhIL-2 and rhTGF-β. 
* p < 0.05 
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Naïve T cells costimulated through CTLA-4 released soluble CD25 at a higher frequency than 
those costimulated through ICAM-1 
CD25, a marker of activated and regulatory T cells, can be released as a soluble form 
(sCD25 or sIL-2Rα) by both types of T cell subsets and is capable of binding IL-2 (58, 59).  
sCD25 can suppress effector T cell proliferation and enhance suppressive function of Treg cells 
(60).  We have observed so far that costimulation through CTLA-4 favored differentiation to 
Treg cells that is dependent on IL-2; yet, minimal IL-2 is produced in these cultures.  We 
hypothesized that cells costimulated through CTLA-4 may release more soluble CD25 than cells 
costimulated through ICAM-1, thus, sequestering secreted IL-2.  Evidence of a higher frequency 
of soluble CD25 in cells costimulated through CTLA-4 may explain dependence on IL-2 for 
Treg induction and low endogenous IL-2 production.  Both ICAM-1 and CTLA-4 caused high 
levels of soluble CD25 production, averaging 23,604 and 26,001 pg/ml, respectively (Fig. 2.31); 
however, there were significantly fewer activated (CD25+) T cells generated by CD3+CTLA-4 
compared to CD3+ICAM-1 (Fig. 2.32).  The amount of soluble CD25 (pg/ml) secreted per 
CD25+ T cell was determined to normalize this observed difference in CD25+ T cell numbers.  
CD25+ T cells stimulated through CD3+CTLA-4 secreted sCD25 at a nearly three-fold higher 
frequency than those through CD3+ICAM-1, averaging 1.08 ± 0.36 pg/ml sCD25 per cell 
compared to 0.38 ± 0.09 pg/ml (p < 0.05) (Fig. 2.33).  The increased rate of sCD25 production in 
the supernate from cells costimulated through CTLA-4 may sequester IL-2, reducing the level of 
IL-2 being detected by ELISA.   
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Fig. 2.31      Fig. 2.32 
 
 
 
 
 
 
 
 
Fig. 2.33       
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Figures 2.31-2.33.  Costimulation through CTLA-4 induced the release of soluble CD25 at a 
higher frequency than ICAM-1.  Human naïve CD4+ T cells were stimulated for 7 days with 
anti-CD3+anti-ICAM-1 or anti-CD3+anti-CTLA-4.  On day 7, supernate was collected and 
analyzed for sCD25 (sIL-2Rα) by ELISA (Fig. 2.31 and Fig. 2.33).  T cells were stained for 
CD25 expression and analyzed by flow cytometry (Fig. 2.32).  Representative of 7 experiments.  
Fig. 2.31.  Average sCD25 ± SEM (pg/ml) released in supernates.  Fig. 2.32.  Average CD25+ T 
cells ± SEM on day 7.  Fig. 2.33, Average sCD25 (pg/ml) produced per CD25+ T cell ± SEM.   
* p < 0.05 
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Stimulation through CD28 suppressed Treg cell induction by CTLA-4 but not ICAM-1 
CD28 and CTLA-4 compete for the shared counter receptors, CD80 and CD86.  CD28 is 
expressed by resting and activated T cells in contrast to CTLA-4 which is constitutively 
expressed by Treg cells or upregulated in activated T cells.  CTLA-4, however, has a much 
higher affinity for both CD80 and CD86 than CD28 (11, 12).  Depending on the relative 
expression levels of CD28, CTLA-4 and their shared counter receptors, CD80 and CD86, in 
some cases CD28 may be the primary signaling protein and in other cases, the balance of CD28 
and CTLA-4 signaling may shift favor to CTLA-4.  We wondered how differentiation to Treg  
cells would be affected by costimulating cells through both CD28 and CTLA-4, giving each 
receptor equal opportunity to signal without competition for CD80 or CD86.  In Fig. 2.34, anti-
CD28 was added to cultures stimulated through CD3+CTLA-4 (closed bars), or alternatively, 
CD3+ICAM-1 (open bars).  The number of Treg cells in each culture was assessed on day 7.  
CD28 signaling reduced differentiation to Treg cells in a dose-dependent manner in cells 
stimulated through CD3+CTLA-4 (closed bars) but not CD3+ICAM-1 (open bars) (Fig. 2.34).  
All stimuli were added at day 0 which may have given CD28 a bit of a head start since CTLA-4 
expression was usually not detectable by flow cytometry until 24-48 hours after stimulation in 
this system (See Fig. 2.39-40 later in Chapter 2).  Inhibition of Treg differentiation began at 0.25 
µg/ml and was maximal when the level of anti-CD28 reached 1.0 µg/ml.  In contrast, even at 
maximum concentration (2 µg/ml), CD28 did not inhibit differentiation to Treg cells induced by 
ICAM-1 costimulation (Fig. 2.34, open bars).   
Varying the concentration of anti-CTLA-4 in conjunction with constant stimulation with 
anti-CD3 (1 µg/ml) + anti-CD28 (2 µg/ml) did not reverse the inhibition of anti-CD28 on Treg  
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Fig. 2.34 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.35 
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Figures 2.34-2.35.  Costimulation through CD28 suppressed differentiation to Treg cells 
induced by CTLA-4 but not by ICAM-1.  Human CD4+ naïve T cells were stimulated with 
anti-CD3+anti-ICAM-1, anti-CD3+anti-ICAM-1+anti-CD28 (2 µg/ml), anti-CD3+anti-CTLA-4 
(20 µg/ml), anti-CD3+anti-CD28 (2 µg/ml), anti-CD3+varying [anti-CD28]+anti-CTLA-4 (20 
µg/ml), or anti-CD3+anti-CD28 (2 µg/ml)+varying [anti-CTLA-4] for seven days.  Anti-CD3 
and anti-ICAM-1 were used at 1 µg/ml and 10 µg/ml, respectively.  On day 7, cells were stained 
for CD25 and Foxp3 and analyzed via flow cytometry.  Representative of 3 experiments each 
performed in duplicate except for  the addition of 0.1 µg/ml anti-CD28 (Fig. 2.34), which is 
representative of 2 experiments each performed in duplicate.  Fig. 2.34, Average number of 
CD25+ Foxp3hi T cells ± SEM generated at day 7.  Closed bars indicate cells that were 
stimulated with anti-CD3 (1 µg/ml) + anti-CTLA-4 (20 µg/ml) with varying concentrations of 
anti-CD28 stimulating Ab shown in Fig 2.34.  Bar 1 indicates cells that were stimulated only 
with anti-CD3 (1 µg/ml) + anti-CTLA-4 (20 µg/ml).  The open bars indicate cells stimulated 
with anti-CD3+anti-ICAM-1 or anti-CD3+anti-ICAM-1+anti-CD28.  Fig. 2.35, Average number 
of CD25+ Foxp3hi T cells ± SEM generated at day 7.  Closed bars indicate cells that were 
stimulated with anti-CD3 (1 µg/ml) + anti-CD28 (2 µg/ml) with varying concentrations of anti-
CTLA-4 stimulating Ab as shown in Fig. 2.35.  Bar 1 indicates cells that were stimulated only 
with anti-CD3 (1 µg/ml) + anti-CD28 (2 µg/ml).   
*p < 0.05 
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induction (Fig. 2.35).  However, the effect of CTLA-4 concentrations greater than 35 µg/ml was 
not determined and may warrant further investigation.   
Next, we addressed the kinetic profile for how late after initiation of the CTLA-4 
costimulation that anti-CD28 could be added and still affect inhibition of differentiation to Treg 
cells.  As seen in Fig. 2.36-2.37, stimulation through CD28 completely inhibited Treg induction 
by CTLA-4 if added in soluble form within the first 24 hours and partially inhibited if added at 
48 hours.  This inhibition by CD28 was not observed in cultures stimulated through 
CD3+ICAM-1 (Fig. 2.38) as was consistent with our findings in Fig. 2.34.  Thus, it appears that 
stimulation through CD28 can suppress differentiation to Treg cells by CTLA-4 but not ICAM-1.      
 
Surface expression of CTLA-4 was induced upon stimulation of naïve CD4+ T cells 
 As mentioned earlier, CD28 is expressed on both resting and activated T cells including 
naïve T cells.  CTLA-4, however, is not detected on the surface of conventional T cells until 48 
hours after activation (13).  Human naïve CD4+ T cells did not express CTLA-4 on their surface, 
as expected (data not shown).  In Fig. 2.39-2.42, we assessed the ability of each stimulus to 
induce CTLA-4 expression in naïve CD4+ T cells at 2, 4, 24, 48, 72, and 96 hours and days 7 
and 14 to determine the onset, peak, and duration of CTLA-4 expression (Fig. 2.39-2.42).  As 
seen in Fig. 2.39 (MFI of CTLA-4) and Fig. 2.40 (% CTLA-4+ cells), CTLA-4 expression was 
detected by flow cytometry as early as 24 hours and peaked at 72 hours following stimulation.  
At peak expression (72h), costimulation through CD28, ICAM-1 or CTLA-4 induced elevated 
levels of CTLA-4 compared to stimulation through only the TCR (CD3).  Although CTLA-4 
expression declined at 96h (Fig. 2.39-2.40), later in differentiation (days 7 and 14) the  
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Fig. 2.36 
 
 
 
 
 
 
 
 
Fig. 2.37 
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Fig. 2.38 
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Figures 2.36-2.38.  CTLA-4 required at least 48 hours of stimulation without signaling 
through CD28 to induce regulatory T cells in vitro.  Human CD4+ naïve T cells were 
stimulated with anti-CD3+anti-CTLA-4 or anti-CD3+anti-ICAM-1 for seven days.  Anti-CD28 
(2 µg/ml) was added on days 0, 1, 2, 3, 4, or 5 in solution.  On day 7, cells were stained for 
CD25 and strong Foxp3 expression and analyzed by flow cytometry.  Representative of 5-6 
experiments (CD3+CTLA-4) or 4 experiments (CD3+ICAM-1).  Fig. 2.36, Upper right 
quadrants identify the CD25+ Foxp3hi (Treg) population with cell numbers indicated.  The days 
indicate when anti-CD28 was added.  Fig. 2.37, Average number of CD25+ Foxp3hi T cells ± 
SEM generated at day 7 through CD3+CTLA-4 with varying the timing of anti-CD28 addition.  
Fig. 2.38, Average number of CD25+ Foxp3hi T cells ± SEM generated at day 7 through 
CD3+ICAM-1 with varying the timing of anti-CD28 addition. 
*p < 0.05, ** p < 0.01 
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Fig. 2.39       
 
 
 
 
 
 
 
Fig. 2.40 
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Fig. 2.41       
 
 
 
 
 
 
 
 
 
Fig. 2.42 
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Figures 2.39-2.42.  Surface expression of CTLA-4 peaked at 72 hours after activation and 
was detected on differentiated cells on days 7 and 14.  Human naïve CD4+ T cells were 
stimulated for 7 days with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-CTLA-
4 or anti-CD3 for 2, 4, 24, 48, 72 and 96 hours and 7 and 14 days after stimulation began, cells 
were analyzed for surface expression of CTLA-4.  For Fig. 2.39-2.40, representative of 4-5 
experiments for all timepoints except 96 hour (n = 2).  For Fig. 2.41-2.42, representative of 7 
experiments.  Fig. 2.39, Average MFI of CTLA-4.  Fig. 2.40, Average percentage of CTLA-4+ 
cells.  Fig. 2.41, Average percentage CTLA-4+ cells ± SEM on day 7.  Fig. 2.42, Average 
percentage CTLA-4+ cells ± SEM on day 14.  
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percentage of cells expressing CTLA-4 increased (Fig. 2.41-2.42).  Thus, it appeared that 
stimulation of naïve T cells induced a transient increase in CTLA-4 expression at 72 hours as 
cells became activated.  The timing of this peak in CTLA-4 expression corresponded with the 
ability of CD28 to inhibit Treg differentiation by CTLA-4 if present during the first 48 hours of 
stimulation (Fig. 2.37).  At 72 hours, addition of CD28 stimulation no longer inhibited the 
generation of Treg cells by CTLA-4.  
 
Costimulation through CTLA-4, ICAM-1, or CD28 influenced surface expression of CD28 and 
ICAM-1 differently 
We sought to characterize the expression of the other two costimulatory proteins during 
the first 96 hours of stimulation to better understand the timing of activation and differentiation 
induced by CD28, ICAM-1, and CTLA-4.  Low levels of ICAM-1 are expressed by naïve T cells 
with increased expression following activation (61-63).  As seen in Fig. 2.43-2.44, CD3+CD28 
induced high levels of ICAM-1 expression in comparison to all other stimuli.  CD3+CTLA-4 
caused slightly increased percentages of ICAM-1+ cells at 24, 48 and 96 hours compared to 
CD3+ICAM-1 (Fig. 2.44).  Upon activation, CD28 costimulation induced a considerable decline 
in the percentage and intensity of CD28 expression through 48 hours of stimulation, but then 
sharply increased CD28 expression from 72-96 hours (Fig. 2.45-2.46).  Overall, the extent and 
pattern of ICAM-1 and CD28 expression generated by costimulation through CD28 differed 
greatly from that observed with costimulation through ICAM-1 or CTLA-4.   Stimulation 
through ICAM-1 and CTLA-4 reflected similar patterns and levels of ICAM-1 and CD28 
expression.   
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Fig. 2.43 
 
 
 
 
 
 
 
Fig. 2.44 
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Figures 2.43-2.44.  Costimulation through ICAM-1 or CTLA-4 induced similar intensities 
of ICAM-1 expression but differed slightly in the percentage of cells expressing ICAM-1. 
Human naïve CD4+ T cells were stimulated for 7 days with anti-CD3+anti-CD28, anti-
CD3+anti-ICAM-1, anti-CD3+anti-CTLA-4 or anti-CD3 for 2, 4, 24, 48, 72 and 96 hours after 
stimulation began, cells were analyzed for surface expression of ICAM-1.  Graphs on the right 
are duplicates of the graph to the left and exclude stimulation through CD3+CD28 so that 
differences among CD3, CD3+ICAM-1, and CD3+CTLA-4 can be observed.  Representative of 
3-4 experiments for all timepoints. Fig. 2.43, Average MFI of CTLA-4.  Fig. 2.44, Average 
percentage ICAM-1+ cells.   
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Fig. 2.45 
  
 
 
 
 
 
 
Fig. 2.46 
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Figures 2.45-2.46.  Costimulation through CD28 altered expression of CD28 greater than 
costimulation through either ICAM-1 or CTLA-4.  Human naïve CD4+ T cells were 
stimulated for 7 days with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-CTLA-
4 or anti-CD3 for 2, 4, 24, 48, 72 and 96 hours after stimulation began, cells were analyzed for 
surface expression of CD28.  Graphs on the right are duplicates of the graph to the left and 
exclude stimulation through CD3+CD28 so that differences among CD3, CD3+ICAM-1, and 
CD3+CTLA-4 can be observed.  Representative of 3 experiments for all timepoints.  Fig. 2.45, 
Average MFI of CD28.  Fig. 2.46, Average percentage CD28+ cells. 
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Expression of CD62L, CD45RO, and CD27 but not CD69, CCR7, or CD25 reflected early 
differentiation events induced by costimulation through CTLA-4 
 (Summarized in Table 2.1 on page 66)  
The expression of several surface proteins was assessed to determine whether activation 
and differentiation induced by costimulation through CTLA-4 could be detected at early 
timepoints and whether expression patterns induced by CTLA-4 differed from costimulation  
through ICAM-1 or CD28.  Activation markers (CD69 and CD25), migration markers (CCR7 
and CD62L), and differentiation markers (CD45RO and CD27) were assessed at 48 and 96 hours 
of stimulation.  CD69 and CD25 were induced by costimulation through CTLA-4 but did not 
differ significantly from levels induced by stimulation through the TCR (CD3) (Fig. 2.47-2.50).  
However, stimulation through CD3+ICAM-1 did not induce high levels of activation early 
during the differentiation process either, consistent with the slightly delayed kinetics we have 
observed with ICAM-1 compared to CD28 costimulation (40).  The expression of migration 
markers, CD62L and CCR7, induced by costimulation through CTLA-4 were comparable to 
ICAM-1 (Fig. 2.51-2.54).  Cells stimulated through CD28 expressed higher levels of CCR7 and 
lower levels of CD62L compared to cells stimulated through CTLA-4 or ICAM-1.  The 
differences in CCR7 and CD62L expression may reflect the variation in timing of the transition 
of naïve T cells (which express high levels of CCR7 and CD62L) to effector, memory, and 
regulatory T cells by the various stimuli.   
CD45RO and strong expression of CD27 were determined to assess how the transition 
from naïve to differentiated T cells is influenced by the various costimulatory proteins (Fig. 
2.55-2.58).  Although not statistically supported, the expression of CD45RO by the four different 
stimulations (Fig. 2.55-2.56) reflected the degree of effector T cells observed on day 7 and was  
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Fig. 2.47      Fig. 2.48 
  
 
 
 
 
 
 
Fig. 2.49      Fig. 2.50 
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Fig. 2.51      Fig. 2.52 
  
 
 
 
 
 
 
Fig. 2.53      Fig. 2.54 
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Fig. 2.55      Fig. 2.56 
  
 
 
 
 
 
 
 
Fig. 2.57      Fig. 2.58 
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Figures 2.47-2.58.  Expression of CD45RO and strong CD27 expression reflected the 
differences in activation, proliferation and differentiation induced by each costimulatory 
protein.  Human naïve CD4+ T cells were stimulated for 48 or 96 hours with anti-CD3+anti-
CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-CTLA-4 or anti-CD3 and analyzed for surface 
expression of CD69, CD25, CCR7, CD62L, CD45RO, and strong expression of CD27.  
Representative of 5 experiments for all surface markers except CCR7 (n = 3).  Fig. 2.47, 
Average percentage of CD69+ cells ± SEM at 48 hours.  2.48, Average percentage of CD69+ 
cells ± SEM at 96 hours.  Fig. 2.49, Average percentage of CD25+ cells ± SEM at 48 hours.  
2.50, Average percentage of CD25+ cells ± SEM at 96 hours.  Fig. 2.51, Average MFI of CCR7 
± SEM at 48 hours.  2.52, Average MFI of CCR7 ± SEM at 96 hours. Fig. 2.53, Average MFI of 
CD62L ± SEM at 48 hours.  2.54, Average MFI of CD62L ± SEM at 96 hours.  Fig. 2.55, 
Average percentage of CD45RO+ cells ± SEM at 48 hours.  2.56, Average percentage of 
CD45RO+ cells ± SEM at 96 hours.  Fig. 2.57, Average percentage of CD27hi+ cells ± SEM at 
48 hours.  2.58, Average percentage of CD27hi+ cells ± SEM at 96 hours. 
* p < 0.05, ** p < 0.01 
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consistent with the kinetics of each stimulus.  The population of CD27hi cells was gated above 
the median fluorescence intensity of the CD27+ naïve T cell population to assess early activating 
and transitional T cells rather than naïve T cells.  This CD27hi population also demonstrated a 
slight increase in CD45RO MFI (data not shown).  The expression of strong CD27 expression at 
96 hours statistically supported differences among the four stimuli early in the differentiation 
process and emulated the degree of proliferation and activation seen on day 7 caused by each 
stimulation (Fig. 2.57-2.58) with CD3+CD28 and CD3+ICAM-1 representing the stronger 
stimuli in contrast to CD3+CTLA-4 or CD3.   
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Table 2.1 
 CD3+CD28 CD3+ICAM-1 CD3+CTLA-4 
% CD69+ cells 48h:  71% 
96h:  77% 
48h:  32% 
96h:  32% 
48h:  30% 
96h:  26% 
% CD25+ cells 48h:  57% 
96h:  62% 
48h:    7% 
96h:  15% 
48h:  3% 
96h:  8% 
CCR7 (MFI) 48h:  3,859 
96h:  2,211 
48h:  2,460 
96h:  1,673 
48h:  2,433 
96h:  1,754 
 
CD62L (MFI) 48h:  14,810 
96h:    9,563 
48h:  20,152 
96h:  17,819 
48h:  20,825 
96h:  17,624 
% CD45RO+ cells 48h:  20% 
96h:  31% 
48h:    9% 
96h:  15% 
48h:  3% 
96h:  9% 
% CD27hi cells 48h:  45% 
96h:  46% 
48h:    9% 
96h:  20% 
48h:  5% 
96h:  8% 
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Table 2.1.  Summary of the expression of surface proteins at 48 and 96 hours of stimulation 
through CD3+CD28, CD3+ICAM-1, and CD3+CTLA-4.  The percentage of CD45RO+ and 
CD27hi cells reflected the degree of activation and proliferation induced by each stimulus at later 
timepoints of differentiation.   
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Costimulation through CTLA-4 differentially influenced expression of CD80 and CD86 on naïve 
T cells 
 The counter receptors for CD28 and CTLA-4, CD80 and CD86, are typically found on 
APCs (antigen presenting cells); however, they can also be expressed to a lesser degree by 
activated T cells (64).  It has been proposed that engagement of CD80:CTLA-4 may have a 
functionally distinct outcome to the engagement of CD86:CTLA-4 and that CTLA-4 favors 
interactions with CD80 (11).  We examined whether costimulation through CTLA-4 would 
differentially upregulate or downregulate CD80 or CD86.   Expression of CD80 and CD86 was 
highest at day 14 in all stimuli (Fig. 2.59-2.60).  Costimulation through CD28 induced higher 
percentages of CD80+ and CD86+ cells on days 2 and 14 compared to ICAM-1 or CTLA-4.  
Costimulation through CTLA-4 maintained relatively lower expression of CD80 and CD86 
through 10 days of stimulation (Fig. 2.59-2.60).  CD3+ICAM-1 induced a significant increase in 
CD86+ cells on day 10 which may warrant future studies to determine whether this is a 
consistent finding.  In general, MFI expression of CD86 was consistently higher than CD80 
regardless of type or duration of stimulus (data not shown).  The implications of T cells 
expressing CD80 and CD86 and the differential regulation of these counter receptors by CTLA-4 
and CD28 offer an additional complexity to the function of CTLA-4 in vivo that will need to be 
investigated further. 
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Fig. 2.59 
 
 
 
 
 
 
 
 
 
Fig. 2.60 
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Figures 2.59-2.60.  CD80 and CD86 expression were differentially regulated by 
costimulation through CD28, ICAM-1, and CTLA-4.  Human naïve CD4+ T cells were 
stimulated for 48 or 96 hours or 7, 10 or 14 days with anti-CD3+anti-CD28, anti-CD3+anti-
ICAM-1, anti-CD3+anti-CTLA-4 or anti-CD3 and analyzed for surface expression of CD80 and 
CD86.  Representative of 3 (48h), 2 (7 or 14d), or 1 (96h or 10d) experiment(s).  Fig. 2.59, 
Average percentage of CD80+ T cells ± SEM.  Fig. 2.60, Average percentage of CD86+ T cells 
± SEM. 
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Part I-Interim Summary: Costimulation through CTLA-4 induced differentiation of naïve CD4+ 
T cells 
 Our data from Part I of this chapter support a role for CTLA-4 as a stimulatory molecule 
by inducing naïve T cells to proliferate and differentiate to effector, memory, and regulatory T 
cells in the absence of exogenous cytokines.  In contrast to the other two costimulatory 
molecules, CD28 and ICAM-1, costimulation through CTLA-4 induced overall less activation 
and slower kinetics of stimulation and favored differentiation to Treg cells, consistent with the 
role of CTLA-4 as a negative regulator.  Also, unlike costimulation through either CD28 or 
ICAM-1, costimulation through CTLA-4 did not support generation of Th1 cells.  Whether 
CTLA-4 can support Th2 function remains to be determined.   
 We also demonstrated how differentiation to Treg cells is influenced by the addition of 
CD28 stimulation to cells costimulated through either ICAM-1 or CTLA-4.  These date revealed 
a difference between ICAM-1 and CTLA-4.  Differentiation to Treg cells through CTLA-4 
costimulation was inhibited by CD28, but Treg differentiation induced by ICAM-1 was resistant 
to inhibition by CD28.  It appears that when both CD28 and CTLA-4 have equal opportunity to 
signal into a T cell, CD28 signaling is dominant to signaling through CTLA-4.  In Part II, we 
continue this investigation of whether costimulation through CTLA-4 can influence 
differentiation when combined with stimulation through CD28.  We also examine how the 
combined stimulation through ICAM-1 and CTLA-4 affects differentiation of naïve T cells.   
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Part II 
 
 Here, we examined the participation of CTLA-4 as an additional stimulus to 
costimulation mediated through ICAM-1 or CD28.  As observed in part I, both ICAM-1 and 
CTLA-4 induced differentiation of human naïve CD4+ T cells to regulatory T cells (Treg cells).  
Whether these costimulatory proteins induce Treg cells by the same pathway remains to be 
determined.  In the first section of Part II, the effect of combined stimulation through ICAM-1 
and CTLA-4 (CD3+ICAM-1+CTLA-4) on Treg differentiation is compared to stimulation 
through each costimulatory molecule separately (CD3+ICAM-1 vs. CD3+CTLA-4).   
Experiments in which anti-CD28 was added to CD3+ICAM-1 or CD3+CTLA-4 stimuli 
indicated a difference between the Treg populations induced by CTLA-4 and ICAM-1 (Part I).  
This also suggested that costimulation through CD28 may be dominant to stimulation through 
CTLA-4 and override signaling by CTLA-4 which seems contrary to earlier in vitro studies in 
murine T cells (14, 15, 65).  We, therefore, tested the ability of anti-CTLA-4 to modulate 
costimulation through CD28 and ICAM-1 by examining other aspects of differentiation in the 
latter section of Part II.   
 
Combined stimulation through ICAM-1 and CTLA-4 augmented differentiation to Treg cells 
 We hypothesized that ICAM-1 and CTLA-4 may induce differentiation to Treg cells by 
distinct mechanisms since CD28 stimulation inhibited Treg differentiation by CTLA-4 but not 
ICAM-1 (Part I).  If ICAM-1 and CTLA-4 use different pathways of Treg induction, then the 
number of Treg cells should increase when the stimuli are combined.  If ICAM-1 and CTLA-4 
utilize the same pathway, then the number of Treg cells may not increase when the stimuli are 
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combined.  We examined how combined stimulation through both ICAM-1 and CTLA-4 would 
impact differentiation to Treg cells compared to each stimulation separately.  Stimulation 
through CD3+ICAM-1+CTLA-4 increased differentiation to Treg cells compared to stimulation 
through each costimulatory protein separately and appeared to be additive (Fig. 2.61 and Fig. 
2.62).  Although the number of Treg cells increased by 2- fold, the production of IL-10 by cells 
stimulated through both ICAM-1 and CTLA-4 was roughly equivalent to stimulation through 
CD3+ICAM-1 (Fig. 2.63).   
The total population of CD25+ T cells (both activated and regulatory cells) also increased 
from 48,070 ± 13,140 (CD3+ICAM-1) or 27,810 ± 7,057 (CD3+CTLA-4) to 72,710 ± 10,120 
cells through CD3+ICAM-1+CTLA-4 (p < 0.05) (Fig. 2.64).  Functionally suppressive Treg 
cells express CD25 more strongly than activated T cells (66) so we also determined whether the 
MFI of CD25 within the three populations of Treg cells differed and therefore, may reflect 
functional differences.  All three stimulations generated Treg populations that expressed 
equivalently high levels of CD25 (Fig. 2.65).   
 
Cells costimulated through CTLA-4 released soluble CD25 at a higher rate than cells 
costimulated through ICAM-1 or combined stimuli 
In part I, we found that the rate at which cells secreted soluble CD25 (sCD25) was 
greater with CTLA-4 costimulation than ICAM-1.  We wondered whether cells stimulated 
through both ICAM-1 and CTLA-4 would reflect the distinct activity observed by one of these 
costimulatory proteins separately or an intermediate level of activity, reflecting some activity 
from both proteins.  We analyzed the production of sCD25 by cells stimulated through 
CD3+ICAM-1+CTLA-4 compared to CD3+ICAM-1 or CD3+CTLA-4 (Fig. 2.66).  Combined  
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Fig. 2.61 
 
 
Fig. 2.62      Fig. 2.63 
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Figures 2.61-2.63.  Combined stimulation through both ICAM-1 and CTLA-4 augmented 
differentiation to Treg cells.  Human naïve CD4+ T cells stimulated for 7 or 10 days with anti-
CD3+anti-ICAM-1, anti-CD3+anti-CTLA-4 or anti-CD3+anti-ICAM-1+anti-CTLA-4 were 
stained for CD25 and strong Foxp3 expression and analyzed by flow cytometry.   Regulatory T 
cells (Treg cells) are defined as CD4+CD25+Foxp3hi.  Representative of thirteen experiments.  
Supernate was collected for analysis of IL-10 production by ELISA.  Fig. 2.61, Upper right 
quadrant identifies regulatory T cells with cell numbers indicated.  Fig. 2.62, Average number of 
CD4+CD25+Foxp3hi T cells (Treg cells) ± SEM at days 7 or 10. Fig. 2.63, Average production 
of IL-10 pg/ml ± SEM at days 7 or 10.  Representative of nine experiments. 
* p < 0.05, ** p < 0.01 
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Fig. 2.64      Fig. 2.65 
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Figures 2.64-2.65.  Combined stimulation through CTLA-4 and ICAM-1 augmented the 
total CD25+ population.  Human naïve CD4+ T cells stimulated for 7 or 10 days with anti-
CD3+anti-ICAM-1, anti-CD3+anti-CTLA-4 or anti-CD3+anti-ICAM-1+anti-CTLA-4 were 
stained for CD25 and strong Foxp3 expression and analyzed by flow cytometry.  Regulatory T 
cells (Treg cells) are defined as CD4+CD25+Foxp3hi.  Representative of thirteen experiments.  
Fig. 2.64, Average number of CD25+ T cells ± SEM.  Fig. 2.65, Average MFI ± SEM of the 
Treg population. 
* p < 0.05, ** p < 0.01 
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Fig. 2.66 
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Figures 2.66.  Stimulation through CD3+CTLA-4 induced the release of soluble CD25 at a 
higher rate than stimulation through CD3+ICAM-1 or CD3+ICAM-1+CTLA-4.  Human 
naïve CD4+ T cells were stimulated for 7 days with anti-CD3+anti-ICAM-1, anti-CD3+anti-
CTLA-4, and anti-CD3+anti-ICAM-1+anti-CTLA-4.  On day 7, supernate was collected and 
analyzed for sCD25 by ELISA.  The cells were stained for CD25 expression and analyzed by 
flow cytomtery to determine the number of CD25+ T cells.  Production of sCD25 was 
normalized to the number of CD25+ T cells generated in each experiment.  Representative of 7 
experiments. Fig. 2.66, Average sCD25 (pg/ml) produced per CD25+ T cell ± SEM.   
* p < 0.05 
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stimulation through ICAM-1 and CTLA-4 generated 0.45 pg/ml sCD25/CD25+ T cell which 
resembled the rate seen in cells stimulated through CD3+ICAM-1 but was considerably less than 
cells stimulated through CD3+CTLA-4 (Fig. 2.66).  Stimulation through the combined stimuli 
appeared to reflect only the activity seen when cells are costimulated through ICAM-1 rather 
than some activity of cells costimulated through each costimulatory protein.   
 
Differentiation to Treg cells by stimulation through CD3+ICAM-1+CTLA-4 was dependent on 
endogenous levels of IL-2 and resembled IL-2 production induced by ICAM-1 
As we observed in part I, Treg populations generated by costimulation through 
either ICAM-1 or CTLA-4 were dependent on IL-2, but cells stimulated through CTLA-4 
produced minimal IL-2 compared to cells stimulated through ICAM-1 (Fig. 2.26).  We examined 
how the combined stimuli would influence IL-2 production.  High levels of IL-2 were produced 
in cells stimulated through both costimulatory proteins (Fig. 2.67).  The activity of cells 
stimulated through both ICAM-1 and CTLA-4 again resembled the activity of ICAM-1 rather 
than a balance between CTLA-4 and ICAM-1 activity.  We also tested whether Treg 
differentiation induced by the combined stimuli was dependent on endogenous levels of IL-2 
similar to costimulation through the individual stimuli (Fig. 2.68).  As expected, blocking 
endogenous IL-2 reduced the Treg population generated by CD3+ICAM-1+CTLA-4.   
 
Human donor cells varied in their responses to ICAM-1 or CTLA-4 costimulation  
  In Fig. 2.62, the combined effect of stimulation through both CTLA-4 and ICAM-1 on 
Treg differentiation appeared additive.  However, as seen in Fig. 2.68 (“isotype control” bars), 
the effect of the combined stimuli appeared to be synergistic which was observed with certain  
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Fig. 2.67 
 
 
 
 
 
 
 
 
 
Fig. 2.68 
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Figures 2.67-2.68.  Stimulation through CD3+ICAM-1+CTLA-4 produced high levels of 
IL-2 and was dependent on endogenous levels of IL-2 for Treg differentiation.  Human 
naïve CD4+ T cells were stimulated for 7 days with anti-CD3+anti-ICAM-1, anti-CD3+anti-
CTLA-4, or anti-CD3+anti-ICAM-1+anti-CTLA-4.  Supernate was collected for analysis of IL-2 
production by ELISA (Fig. 2.72).  Isotype controls, anti-IL-2 antibody, or anti-IL-10 antibody 
were added to medium at the start of stimulations as indicated.  On day 7, T cells stained for 
CD25 and strong Foxp3 expression were analyzed by flow cytometry.  Treg cells were defined 
as CD4+CD25+Foxp3hi.  Representative of 4 experiments.  Fig. 2.72, Average pg/ml IL-2 ± 
SEM.  Fig. 2.73, Average number of Treg cells ± SEM with added isotype control, anti-IL-2, or 
anti-IL-10.   
* p < 0.05 
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individuals.  To further investigate these differences, we examined the type of dominance 
exerted by costimulation through either ICAM-1 or CTLA-4 to induce differentiation to 
regulatory T cells in every experiment where the three types of stimulation were used 
(CD3+ICAM-1, CD3+CTLA-4 and CD3+ICAM-1+CTLA-4).  Donor cells were classified as 
ICAM-1-dominant, CTLA-4-dominant, or co-dominant depending on the number of Treg cells 
generated through CD3+ICAM-1 compared to CD3+CTLA-4.  The algorithm used is outlined in 
Fig. 2.69.  If the number of Treg cells generated by ICAM-1 was greater than 1.5 fold compared 
to the number of Treg cells generated through CTLA-4, that experiment was classified as ICAM-
1-dominant and vice versa if CTLA-4 costimulation generated 1.5 fold more Treg cells than 
ICAM-1.  If the number of Treg cells induced through ICAM-1 or CTLA-4 costimulation was 
less than 1.5 fold different, then the donor cells were classified as co-dominant (or dominant to 
both costimulatory proteins).  Using this metric, out of 21 experiments analyzed, 9 were ICAM-
1-dominant, 5 were CTLA-4-dominant, and 7 were co-dominant.  Thus, human donor cells 
differed in their ability to respond to these costimulatory proteins.   
 
The consequence of combined stimulation through ICAM-1 and CTLA-4 on Treg induction 
differed greatly depending on the type of dominance exhibited by donor cells 
 We compared the effect of stimulation through CD3+ICAM-1+CTLA-4 on the 
differentiation of naïve T cells to Treg cells among the three different types of dominance 
observed in donor cells.  As described in Fig. 2.69, the fold change in Treg induction was 
determined in ICAM-1-dominant experiments by comparing the number of Treg cells seen with 
CD3+ICAM-1 versus CD3+ICAM-1+CTLA-4.  Addition of anti-CTLA-4 to donor cells 
stimulated through CD3+ICAM-1 resulted in a nearly 6-fold increase in Treg cells (Fig. 2.70),  
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Fig. 2.69 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.70 
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Figures 2.69-2.70.  The effect of the addition of a third stimulus, either anti-CTLA-4 or 
anti-ICAM-1, on Treg cell induction depended on the type of dominance of donor cells.  
Human naïve CD4+ T cells were stimulated for 7 days with anti-CD3+anti-ICAM-1, anti-
CD3+anti-CTLA-4, or anti-CD3+anti-ICAM-1+anti-CTLA-4. On day 7 or 10, T cells stained for 
CD25 and strong Foxp3 expression were analyzed by flow cytometry.  Treg cells were defined 
as CD4+CD25+Foxp3hi.  Representative of 21 experiments (n = 9, ICAM-1-dominant; n = 5, 
CTLA-4-dominant; n = 7, co-dominant or both dominant).  Fig. 2.69, Algorithm developed to 
determine an individual’s dominance in relation to Treg induction by either ICAM-1 or CTLA-4, 
and then subsequently, the fold change in Treg induction by the addition of a third stimulus 
provided by: anti-CTLA-4 (ICAM-1 dominant), anti-ICAM-1 (CTLA-4 dominant), or either 
anti-CTLA-4 or anti-ICAM-1 (BOTH or co-dominant).  Fig. 2.70, Average fold change in Treg 
cell numbers ± SEM induced by CD3+ICAM-1+CTLA-4 compared to either CD3+ICAM-1 or 
CD3+CTLA-4.   
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approximately three times greater than what was seen in Fig. 2.62 when experiments were not 
separated by type of dominance.  In comparison, addition of anti-ICAM-1 to CTLA-4-dominant 
donor cells stimulated through CD3+CTLA-4 reduced the number of Treg cells by four-fold 
compared to costimulation through only CTLA-4 (Fig. 2.70).  If donor cells expressed co-
dominance for Treg cell induction, then the combined effect of CD3+ICAM-1+CTLA-4 showed 
no overall change in the number of Treg cells (BOTH, Fig. 2.70) compared to costimulation 
through either ICAM-1 or CTLA-4 separately.  Therefore, the additive effect seen when all 
experiments are combined does not accurately reflect the consequence of combined stimulation 
through both ICAM-1 and CTLA-4.  ICAM-1 may impair costimulation through CTLA-4 
whereas CTLA-4 may augment costimulation through ICAM-1 under certain circumstances.  
This is important to consider when interpreting data generated through CD3+ICAM-1+CTLA-4.  
These observations also suggest that the mechanism of differentiation to Treg cells by ICAM-1 
and CTLA-4 differ.   
 
The ability of CTLA-4 to modulate differentiation induced by either ICAM-1 or CD28 is 
examined 
In the remaining section of part II, the functional consequence of adding anti-CTLA-4 to 
either ICAM-1 or CD28 costimulation is examined.  Our first goal was to determine whether 
combined stimulation through ICAM-1 and CTLA-4 augments differentiation induced by 
ICAM-1 and thus, resembles the effect observed with Treg differentiation.  Our second goal was 
to assess whether CTLA-4 stimulation can influence differentiation induced by CD28.  In part I, 
stimulation through CD3+CD28+CTLA-4 did not generate Treg cells, indicating inhibition of 
CTLA-4 costimulation by CD28 which was unexpected.  We evaluated other aspects of 
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differentiation to determine whether signaling through CTLA-4 can modulate the differentiation 
process induced by CD28.  In general, costimulation through CTLA-4 was able to modulate the 
differentiation process induced by ICAM-1 and CD28 but did not influence differentiation by 
ICAM-1 and CD28 in the same manner.   
 
Costimulation through CTLA-4 differentially influenced memory and effector differentiation 
We examined differentiation of naïve T cells to effector and memory cells on days 7 and 
14 to examine the questions regarding combined stimuli.  Addition of CTLA-4 stimulation to 
CD28 costimulation enhanced differentiation to memory cells on both days 7 and 14 but 
suppressed differentiation to effector cells (representative figures in Fig. 2.71 and Fig. 2.74, 
summarized in Fig. 2.72-2.73 and Fig. 2.75-2.76), causing a 2.5-fold increase in memory 
differentiation and 2.3-fold decrease in effector differentiation at day 14 (Fig. 2.75-2.76).  In 
contrast, addition of CTLA-4 stimulation to CD3+ICAM-1 enhanced both memory and effector 
differentiation observed on day 7 that disappeared by day 14 (Fig. 2.71-2.73), indicating an 
overall boost in differentiation but not modulation as was observed with CD28.  The number of 
differentiated cells (CD45RO+; includes both memory and effector T cells) on day 7 was 
elevated with CD3+ICAM-1+CTLA-4 but unremarkable by day 14 (Fig. 2.77-2.78), further 
supporting an overall enhancement by CTLA-4 on differentiation induced by ICAM-1 but not 
regulation.  CTLA-4 had no effect on the overall numbers of differentiated cells induced by 
CD28 on either day 7 or 14, indicating that stimulation through CTLA-4 is able to shift 
differentiation induced by CD28 to favor generation of memory cells.  This also supports the 
ability of CTLA-4 to regulate stimulation though CD28, which was not evident in the Treg 
differentiation studies of these costimulatory proteins.   
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Fig. 2.71 
 
 
 
 
 
 
 
 
 
Fig. 2.72      Fig. 2.73 
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Fig. 2.74 
 
 
 
 
 
 
 
 
 
 
Fig. 2.75      Fig. 2.76  
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Figures 2.71-2.76.  CTLA-4 stimulation enhanced differentiation to memory T cells by 
CD28 and augmented differentiation by ICAM-1.  Human naïve CD4+ T cells stimulated for 
7 or 14 days with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-CD28+anti-
CTLA-4, or anti-CD3+anti-ICAM-1+anti-CTLA-4 were stained for CD11a, CD27 and CD45RO 
expression and analyzed by flow cytometry.  Representative of fourteen (CD28) or thirteen 
(ICAM-1) experiments.  Fig. 2.71 and 2.74. representative figures of the number of 
CD4+CD45RO+CD11a+CD27hi T cells (effector T cells, upper right quadrant) and 
CD4+CD45RO+CD11a+CD27lo T cells (memory T cells, lower right quadrant) on day 7 (Fig. 
2.71) or day 14 (Fig. 2.74).  Fig. 2.72 and 2.75, average number of effector T cells ± SEM on 
day 7 (Fig. 2.72) or day 14 (Fig. 2.75).  Fig. 2.73 and 2.76, average number of memory T cells ± 
SEM at day 7 (Fig. 2.73) or day 14 (Fig. 2.76). 
* p <0.05 
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Fig. 2.77 
 
 
 
 
 
 
 
 
 
 
Fig. 2.78 
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Figures 2.77-2.78.  Costimulation through CTLA-4 augmented the overall number of 
differentiated induced by ICAM-1 on day 7 but not CD28.  Human naïve CD4+ T cells 
stimulated for 7 or 14 days with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-
CD28+anti-CTLA-4, or anti-CD3+anti-ICAM-1+anti-CTLA-4 were stained for CD45RO 
expression and analyzed by flow cytometry.  Representative of fourteen (CD28) or thirteen 
(ICAM-1) experiments.  Fig. 2.77. Average number of CD45RO+ T cells ± SEM on day 7.  Fig. 
2.78, Average number of CD45RO+ T cells ± SEM on day 14.   
* p < 0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   125	  
Costimulation through CTLA-4 enhanced proliferation of naïve T cells stimulated through 
ICAM-1 but not CD28 without affecting cell viability 
 Next, we assessed the effect of CTLA-4 on naïve T cell proliferation induced by ICAM-1 
or CD28.  CTLA-4 augmented proliferation induced by costimulation through ICAM-1, 
demonstrating up to a three-fold increase in the percentage of divided cells in some cases (Fig. 
2.79 and 2.81).  Although the addition of anti-CTLA-4 to stimulation through CD3+CD28 
resulted in a statistically significant increase in the percentage of cells that divided at least once, 
this was a modest increase and was not reflected in cells that had divided two more times (Fig. 
2.80).  Overall, CTLA-4 augmented proliferation induced by ICAM-1 but not CD28.  We also 
determined the degree of cell death in these in vitro cultures, and addition of CTLA-4 did not 
affect cell viability with either type of stimulation (data not shown).   
 
CTLA-4 stimulation sustained surface expression of CTLA-4 in cells stimulated through CD28  
 We examined the surface expression of the three costimulatory proteins (CD28, ICAM-1, 
and CTLA-4) to determine whether the surface expression of any was altered during combined 
stimulation and consequently, may affect the degree of stimulation through that protein.  The 
only change in CTLA-4 expression was an increase at 96 hours of combined stimulation through 
CTLA-4 and CD28 (Fig. 2.82).  Expression of CTLA-4 in cells stimulated through ICAM-1 with 
or without CTLA-4 stimulation did not differ (Fig. 2.83).   
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Fig. 2.79 
 
 
 
 
 
 
 
 
Fig. 2.80 
 
 
 
 
 
 
Fig. 2.81 
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Figures 2.79-2.81.  CTLA-4 augmented naïve T cell proliferation induced by costimulation 
through ICAM-1.  Human naïve CD4+ T cells were stained with 2.5 µM CFSE on day 0 and 
stimulated for 7 days with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-
CD28+anti-CTLA-4 or anti-CD3+anti-ICAM-1+anti-CTLA-4.  CFSE dilution was analyzed by 
flow cytometry.  Representative of 4 experiments.  The # of cells divisions along the x-axes 
indicates the percentage of cells that have divided 1 or more times (1+), 2 or more times (2+), 3 
or more times (3+) and so on.  Fig. 2.79, Percentage of divided cells on day 7 indicated.  Fig. 
2.80, Average percentage of divided cells ± SEM comparing CD3+CD28 (open bars) and 
CD3+CD28+CTLA-4 (closed bars).  Fig. 2.81, Average percentage of divided cells ± SEM 
comparing CD3+ICAM-1 (open bars) and CD3+ICAM-1+CTLA-4 (closed bars). 
* p < 0.05 
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Fig. 2.82 
  
 
 
 
 
 
 
 
Fig. 2.83 
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Figures 2.82-2.83.  Costimulation through CTLA-4 sustained expression of CTLA-4 
induced by CD28.  Human naïve CD4+ T cells were stimulated with anti-CD3+anti-CD28, anti-
CD3+anti-ICAM-1, anti-CD3+anti-CD28+anti-CTLA-4 or anti-CD3+anti-ICAM-1+anti-CTLA-
4.  At 2, 4, 24, 48, 72 or 96 hours, cells were analyzed for surface expression of CTLA-4.  
Representative of 4-5 experiments for all timepoints except 96 hour (n = 2).  Fig. 2.82, Average 
MFI of CTLA-4 comparing stimulation through CD3+CD28 and CD3+CD28+CTLA-4.  Fig. 
2.83, Average MFI of CTLA-4 comparing stimulation through CD3+ICAM-1 and 
CD3+ICAM+1+CTLA-4.  
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The addition of CTLA-4 stimulation did not affect expression of ICAM-1 but did significantly 
modulate expression of CD28 in cells costimulated through CD28 
 In Fig. 2.84-2.90, the effect of the addition of CTLA-4 stimulation on surface expression 
of ICAM-1 or CD28 was determined.  Expression of ICAM-1 was unaffected by the addition of 
anti-CTLA-4 to either CD28 or ICAM-1 costimulation (Fig. 2.84-2.85).  However, the addition 
of anti-CTLA-4 maintained higher levels of CD28 expression from 2-72 hours of stimulation in 
cells stimulated through CD28 compared to stimulation in the absence of CTLA-4 (Fig. 2.86-
2.88).  At 96 hours, cells stimulated through CD3+CD28+CTLA-4 exhibited lower CD28 
expression than cells stimulated through CD3+CD28 (Fig. 2.87). The addition of anti-CTLA-4 to 
cells costimulated through ICAM-1 did not alter surface expression CD28 (Fig. 2.89).   
At 96 hours, when CTLA-4 stimulation decreased expression of CD28, it concurrently enhanced 
expression of CTLA-4 in cells stimulated through CD28.  The implications of these expression 
patterns modulated by costimulation through CTLA-4 and are likely to have stark functional 
consequences in vivo.  The functional consequences of these differences in the expression of 
CD28 and CTLA-4 between CD3+CD28 and CD3+CD28+CTLA-4 stimulations warrant further 
investigation. 
 
Costimulation through CTLA-4 combined with either ICAM-1 or CD28 generally did not alter 
expression of activation, migration or differentiation markers at early timepoints 
 The expression of CD69, CD25, CCR7, CD62L, CD45RO and strong CD27 expression 
was assessed at 48 and 96 hours of stimulation through CD3+CD28, CD3+CD28+CTLA-4, 
CD3+ICAM-1 or CD3+ICAM-1+CTLA-4 to determine whether they were any differences 
 
	   131	  
Fig. 2.84 
  
 
 
 
 
 
 
Fig. 2.85 
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Figures 2.84-2.85. Costimulation through CTLA-4 did not alter expression of ICAM-1 
induced by CD28 or ICAM-1.  Human naïve CD4+ T cells were stimulated with anti-
CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-CD28+anti-CTLA-4 or anti-
CD3+anti-ICAM-1+anti-CTLA-4.  2, 4, 24, 48, 72 or 96 hours after stimulation began, cells 
were analyzed for surface expression of ICAM-1.  Representative of 4-6 experiments.  Fig. 2.84, 
Average MFI of ICAM-1 comparing stimulation through CD3+CD28 and CD3+CD28+CTLA-4.  
Fig. 2.85, Average MFI of ICAM-1 comparing stimulation through CD3+ICAM-1 and 
CD3+ICAM+1+CTLA-4.   
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Fig. 2.86 
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Figures 2.86-2.89.  Stimulation through CD3+CD28+CTLA-4 maintained expression of 
CD28 compared to stimulation through CD3+CD28.  Human naïve CD4+ T cells were 
stimulated with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-CD28+anti-
CTLA-4 or anti-CD3+anti-ICAM-1+anti-CTLA-4.  2, 4, 24, 48, 72 or 96 hours after stimulation 
began, cells were analyzed for surface expression of CD28.  Representative of 3-4 experiments.  
Fig. 2.86, Percentage of CD28+ T cells at 48 hours induced through stimulation through 
CD3+CD28 or CD3+CD28+CTLA-4.  Fig. 2.87, Average MFI of CD28 comparing stimulation 
through CD3+CD28 and CD3+CD28+CTLA-4.  Fig. 2.88, Average percentage of CD28+ T 
cells comparing stimulation through CD3+CD28 and CD3+CD28+CTLA-4.  Fig. 2.89, Average 
MFI of CD28 comparing stimulation through CD3+ICAM-1 and CD3+ICAM+1+CTLA-4.   
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induced by the addition of CTLA-4 (summarized in Table 2.2).  Expression of CCR7 was also 
determined on days 7 and 14.  Overall, the addition of anti-CTLA-4 to either ICAM-1 or CD28 
costimulation did not influence the expression of these various markers as summarized in Table 
2.2.  The only effect observed was a slight increase in the percentage of CD25+ T cells at 96 
hours with the addition of anti-CTLA-4 to costimulation through CD28 (Fig. 2.90).   
 
Induction of CD80 and CD86 on T cells followed a similar pattern and level of expression and 
was moderately regulated by the addition of anti-CTLA-4 to costimulation through CD28 
 As mentioned earlier, expression of the counter receptors for CD28 and CTLA-4, CD80 
and CD86, are typically associated with APCs but can be induced in activated T cells.  We 
assessed whether the addition of CTLA-4 stimulation would modulate the expression of these 
ligands on cells stimulated through either CD28 or ICAM-1.  The pattern and degree of CD80+ 
or CD86+ T cells demonstrated a similar pattern and level of expression across 2 to 14 days of 
stimulation regardless of stimulus (Fig. 2.91-2.94).  Addition of anti-CTLA-4 to cells stimulated 
through CD28 induced slightly higher percentages of T cells expressing CD80 or CD86 at 4 and 
10 days but lower percentages at day 14 (Fig. 2.91 and Fig. 2.93).  The addition of anti-CTLA-4 
to cells costimulated through ICAM-1 did not influence expression of CD80 or CD86 (Fig. 2.92 
and Fig. 2.94).  Addition of stimulation through CTLA-4 appeared to modulate the expression of 
the CD80 and CD86 in cells stimulated through CD28 but not ICAM-1.   
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Table 2.2 
 
 
 
 
 
 
 
 
 
 
 
 
        Surface expression analyzed by flow cytometry at 48 and 96 hours of stimulation. 
 
 
Fig. 2.90 
 
 
 
 
 
 
 
 
 CD3+CD28+CTLA-4 
(compared to CD3+CD28) 
CD3+ICAM-1+CTLA-4 
(compared to CD3+ICAM-1) 
CD69 No change No change 
CCR7 No change 
(includes days 7 and 14)  
No change 
(includes days 7 and 14)  
 
CD62L No change No change 
CD25 Increased at 96 hr No change 
CD45RO No change No change 
CD27hi No change No change 
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Table 2.1 and Figure 2.90.  Costimulation through CTLA-4 combined with either ICAM-1 
or CD28 generally did not alter expression of activation, migration or differentiation 
markers.  Human naïve CD4+ T cells were stimulated for 48 or 96 hours with anti-CD3+anti-
CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-CD28+anti-CTLA-4 or anti-CD3+anti-ICAM-
1+anti-CTLA-4 and analyzed for surface expression of CD69, CD25, CCR7, CD62L, CD45RO, 
and strong expression of CD27.  Expression of CCR7 was also assessed at days 7 and 14.  
Representative of 5 experiments for all surface markers except CCR7 (n = 3).  Table 2.1, 
Summarizes observations of the effect on expression of indicated surface proteins by adding 
anti-CTLA-4 to either anti-CD3+anti-CD28 or anti-CD3+anti-ICAM-1.  2.90, Average 
percentage of CD25+ cells ± SEM at 96 hours comparing stimulation through CD3+CD28 to 
CD3+CD28+CTLA-4.  
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Fig. 2.91 
 
 
 
 
 
 
 
 
 
Fig. 2.92 
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Fig. 2.93 
 
 
 
 
 
 
 
Fig. 2.94 
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Figures 2.91-2.94.  Induction of CD80 and CD86 expression on T cells followed a similar 
pattern and level of expression.  Human naïve CD4+ T cells were stimulated for 48 or 96 hours 
or 7, 10 or 14 days with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, anti-CD3+anti-
CD28+anti-CTLA-4 or anti-CD3+anti-ICAM-1+anti-CTLA-4 and analyzed for surface 
expression of CD80 and CD86.  Representative of 3 (48h), 2 (7 or 14d), or 1 (96h or 10d) 
experiment(s).  Fig. 2.91, Average percentage of CD80+ T cells ± SEM comparing stimulation 
through CD3+CD28 and CD3+CD28+CTLA-4.  Fig. 2.92, Average percentage of CD80+ T 
cells ± SEM comparing stimulation through CD3+ICAM-1 and CD3+ICAM-1+CTLA-4.  Fig. 
2.93, Average percentage of CD86+ T cells ± SEM comparing stimulation through CD3+CD28 
and CD3+CD28+CTLA-4.  Fig. 2.94, Average percentage of CD86+ T cells ± SEM comparing 
stimulation through CD3+ICAM-1 and CD3+ICAM-1+CTLA-4.   
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Part II-Interim Summary: CTLA-4 regulated differentiation by ICAM-1 and CD28 differently 
 Our data from Part II of this chapter addressed two questions: 1) whether CTLA-4 could 
modulate differentiation induced by CD28 and 2) whether the mechanisms by which CTLA-4 
and ICAM-1 generate regulatory T cells differ.  Although signaling through CD28 inhibited 
differentiation to Treg cells by CTLA-4 (Part I), costimulation through CTLA-4 regulated 
effector and memory differentiation induced by CD28 by shifting differentiation to favor 
memory cells at the cost of effector cells.  This suggests that an activating cell that receives 
signals from both CD28 and CTLA-4 may be influenced by both stimuli.  The degree to which 
each costimulatory molecule contributes to directing cell fate most likely will depend on the 
relative expression level of CD28, CTLA-4 and their counter receptors, CD80 and CD86.  We 
show that under circumstances where both proteins have equal opportunity to signal, neither one 
was necessarily dominant.  Both influenced differentiation.  CD28 prevented differentiation to 
Treg cells by CTLA-4, and CTLA-4 prevented differentiation to effector T cells by CD28, 
producing a large memory population.  As we have previously published (41, 42), CD28 directs 
cells to Th1 and Th2, and CTLA-4 directed cells to Treg but not Th1 cells in the present work.  
Whether stimulation through CD3+CTLA-4 induces Th2 cells remains to be determined.  Future 
studies should also address whether CTLA-4 combined with CD28 shifts the Th1/Th2 balance. 
 Our observations from combined stimulation through ICAM-1 and CTLA-4 suggest 
distinct mechanisms of Treg induction.  Responses to costimulation through ICAM-1 or CTLA-4 
varied among donors resulting in three types of dominance: ICAM-1-dominance, CTLA-4-
dominance or co-dominance.  Although originally, it appeared that the combined stimulation 
through ICAM-1 and CTLA-4 was additive, separating experiments based on dominance 
resulted in a different interpretation.  Under conditions of ICAM-1 dominance, addition of 
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CTLA-4 stimulation was synergistic, augmenting differentiation to Treg cells by ICAM-1.  In 
CTLA-4-dominant donor cells, though, the addition of ICAM-1 inhibited differentiation to Treg 
cells by CTLA-4.  In the discussion at the end of this chapter, we propose hypotheses for these 
distinct outcomes based on dominance.   
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Part III 
Costimulation through CTLA-4 did not induce differentiation of murine CD4+ T cells to Treg 
cells in the absence of exogenous cytokines 
 In Dr. Kelli William’s dissertation and published work (41, 57), she demonstrated that 
costimulation through ICAM-1 induced differentiation of human naïve CD4+ T cells to Treg 
cells, but that ICAM-1 costimulation failed to induce differentiation of murine CD4+ T cells to 
Treg cells.  Here we tested whether costimulation through CTLA-4 either as a single 
costimulatory molecule or combined with CD28 or ICAM-1 stimulations could generate Treg 
cells in the absence of exogenous cytokines.  Table 2.3 describes the antibody clone and 
concentrations used for these experiments.  Stimulation through CTLA-4 did not generate Treg 
cells regardless of the other stimulus or stimuli (Fig. 2.95-2.97).  In fact, addition of anti-CTLA-
4 to either ICAM-1 or CD28 costimulation was inhibitory (Fig. 2.96-2.97).  Although Dr. 
Williams did not observe Treg induction by ICAM-1 in her murine studies, it did appear that 
both clones of anti-ICAM-1 generated small but recognizable Treg populations, 4% or 6% in the 
representative figure (upper right two panels in Fig. 2.95 and summarized in Fig. 2.97).  
Although no one has demonstrated that costimulation through CTLA-4 in the absence of 
exogenous cytokines can induce Treg differentiation in mice, stimulation through CTLA-4 in 
conjunction with CD28+IL-2+TGF-β has been shown to enhance differentiation of murine naïve 
T cells to Treg cells (38).  This may warrant future studies in which murine naïve CD4+ T cells 
are used instead of the total CD4+ T cell population and multiple anti-mouse CTLA-4 antibodies 
are tested at varying concentrations.   
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Table 2.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stimulating Antibody Clone Concentration (µg/ml) 
Anti-CD3 
 
500A2 0.5 
Anti-CD28 
 
37.51 2.5 
Anti-ICAM-1(KAT) 
 
KAT-1 10 
Anti-ICAM-1(YN1) 
 
YN1/1.7.4 10 
Anti-msCTLA-4 
(anti-murine CTLA-4) 
9H10 20 
Anti-huCTLA-4 
(anti-human CTLA-4) 
BN13 20 
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Fig. 2.95	   
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.96 
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Fig. 2.97 
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Table 2.3 and Figures 2.95-2.97.  Costimulation through CTLA-4 did not induce 
differentiation of splenic CD4+ T cells to regulatory T cells in mice.  CD4+ T cells were 
isolated from the spleens of female C57Bl/6 mice 10 weeks of age and stimulated for 5 days 
using anti-CD3, anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1(KAT), anti-CD3+anti-ICAM-
1(YN1), anti-CD3+anti-msCTLA-4, anti-CD3+anti-huCTLA-4, anti-CD3+anti-
CD28+msCTLA-4, anti-CD3+anti-CD28+huCTLA-4, anti-CD3+anti-ICAM-
1(KAT)+msCTLA-4, anti-CD3+anti-ICAM-1(KAT)+huCTLA-4, anti-CD3+anti-ICAM-
1(YN1)+msCTLA-4, and anti-CD3+anti-ICAM-1(YN1)+huCTLA-4 in the absence of 
exogenous cytokines.  T cells stained for CD25 and strong Foxp3 expression were analyzed by 
flow cytometry.  Representative of 3 experiments each performed in triplicate.  Fig. 2.95, 
Percentage of Treg cells indicated for each stimulation.  Representative positive control (anti-
CD3+anti-CD28+IL-2+TGF-β) to the right of panels with average percentage of Treg cells 
induced from all positive control experiments indicated parenthetically.  Fig. 2.96, Average 
number of Treg cells ± SEM on day 5.  Fig 2.97, Average percentage of Treg cells ± SEM on 
day 5.  Table 2.3, identifies the target protein, clone, and concentration used in all experiments.   
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Discussion:  
Costimulation through CTLA-4 induced differentiation of human naïve CD4+ T cells  
We demonstrate for the first time that costimulation through CTLA-4 in the absence of 
exogenous cytokines induced activation, differentiation and proliferation of human naïve CD4+ 
T cells.  Stimulation through CD3+CTLA-4 generated a Treg population capable of producing 
IL-10 and releasing sCD25 at a high frequency.  In general, costimulation through CTLA-4 was 
weaker than costimulation through CD28 or ICAM-1 on day 7 in the ability to induce 
proliferation, but appeared to be indistinguishable by day 10.  This delay may partially be 
explained by the slower upregulation of CTLA-4 on the surface of activated naïve T cells 
compared to expression of CD28 or ICAM-1.  However, costimulation through CTLA-4 also 
favored differentiation to Treg cells compared to CD28 or ICAM-1 costimulation.  These data 
support a novel mechanism by which CTLA-4 functions as a stimulatory protein to induce Treg 
differentiation, which is consistent with the role of CTLA-4 as a negative regulator of the 
immune response.   
 
CTLA-4 and ICAM-1 may drive differentiation to regulatory T cells by distinct mechanisms 
 The mechanisms by which ICAM-1 and CTLA-4 drive naïve T cell differentiation to 
Treg cells may differ.  Treg cells induced through CTLA-4 but not ICAM-1 were sensitive to 
inhibition by CD28 costimulation.  Cultures stimulated through CD3+CTLA-4 released sCD25 
at a higher frequency than those through CD3+ICAM-1.  Exogenous IL-2 enhanced the number 
of Treg cells induced by costimulation through ICAM-1 but had no effect on the number of Treg 
cells induced by CTLA-4.  Also, costimulation through ICAM-1 generated high levels of IL-2 
and IFN-γ production and greater numbers of activated cells, which was not observed in cells 
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costimulated through CTLA-4.  These observations suggest different pathways of differentiation 
utilized by CTLA-4 and ICAM-1.   
 The outcome of naïve CD4+ T cell differentiation when both ICAM-1 and CTLA-4 were 
engaged (CD3+ICAM-1+CTLA-4) further supports the hypothesis that the mechanism of 
differentiation by these two costimulatory proteins differs.  Combined stimulation through both 
ICAM-1 and CTLA-4 induced higher numbers of activated, effector, memory and regulatory T 
cells compared to stimulation through either costimulatory protein alone.  Cells stimulated 
through either CD3+ICAM-1 or CD3+ICAM-1+CTLA-4 produced roughly equivalent levels of 
IL-10 and IL-2 and released sCD25 at the same frequency.  In contrast, differentiation outcomes 
from stimulation through CD3+CTLA-4 or CD3+ICAM-1+CTLA-4 were routinely not 
equivalent.  Finally, we observed three types of responses by donor cells—ICAM-1 dominance, 
CTLA-4 dominance or co-dominance.  Differentiation outcome from combined stimulation 
through CTLA-4 and ICAM-1 is dictated by responsiveness of donor cells to each costimulatory 
protein separately.  Treg differentiation was greatly augmented by the addition of anti-CTLA-4 
in ICAM-1 dominant cells but reduced by the addition of anti-ICAM-1 in CTLA-4 dominant 
donor cells.  Thus, ICAM-1 appeared to inhibit differentiation to Treg cells by CTLA-4, but 
CTLA-4 augmented differentiation to Treg cells by ICAM-1.  These opposing outcomes between 
the types of dominance support distinct mechanisms of differentiation utilized by each 
costimulatory protein.   
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Hypotheses for the opposing outcomes on Treg differentiation by stimulation through 
CD3+ICAM-1+CTLA-4 
  We hypothesize that ICAM-1 and CTLA-4 use distinct mechanisms to induce 
differentiation to regulatory T cells.  First of all, the two costimulatory proteins may utilize 
different signaling pathways.  Signaling events were not examined in the present study, however, 
so we are unable to determine if this occurs.  Another hypothesis is that costimulation through 
ICAM-1 directs differentiation to Treg cells by inducing a stronger activating signal compared to 
CTLA-4.   Weak costimulation is one proposed mechanism for induction of Treg cells in the 
periphery (67).  We observed that costimulation through CTLA-4 tended to be weaker than 
ICAM-1 or CD28 costimulation, and thus, may induce low levels of activation to direct naïve T 
cells to differentiate into Treg cells.   
The effects of stimulation through CD3+ICAM-1+CTLA-4 on Treg differentiation 
indicate distinct mechanisms utilized by ICAM-1 and CTLA-4.  CTLA-4 can upregulate LFA-1 
adhesion and clustering (68).  One hypothesis to explain the disparate effects on Treg 
differentiation between the three types of dominance may be that CTLA-4 signaling added to 
donor cells that respond well to ICAM-1 costimulation (either ICAM-1 dominant or co-
dominant) upregulates LFA-1.  LFA-1 on the activating T cell may interact with other T cells in 
culture boosting activating signals by its own signaling or by enhancing adhesion, and thus, T 
cell:T cell interactions.  In the ICAM-1 dominant individuals, this may explain the synergistic 
effect of stimulation through CD3+ICAM-1+CTLA-4.  In donor cells that do not respond well 
with ICAM-1 but do respond to CTLA-4, costimulation through CTLA-4 may provide a weak 
costimulatory signal driving naïve T cell differentiation to Treg cells.  However, when ICAM-1 
signaling is present, the stronger activating signals override this weak costimulation preventing 
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differentiation to Treg cells by CTLA-4.  In donor cells that respond well to either ICAM-1 and 
CTLA-4 costimulation, there is no overall change in the Treg numbers induced by CD3+ICAM-
1+CTLA-4.  The aforementioned hypotheses would also explain this observation in co-dominant 
donor cells.  Both mechanisms may be at work in these cultures: CTLA-4 augmenting Treg 
induction by ICAM-1 and ICAM-1 suppressing Treg induction by CTLA-4.  These effects 
counteract each other resulting an overall observation of no change in co-dominant cells.  
 
IL-2 was essential for the differentiation of Treg cells by costimulation through ICAM-1, CTLA-4 
and combined stimulation through both ICAM-1 and CTLA-4 
Regulatory T cells require IL-2 for survival but produce very little IL-2 of their own (69), 
which is consistent with our observation that Treg differentiation was dependent on IL-2 
regardless of stimulus.  The high levels of IL-2 production observed by cells stimulated through 
CD3+ICAM-1 or CD3+ICAM-1+CTLA-4 may have been generated by other T cell populations 
in these cultures.  Th1 cells produce significant amounts of IL-2, and as shown previously (40) 
and verified in chapters 2 and 3 of this dissertation, costimulation through ICAM-1 induces 
differentiation of naïve T cells to Th1 cells.  Costimulation through CTLA-4 favored 
differentiation to Treg cells and did not induce Th1 function.  This may explain the dependency 
of Treg differentiation on IL-2 but low level of IL-2 produced by cells costimulated through 
CTLA-4.  In cultures stimulated through CTLA-4, the ratio of regulatory T cells to conventional 
T cells is higher so any IL-2 being produced is most likely being consumed but not replenished 
by the Treg cells.  The higher frequency at which sCD25 was produced by cells stimulated 
through CD3+CTLA-4 may have also played a role in the low levels of IL-2 production.  These 
	   152	  
data support a role for CTLA-4 as a negative regulator of T cells by activating Treg 
differentiation.   
 
The balance and strength of CTLA-4 and CD28 signaling may influence cell fate 
Our findings concerning CD28 and CTLA-4 costimulation do not conflict with previous 
findings that CTLA-4 may regulate CD28 signaling (14-17).  The addition of anti-CTLA-4 to 
stimulation through CD3+CD28 was unable to induce Treg differentiation, and therefore, CD28 
appeared to suppress the effects of CTLA-4 signaling.  However, if our hypothesis for the 
mechanism of Treg induction by CTLA-4 is correct, then this inhibition by CD28 may be 
explained similar to what happens in CTLA-4-dominant donor cells when anti-ICAM-1 is added.  
Stronger activating signals generated through CD28 costimulation may overcome weak 
costimulation through CTLA-4 that may be central to the mechanism by which CTLA-4 induces 
Treg differentiation.  This would also explain why we observe an effect on memory and effector 
differentiation by CTLA-4 when combined with CD28 but not Treg differentiation.   An increase 
in activating signals provided by CD28 would be unlikely to inhibit generation of memory and 
effector T cells.  In addition, the signaling pathway of CTLA-4 rather than weak costimulation 
may play a greater role in influencing memory and effector differentiation.   
CTLA-4 may regulate effector and memory differentiation.  Stimulation through CTLA-4 
shifting naïve T cell differentiation by CD28 to memory cells rather than activated, effector cells.  
Krummel and Allison proposed that inhibitory signaling through CTLA-4 may protect some T 
cells from activation-induced cell death, supporting the generation of memory T cells (70).  
Although CTLA-4 was initially thought to promote apoptosis (71), later findings revealed that 
CTLA-4 actually provides a protective mechanism against cell death (15, 72, 73), supporting this 
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theory.  Blocking CTLA-4 function in vivo can inhibit the generation of memory cells (74).  It 
appears that CTLA-4 may function in the participation of memory T cell differentiation. 
Our data also refute the conclusion originally drawn from our Treg differentiation studies 
that CD28 is strictly dominant to CTLA-4 since costimulation through CTLA-4 was able to 
modulate effector and memory differentiation by CD28.  Whether stimulation through CTLA-4 
when combined with costimulation through CD28 influences T helper subsets, particularly the 
balance between Th1 and Th2, may warrant further study.  The differentiation outcome of an 
activating naïve T cell may vary depending on the relative expression levels of CTLA-4, CD28 
and the B7 ligands (CD80 and CD86) in the microenvironment because this will influence the 
degree of CD28 and CTLA-4 signaling.  Differences between the engagement of CD80-CTLA-4 
and CD86-CTLA-4 (52) may also alter the type or strength of signaling by CTLA-4, causing 
distinct differentiation outcomes.   
 
Summary 
Costimulation through CTLA-4 induced differentiation of human naïve CD4+ T cells and 
differentially regulated differentiation induced by CD28 and ICAM-1 costimulation.  CTLA-4 
suppressed effector and enhanced memory differentiation induced by CD28, consistent with its 
known ability to regulate the function of CD28.  Our data also suggest a novel stimulatory role 
for CTLA-4 in cells stimulated through CD3+ICAM-1+CTLA-4.  We also show for the first 
time that costimulation of human naïve CD4+ T cells through CTLA-4 induced differentiation to 
regulatory T cells in the absence of exogenous cytokines.  It will be important to further define 
and clarify the function of CTLA-4 in human T cells.  Such studies will be extremely valuable 
predicting efficacy and unwanted side effects of therapeutic treatments used in the clinical 
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setting involving CTLA-4.  Collectively, these findings support a novel role for CTLA-4 in 
human Treg differentiation. 
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Chapter 3 
 
Costimulation of naïve CD4+ T cells through ICAM-1, CD28 or LFA-1 did not induce 
differentiation to Th17 cells 
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Introduction 
 A principal hypothesis under investigation in this laboratory is that the nature of the 
costimulatory signal delivered during naïve T cell activation guides the outcome of 
differentiation to specific cell fates.  T helper 17 (Th17) cells represent an important component 
of host defense against bacterial and fungal pathogens.   These cells promote inflammatory 
responses and are particularly important for host defense in tissues with mucosal epithelia.  
Although many studies have examined the cytokines involved in generating this subpopulation 
from naïve T cells, differential response to costimulatory signaling has not been examined.  In 
this chapter, we examined whether costimulatory proteins in the absence of exogenous cytokines 
could induce the differentiation of naïve T cells into Th17 cells.   
  The role of cytokines in differentiation of naïve T cells to Th17 cells has been well 
studied and is more complex in humans compared to mice.  The addition of TGF-β + IL-6 or IL-
21 to in vitro stimulation generates murine Th17 cells from naïve T cells (1-3).  In humans, 
cytokine polarization of naïve T cells to Th17 cells is less defined, suggesting possibly multiple 
pathways to Th17 differentiation.  Naïve T cells isolated from cord blood can be induced to Th17 
cells by stimulation and addition of exogenous TGF-β+IL-21, TGF-β+IL-23+IL-1β, IL-6 or 
TNF-α, or finally, TGF-β+IL-1β+IL-6, IL-21, or IL-23 (4-6).  Stimulated naïve T cells isolated 
from peripheral blood differentiate to Th17 cells in presence of exogenous IL-1β+IL-6 or IL-
1β+IL-23 (7-8).    
  According to several studies, Th17 cells appear to have a protective role against both 
bacterial and fungal infections beyond that of Th1 and Th2 responses (reviewed in 9).  Th17 
cells secrete IL-17 which is considered the hallmark of this T helper subset (1, 2).  They secrete 
various effector cytokines, including IL-17A, IL-17F, IL-21 and IL-22, which activate numerous 
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cell types to secrete proinflammatory cytokines and chemokines resulting in a robust 
inflammatory response (10-12).  Th17 cells also may play a significant role in autoimmune 
diseases and have been implicated in rheumatoid arthritis (13), multiple sclerosis (14), and 
inflammatory bowel disease (15).  By understanding the biological factors that guide Th17 
generation and function, improved therapies can be developed for treating autoimmunity driven 
by Th17 cells.  Although much work has been done to elucidate the cytokines responsible for 
Th17 differentiation, the influence of costimulatory proteins has not been investigated.  In the 
present study, we found that none of the costimulatory proteins assayed induced differentiation 
of naïve CD4+ T cells to Th17 cells in the absence of exogenous cytokines.   
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Materials and Methods 
Antibodies and reagents 
Antibodies used to stain cells for flow cytometry were: anti-IL-17A-PE (eBioscience), 
anti-IL-17A-APC (eBioscience), anti-CD4-FITC (Invitrogen), anti-CD45RO-FITC (Invitrogen), 
and anti-RORγt-APC.  eBioscience FoxP3 buffers and protocol were used for intracellular 
staining of RORγt and various modifications of this protocol were used for intracellular staining 
of IL-17A.  Monensin or brefeldin A (BD Biosciences) was added to cultures 5-6 hours before 
staining for IL-17A.  Flow cytometry was performed using an Accuri C6 (BD Accuri 
Cytometers, Ann Arbor, MI) and data analysis using CFlow (Accuri).   
 
Human Subjects 
Peripheral blood cells (240 ml into heparin) were obtained after informed consent from 
healthy adult volunteers of both genders, ages 20-30 years, who had been free of infection for 14 
days and did not have immune disorders.  Procedures were approved by the University of Kansas 
Institutional Review Board.   
 
Human naïve CD4+ T cell purification 
Human naïve CD4+ T cells were isolated as described in Chapter 2.  
 
Human Naïve CD4+ T cell stimulation 
Human naïve CD4+ T cells were stimulated through plate-bound antibodies as we have 
previously described (16, 17) and described in Chapter 2.  Anti-LFA-1 (HB202, purified from 
	   170	  
hybridoma) used at 5 µg/ml.  PBMCs were stimulated with PDB (10-6 M) and ionomycin (1 
ug/ml) for 6 hours. 
 
ELISA 
Supernates from stimulated cells were collected for analysis of IL-17A production using 
the Ready-Set-Go! ELISA kit and protocol (eBioscience).  Plates were read at 450 nm using the 
EL311 Microplate Autoreader (Bio-Tek Instruments, Inc., Winooski, VT).   
 
Statistical Analysis 
The one-way, paired student’s t-test was used to determine statistical differences for the 
IL-17A ELISA using GraphPad Prism (GraphPad Software Inc., La Jolla, CA).  
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Results 
 A multiplex assay (n = 1) performed by Drs. Abby Dotson and Kelli Williams revealed 
that naïve T cells costimulated through CD28 produced 120 and 180 pg/ml IL-17 on days 7 and 
14, respectively (18).  Costimulation through ICAM-1 generated less IL-17: 80 and 60 pg/ml on 
days 7 and 14.  Based on this experiment, we examined the possibility that costimulation of 
naïve CD4+ T cells through CD28, ICAM-1 or LFA-1 may induce differentiation to Th17 cells 
by examining the production of IL-17A, the hallmark cytokine of Th17 function.  As expected, 
freshly isolated human naïve CD4+ T cells did not express IL-17A (Fig. 3.1), but we were able 
to induce intracellular expression of IL-17A in PBMCs stimulated with PDB and ionomycin for 
6 hours (Fig. 3.2), indicating that intracellular production of IL-17A could be detected by flow 
cytometry.   
We tested whether costimulatory proteins could induce differentiation of naïve CD4+ T 
cells to Th17 cells by examining production of IL-17 by two methods: flow cytometry and 
ELISA.  Several days were examined for IL-17A production by differentiating naïve T cells: 
days 1 (data not shown, n = 2), 3, 5, 7, 9-10, and 12-14.  As seen in Fig. 3.3-3.5, none of the 
costimulatory proteins (CD28, ICAM-1, or LFA-1) was able to induce production of IL-17A at 
any timepoint during differentiation.  Costimulation through CTLA-4 (n = 1) was also not able to 
generate Th17 cells (data not shown).  Supernates from cultures that were not used for 
intracellular staining were collected and analyzed for IL-17A by ELISA to verify the results 
obtained by flow cytometry.  The highest average IL-17A production observed from any 
costimulatory regimen was 43 pg/ml by cells costimulated through LFA-1 on day 7 (Fig. 3.6).  
No statistically significant differences were observed among the various stimuli.   
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Fig. 3.1 
 
 
 
 
 
 
Fig. 3.2 
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Figures 3.1-3.2.  Expression of IL-17A in naïve CD4+ T cells and stimulated PBMCs.  
Freshly isolated naïve CD4+ T cells or PBMCs were stained for expression of IL-17A.  PBMCs 
were also stained for CD4 and stimulated with PDB and ionomycin for 6 hours to induce 
production of IL-17A.  Fig. 3.1, MFI of IL-17A in naïve CD4+ T cells comparing isotype 
control (black) to staining for IL-17A (red).  Representative of 5 experiments.  Fig. 3.2, 
Comparison of IL-17A expression between freshly isolated PBMCs and PBMCs stimulated 
through PDB.  MFI of IL-17A is indicated for the CD4+IL-17A+ population (upper right 
quadrant).  Representative of two experiments.   
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Fig. 3.3 
 
 
 
 
 
 
 
 
 
Fig. 3.4 
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Fig. 3.5 
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Figures 3.3-3.5.  Costimulation of naïve CD4+ T cells by CD28, ICAM-1 or LFA-1 did not 
induce differentiation to Th17 cells in the absence of exogenous cytokines.  Human naïve 
CD4+ T cells stimulated for 3, 5, 7, 9-10, or 12-14 days with anti-CD3+anti-CD28, anti-
CD3+anti-ICAM-1 or anti-CD3+anti-LFA-1 were stained for expression of CD45RO and IL-
17A and analyzed by flow cytometry.  Representative of 5-6 experiments (CD28 or ICAM-1) or 
3-4 experiments (LFA-1).  Fig. 3.3, MFI of IL-17A in CD45RO+IL-17A+ T cells (upper right 
quadrant) or CD45RO(-)IL-17A+ T cells (lower right quadrant) stimulated through CD3+CD28. 
Fig. 5.4, MFI of IL-17A in CD45RO+IL-17A+ T cells (upper right quadrant) or CD45RO(-)IL-
17A+ T cells (lower right quadrant) stimulated through CD3+ICAM-1. Fig. 3.5, MFI of IL-17A 
in CD45RO+IL-17A+ T cells (upper right quadrant) or CD45RO(-)IL-17A+ T cells (lower right 
quadrant) stimulated through CD3+LFA-1.     
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Fig. 3.6 
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Figure 3.6.  Naïve CD4+ T cells stimulated through CD28, ICAM-1 or LFA-1 produced 
minimal amounts of IL-17A.  Supernates from human naïve CD4+ T cells stimulated for 3, 5, 
7, 9-10, or 12-14 days with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1 or anti-CD3+anti-
LFA-1 were collected and analyzed for production of IL-17A by ELISA.  Representative of 3-10 
experiments (CD28 or ICAM-1; n = 5: day 3; n = 6: day 5; n = 10: day 7; n = 3: days 9-10; n = 4: 
days 12-14) or 2 experiments (LFA-1).  Average pg/ml IL-17A ± SEM with each costimulatory 
regimen as indicated.   
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Discussion 
In this chapter, we extended our ongoing investigation of how the choice of costimulatory 
signal guides differentiation of naïve T cells to various cell fates by examining Th17 
differentiation.  Our data indicate the costimulatory proteins tested (CD28, ICAM-1, LFA-1 and 
CTLA-4) cannot induce differentiation of naïve T cells to Th17 cells in the absence of 
exogenous cytokines.  This could suggest that Th17 differentiation relies more heavily on 
cytokines for polarization than costimulatory signaling.  Alternatively, we have only examined a 
few costimulatory proteins in this study so it is possible that another type of costimulation may 
have a different outcome such as OX40, ICOS, or 4-1BB.  Whether costimulatory proteins can 
induce activation or expansion of Th17 cells from mixed or mature T cell populations in the 
absence of exogenous cytokines could be examined in future studies.  In Chapter 7 (Summary), 
we summarize the data collected from our published and unpublished work on how the various 
costimulatory proteins influence T cell subsets. 
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Chapter 4 
 
Expression and function of CD23 in naïve and mature T cells 
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Introduction 
 According to a recent CDC report (1), 25.7 million people in the U.S. suffer with asthma, 
and it is estimated that 60% of these cases are due to allergic asthma (2).  The humoral immune 
response is mediated by Th2 cells that induce B cells to make antibody (Ab) against the target 
antigen.  IgE is the predominant isotype produced by B cells during a parasitic infection.  In 
individuals with type I hypersensitivity (allergy), this anti-parasitic program is thought to be 
misdirected against non-self antigens, or allergens, that are not generally recognized by the rest 
of the human population (3).    
CD23, the low affinity IgE receptor, is expressed by a number of cells including: 
monocytes, macrophages, eosinophils, intestinal epithelia, follicular dendritic cells, B cells and T 
cells (4-7).  CD23 is upregulated on B cells in response to IL-4 and influences the IgE response 
by regulating class-switching and production of IgE by B cells through a complex system that is 
still being elucidated (8-10).  Dr. Marcia Chan (Children’s Mercy Hospital, Kansas City, MO) 
has been investigating the role of CD23 in B cell function in pediatric patients with allergic 
asthma.  Single nucleotide polymorphisms (SNPs) in the fcεr2 gene that encode CD23 have been 
associated with atopy and high IgE levels in serum (11-13).  One particular SNP in the fcεr2 
gene that is associated with a relatively high incidence of atopy causes a tryptophan residue to 
replace an arginine residue at amino acid 62 (R62W) (13).  Dr. Chan is currently investigating 
the participation of this SNP (R62W) in IgE-mediated allergic responses in asthmatics and how 
this SNP influences the function of B cells in these patients.   
Despite the upregulation of CD23 on T cells in response to mitogenic stimuli, exogenous 
IL-4 or allergens (5, 6, 14-16), neither the function of CD23 on T cells nor the expression of 
CD23 on human naïve CD4+ T cells has been determined.  Based on the role of Th2 cells in 
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mediating the IgE response and the regulation of IgE synthesis by CD23, we hypothesized that 
engagement of CD23 by IgE on T cells may function to induce the Th2 response.  Therefore, we 
propose that IgE:CD23 complexes on T cells enhance Th2 responses to either appropriately 
targeted parasites or inappropriately targeted allergens in atopic individuals.  We used our in 
vitro system of activation and differentiation (17-19) to model how stimulation through CD23 
would modulate naïve and mature T cells in healthy individuals (part I) compared to atopic 
individuals with asthma (part II).  We hypothesize that CD23 may function to exaggerate the Th2 
response in patients with allergic asthma compared to healthy controls.  Much of the data 
presented in this chapter are preliminary, and additional studies should clarify any tentative 
conclusions drawn.  
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Materials and Methods 
Antibodies and reagents 
Antibodies used to stain cells for flow cytometry were: anti-CD11a-FITC (BD 
Biosciences), anti-CD27-PE (Invitrogen), anti-CD27-PECy5 (eBioscience), anti-CD45RO-APC 
(Invitrogen), anti-CD45RO-Tri Color (Invitrogen), anti-Foxp3-PE (Miltenyi Biotec), anti-Gata3-
PE (eBioscience), anti-Tbet (eBioscience), anti-phosphoERK1/2-Alexa Fluor 488 (Cell 
Signaling), anti-CD23-APC (eBioscience) and anti-CD25-Tri Color (Invitrogen).  eBioscience 
Foxp3 buffers and protocol were used for intracellular staining of CD23, Foxp3, Tbet, and 
Gata3.  Staining cells with CFSE and flow cytometry were performed as described in Chapter 2. 
 
Human Subjects 
Peripheral blood (240 ml into heparin) was obtained after informed consent from healthy 
adult volunteers of both genders, ages 20-30 years, who had been free of infection for 14 days 
and did not have immune disorders for Part I.  Peripheral blood cells (15-20 ml into heparin) 
were obtained after informed consent from allergic asthma patients, ages 16-17 years for Part II.  
Procedures were approved by the University of Kansas Institutional Review Board. 
 
Human naïve CD4+ T cell purification (240 ml) 
Human naïve CD4+ T cells were isolated as described in Chapter 2.  
 
Human CD45RO+ T cell purification 
 PBMCs were isolated as described in Chapter 2.  T cells were e-rosetted with sheep red 
blood cells as previously described (20), and then negatively selected for CD45RO+ T cells by 
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combining the use of Human CD45RA Tetramer (15 minutes at RT) followed by magnetic 
colloid (15 minutes at RT) (STEMCELL Technologies).   
 
Human T cell stimulation (for cells from 240 ml peripheral blood) 
Human naïve CD4+ naïve T cells or mature CD45RO+ T cells were stimulated through 
plate-bound antibodies as we have previously described (17, 19).  Same clones and 
concentrations were used as described in Chapter 2.  Anti-CD23 (Bu38) was used at 10 µg/ml 
(Ancell).  Exogenous cytokines were added at the start of stimulation for select experiments.  
Recombinant human cytokine TGF-β1 (R&D Systems) was used at 10 ng/ml, IL-2 (Boehringer 
Mannheim) at 10 U/ml, and IL-4 (R&D Systems) at 1 ng/ml.  
 
Modified T cell stimulation for cells from 15-20 ml peripheral blood 
 The same concentration and method of stimulation was used as described above with 
some modifications for a low blood volume.  Flat-bottom 384-well plates were used instead of 
96-well plates.  Immediately after plating antibodies (60 µl/well), plates were centrifuged at 800 
RPM briefly and then incubated at 37°C for 2-3 hours.  After washing the plates with sterile 
PBS, cells were plated at 1.25 x106 cells/ml (75,000 cells/well) in 60 µL complete RPMI 1640.  
Plates were centrifuged again at 800 RPM briefly prior to addition of exogenous cytokines and 
incubation. 
 
Intracellular staining of phosphorylated ERK 
 At the indicated timepoints, 4% formaldehyde in staining buffer (0.5% BSA in PBS) was 
added to wells for a final concentration of 2% formaldehyde.  Cells were incubated for 10 
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additional minutes at 37°C.  Once transferred to Eppendorf tubes for intracellular staining, cells 
were washed and permeabilized in 90% methanol for 30 minutes on ice.  Cells were washed 
twice with staining buffer and resuspended in 100 µl staining buffer.   Cells were incubated in 
staining buffer with anti-phospho-ERK-Alexa Fluor 488 (2.5 µl/test) for 1 hour at RT in the 
dark, washed and finally resuspended in staining buffer for collection by flow cytometry. 
 
Statistical Analysis 
The one-way, paired student’s t-test was used to determine statistical differences unless 
otherwise indicated.  All statistical analysis was performed using GraphPad Prism (GraphPad 
Software Inc., La Jolla, CA).  
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Results 
Part I: Characterization and function of CD23 in T cells from healthy subjects 
Costimulatory proteins induced moderate levels of CD23 expression that is enhanced by 
exogenous IL-4 
We first sought to determine the expression level and patterns of CD23 using our in vitro 
model of naïve T cell differentiation (17, 19).  Resting T cells do not express CD23 (5, 6).  As 
expected, freshly isolated naïve CD4+ T cells did not express surface or intracellular CD23 (Fig. 
4.1), but expression could be induced by stimulation through either CD3+CD28 or CD3+LFA-1 
(CD11a) in the absence of exogenous cytokines (Fig. 4.2).  Costimulation through CD28 or 
LFA-1 induced moderate expression of CD23 on naïve CD4+ T cells with highest expression at 
day 7 (CD28) or day 5 (CD11a).  Stimulation through the CD3 or CD3+ICAM-1 did not increase 
expression of CD23 above baseline (day 0) levels.   
Studies on mature T cells populations have shown that the addition of IL-4 can augment 
expression of CD23 (5).  In naïve CD4+ T cells, with all stimuli except CD3+LFA-1, addition of 
IL-4 increased the degree of CD23 expression with most robust upregulation of CD23 observed 
on day 7 (Fig. 4.3-4.7).  Although costimulation through LFA-1 appeared to induce high levels 
of CD23 expression (Fig. 4.2), results were inconsistent with subsequent experiments and LFA-1 
routinely resulted in fewer cells possibly to increased cell death (Fig. 4.3).  Therefore, for the 
remaining experiments, we eliminated stimulation through CD3+LFA-1.  We also examined 
expression of CD23 on cells stimulated through CD3+CD23, CD3+ICAM-1+CD23 or 
CD3+CD28+CD23, but were unable to detect any surface expression of CD23 when stimulating  
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 4.2 
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Figures 4.1-4.2. Stimulation of human naïve CD4+ T cells in the absence of exogenous 
cytokines was sufficient to induce moderate levels of CD23 expression.  Human naïve CD4+ 
T cells stimulated for 3, 4, 5, 7 or 10 days with anti-CD3, anti-CD3+anti-CD28, anti-CD3+anti-
ICAM-1 or anti-CD3+anti-CD11a were analyzed for expression of CD23 by flow cytometry.  
CD23 expression was also assessed on freshly isolated naïve CD4+ T cells (Day 0).  Fig. 4.1, 
Surface (left panel, n = 6) or intracellular (right panel, n = 3) expression of CD23 in human naïve 
CD4+ T cells.  Fig. 4.2. Average MFI of CD23 ± SEM.  Representative of 3-7 independent 
experiments.   
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Fig. 4.3 
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Figures 4.3-4.7.  Addition of exogenous IL-4 enhanced expression of CD23 by 
differentiating naïve T cells.  Human naïve CD4+ T cells stimulated for 3, 4, 5, 7 or 10 days 
with anti-CD3, anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1 or anti-CD3+anti-CD11a in the 
presence or absence of IL-4 (1 ng/ml) were analyzed for expression of CD23.  Cells were also 
analyzed at day 0 for CD23 expression.  Representative of 3-7 independent experiments.  Fig. 
4.3, histogram plots of CD23 expression of cells stimulated as indicated without exogenous IL-4 
(black line) or with exogenous IL-4 (red line) on day 7.  Fig. 4.4-4.7 average MFI ± SEM at 3, 4, 
7 and 10 days with each costimulatory regimen with or without the addition of exogenous IL-4. 
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through CD23 (data not shown).  This may reflect an inhibition of CD23 expression by CD23 
stimulation or that the stimulating antibody engaging CD23 interferes with the binding of the 
detection anti-CD23 antibody.  Future studies examining mRNA expression may help resolve 
this issue.    
 
Costimulation through CD23 did not provide a second signal for proliferation or differentiation 
of human naïve CD4+ T cells 
The ability of naïve T cells to express CD23 upon activation and differentiation suggests 
that CD23 will serve a functional purpose in these cells.  We tested whether CD23 can function 
as a costimulatory molecule in human naïve CD4+ T cells when combined with stimulation 
through the TCR.  Naïve T cells stimulated through CD3+CD23 did not proliferate (Fig. 4.8-
4.9), differentiate to effector or memory T cells (Fig. 4.10-4.12), express Th1 or Th2 
transcription factors, Tbet and Gata3, respectively (Fig. 4.13-4.16), or differentiate to regulatory 
T cells (Fig. 4.17-4.18).  Overall stimulations through CD3 or CD3+CD23 were unremarkable in 
all assays.  CD23, therefore, did not function independently as a costimulatory protein to induce 
human naïve T cell proliferation or differentiation.   
 
Addition of stimulation through CD23 enhanced proliferation though ICAM-1 but not CD28 
costimulation 
 Next, we tested our hypothesis that CD23 regulates naïve T cell differentiation by 
supporting Th2 function but not Th1, thus stimulating cells to produce IL-4 and promote IgE-
driven responses in an allergic reaction.  We compared the effects of adding stimulation through 
CD23 to two models of differentiation: CD3+CD28 and CD3+ICAM-1.  Addition of anti-CD23 
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Fig. 4.8 
         
 
 
 
 
 
 
Fig. 4.9 
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Figures 4.8-4.9.  Costimulation through CD23 did not stimulate proliferation of naïve T 
cells. Human naïve CD4+ T cells were stained with 2.5 µM CFSE on day 0 and stimulated for 7 
days with anti-CD3 or anti-CD3+anti-CD23 were analyzed for CFSE dilution.  Representative of 
four experiments.  Fig. 4.8, Percentage of divided cells with number of divided cells indicated 
parenthetically.  Fig. 4.9, Average number of divided cells ± SEM.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   197	  
Fig. 4.10        
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Figures 4.10-4.12.  Costimulation through CD23 did not induce naïve CD4+ T cells to 
differentiate to effector or memory cells.  Human naïve CD4+ T cells stimulated for 7 or 14 
days with anti-CD3 or anti-CD3+anti-CD23 were stained for expression of  CD45RO, CD27, 
and CD11a and analyzed by flow cytometry.  Effector T cells were defined as 
CD4+CD45RO+CD11a+CD27hi, and memory T cells as CD4+CD45RO+CD11a+CD27lo.  
Representative of two experiments.  Fig. 4.10, representative figure of the number of effector T 
cells (upper right quadrant) and memory T cells (lower right quadrant) on day 7.  Fig. 4.11, 
Average number of effector or memory T cells ± SEM on day 7.  Fig. 4.12, Average number of 
effector or memory T cells ± SEM on day 14. 
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Fig. 4.13      Fig. 4.14 
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Figures 4.13-4.16.  Costimulation through CD23 did not induce expression of the 
transcription factors, Gata3 (Th2) or Tbet (Th1).  Human naïve CD4+ T cells stimulated for 7 
or 10 days with anti-CD3 or anti-CD3+anti-CD23 were stained for expression of CD45RO and 
Gata3 (Fig. 4.13-4.14) or CD45RO and Tbet (Fig. 4.15-4.16) and analyzed by flow cytometry.  
Representative of 5 (Fig. 4.13-4.14) or 3 (Fig. 4.15-4.16) experiments.  Fig. 4.13 and Fig. 4.15, 
Representative figure indicating the percentages of each population.  Fig. 4.14, Average MFI of 
Gata3 ± SEM. Fig. 4.15, Average MFI of Tbet ± SEM. 
 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
	   201	  
Fig. 4.17 
       
 
        
 
 
 
 
Fig. 4.18 
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Figures 4.17-4.18.  Costimulation through CD23 did not support the differentiation of naïve 
T cells to regulatory T cells.  Human naïve CD4+ T cells stimulated for 7 days with anti-CD3 
or anti-CD3+anti-CD23 were stained for CD25 and strong Foxp3 expression and analyzed by 
flow cytometry.  Representative of 4 experiments.  Fig. 4.17, percentage of regulatory T cells 
(CD4+CD25+Foxp3hi, upper right quadrant) generated at day 7 with each stimulation.  Fig. 4.18, 
average number of Treg cells ± SEM at day 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   203	  
to cells costimulated through CD3+ICAM-1 enhanced the number of cells that had proliferated 
from 7,107 ± 2,199 to 18,726 ± 8,050 but did not influence the degree of proliferation by cells 
stimulated through CD3+CD28 (Fig. 4.19-4.20).  Responses of donor cells to costimulatory 
proteins can vary greatly.  The degree of proliferation induced by CD28 in these two experiments 
was uncharacteristically low so further studies are needed to determine how addition of CD23  
stimulation influences cells that exhibit the typical proliferation activated by CD3+CD28.  We 
also examined the amount of cell death in cultures where anti-CD23 was added to either 
CD3+CD28 or CD3+ICAM-1.  In this one experiment (Fig. 4.21), stimulation through CD23 
enhanced cell death in cells costimulated through CD28 but not ICAM-1.  Thus far, CD23 
differentially regulated costimulation through CD28 and ICAM-1 resulting in distinct outcomes 
on proliferation and cell viability. 
 
Addition of stimulation through CD23 exerted opposing effects on differentiation induced though 
CD28 and ICAM-1 costimulation 
 As we have frequently observed in our lab, both CD28 and ICAM-1 induce 
differentiation of human naïve CD4+ T cells to effector and memory T cells.  We tested whether 
stimulation CD23 would shift the differentiation process by these costimulatory proteins to favor 
either effector or memory cells.  On day 7, addition of CD23 to cells stimulated through 
CD3+CD28 decreased differentiation to both effector and memory cells from 6,846 ± 1,635 to 
2,027 ± 453 effector T cells and from 3,534 ± 2,256 to 754 ± 325 memory T cells (Fig. 4.22-
4.24).  CD23 did not appear to inhibit effector and memory differentiation at 14 days to the 
degree observed on day 7 which may be a result of the two experiments of day 14 not generating 
robust differentiation by CD28 costimulation (Fig. 4.25-4.26).  Additional experiments should  
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Fig. 4.19 
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Figures 4.19-4.21.  Stimulation through CD23 enhanced proliferation of naïve T cells 
costimulated through ICAM-1 but not CD28.  CD23 may enhance cell death in cells 
costimulated through CD28.  Human naïve CD4+ T cells were stained with 2.5 µM CFSE on 
day 0 and stimulated for 7 days with anti-CD3+anti-CD28, anti-CD3+anti-CD28+anti-CD23, 
anti-CD3+anti-ICAM-1 or anti-CD3+anti-ICAM-1+anti-CD23 and analyzed for CFSE dilution 
or expression of Annexin V and 7-AAD on day 7.  Representative of three (ICAM-1) or two 
(CD28) experiments (Fig. 4.19-4.20) or 1 experiment (Fig. 4.21).  Fig. 4.19, Percentage of 
divided cells with number of divided cells indicated parenthetically.  Fig. 4.20, Average number 
of divided cells ± SEM.  Fig. 4.21, Percentage of Annexin V+7-AAD+ cells on day 7. 
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Fig. 4.22 
 
 
 
 
 
 
 
 
           
Fig. 4.23     Fig. 4.24 
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Fig. 4.25     Fig. 4.26 
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Figures 4.22-4.26.  Costimulation through CD23 suppressed effector and memory 
differentiation induced by CD28 costimulation but not ICAM-1 costimulation. Human naïve 
CD4+ T cells stimulated for 7 or 14 days with anti-CD3+anti-CD28, anti-CD3+anti-CD28+anti-
CD23, anti-CD3+anti-ICAM-1 or anti-CD3+anti-ICAM-1+anti-CD23 were stained for 
expression of CD45RO, CD27, and CD11a and analyzed by flow cytometry.  Effector T cells 
were defined as CD4+CD45RO+CD11a+CD27hi, and memory T cells as 
CD4+CD45RO+CD11a+CD27lo.  Representative of two (day 14) or three (day 7) experiments.  
Fig. 4.22, representative figure of the number of effector T cells (upper right quadrant) and 
memory T cells (lower right quadrant) on day 7.  Fig. 4.23, Average number of effector T cells ± 
SEM on day 7.  Fig. 4.24, Average number of memory T cells ± SEM on day 7.  Fig. 4.25, 
Average number of effector T cells ± SEM on day 14.  Fig. 4.26, Average number of memory T 
cells ± SEM on day 14. 
* p < 0.05 
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resolve this issue.  In contrast to CD28 costimulation, the addition of CD23 did not inhibit 
efffector and memory differentiation stimulated through CD3+ICAM-1 (Fig. 2.22-2.26).  CD23 
appears to exert inhibitory effects on costimulation induced by CD28 but not ICAM-1. 
 
Stimulation through CD23 inhibited expression of both Gata3 and Tbet in cells costimulated 
through CD3+CD28 
 Our data on proliferation and differentiation of effector and memory cells suggest that 
CD23 inhibits differentiation induced by CD28 signaling but not ICAM-1.  In our in vitro model 
of differentiation, costimulation through CD28 generates both Th1 and Th2 cells whereas 
costimulation through ICAM-1 induces Th1 and Treg cells but not Th2 (17-19).  The inhibitory 
effects of anti-CD23 when combined with CD28 costimulation may be due to a selective 
inhibition of Th2 differentiation that is not seen in cultures stimulated through ICAM-1 because 
stimulation through ICAM-1 does not induce Th2 cells.  We tested whether the inhibition by 
CD23 was selective for Th1 or Th2 function by staining for the transcription factors, Gata3 (Th2) 
and Tbet (Th1).  The addition of anti-CD23 to stimulation through CD3+CD28 caused 
significant decreases in the expression of both Gata3 and Tbet (Fig. 4.27-4.30).  Gata3 (Th2) and 
Tbet (Th1) expression were reduced by nearly 2-fold and 3-fold, respectively, comparing 
stimulation through CD3+CD28 to CD3+CD28+CD23 (Fig. 4.28 and Fig. 4.30).  Addition of 
anti-CD23 did not affect expression of Gata3 or Tbet in cells stimulated through ICAM-1, 
though (Fig 4.27-4.30).  Thus, inhibition by CD23 is selective to costimulation through CD28 
and may suppress both Th1 and Th2 differentiation.  We plan to analyze supernates for 
production of Th1 and Th2 cytokines in these cultures to verify modulation of Th1 and Th2 cells.   
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Fig. 4.27 
        
 
 
 
 
 
Fig. 4.28 
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Figures 4.27-4.28.  Costimulation through CD23 inhibited expression of the Th2 associated 
transcription factor, Gata3 (Th2), in cells costimulated through CD28 but not ICAM-1.  
Human naïve CD4+ T cells stimulated for 7 or 10 days with anti-CD3+anti-CD28, anti-
CD3+anti-CD28+anti-CD23, anti-CD3+anti-ICAM-1 or anti-CD3+anti-ICAM-1+anti-CD23 
were stained for Gata3 expression and analyzed by flow cytometry.  Representative of 5 (CD28) 
or 4 (ICAM-1) experiments.  Fig. 4.27,  MFI of Gata3 in cells stimulated through CD3+CD28 or 
CD3+ICAM-1 without stimulation through CD23 (black lines) or with stimulation through 
CD23 (red lines) at day 7.  Fig. 4.28, Average MFI of Gata3 ± SEM on days 7 or 10.  
** p < 0.01 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
	   212	  
Fig. 4.29        
 
 
 
 
 
 
Fig. 4.30 
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Figures 4.29-4.30. Costimulation through CD23 inhibited expression of the Th1 associated 
transcription factor, Tbet, in cells costimulated through CD28.  Human naïve CD4+ T cells 
stimulated for 7 or 10 days with anti-CD3+anti-CD28, anti-CD3+anti-CD28+anti-CD23, anti-
CD3+anti-ICAM-1 or anti-CD3+anti-ICAM-1+anti-CD23 were stained for Tbet expression and 
analyzed by flow cytometry.  Representative of 4 (CD28) or 3 (ICAM-1) experiments.  Fig. 4.29,  
MFI of Tbet of cells stimulated through CD3+CD28 or CD3+ICAM-1 without stimulation 
through CD23 (black lines) or with stimulation through CD23 (red lines) at day 7.  Fig. 4.30, 
Average MFI of Tbet ± SEM on days 7 or 10.  
** p < 0.01 
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Costimulation through CD23 may support differentiation to Treg cells 
 Next, we tested whether the other subset of T cells generated through ICAM-1 
costimulation would be affected by the addition of stimulation through CD23.  At 7 days, 
stimulation through CD3+ICAM-1+CD23 did not enhance the number of regulatory T cells (Fig. 
4.31); however, the percentage of Treg cells was slightly increased by the addition of CD23 (p = 
0.17) (Fig. 4.32).  Repeated experiments will be required to determine if CD23 can enhance 
differentiation to Treg cells induced by costimulation through ICAM-1 due to donor variability.   
 IL-4 supports differentiation to Th2 cells, and the combination of IL-2 and TGF-β 
induces differentiation to Treg cells.  We examined the effect of CD23 stimulation on 
differentiation to Treg cells under these two different polarizing conditions, adding either 
exogenous IL-4 (n = 2) or the combination of IL-2 and TGF-β (n = 1).  The addition of 
exogenous IL-4 when CD23 stimulation is combined with CD28 appears to augment or induce 
differentiation of naïve T cells to Treg cells (Fig. 4.33).  This observation that CD23 may induce 
Treg cells in the presence of high levels of IL-4 is intriguing and seems consistent with the 
inhibitory effects observed when combined with CD3+CD28 stimulation.  In the absence of 
exogenous cytokines, addition of CD23 enhanced Treg differentiation by ICAM-1, but adding 
IL-4 to this stimulation inhibited Treg differentiation (Fig. 4.33).  Stimulation through CD23 
does not influence Treg differentiation in the presence of exogenous IL-2 and TGF-β (data not 
shown).  We also examined the expression of CD23 and the receptor for IL-4 (IL-4R) on 
peripheral T cells stimulated in the presence of IL-2 and TGF-β to determine if CD23 or IL-4 
may be involved in the induction of Treg cells under classic polarizing cytokines.  Stimulation of 
total peripheral T cells (CD4+ and CD8+) through either CD3+CD28 or CD3+ICAM-1 in the  
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Fig. 4.31 
        
 
 
 
 
 
 
Fig. 4.32 
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Figures 4.31-4.32.  Costimulation through CD23 did not alter the differentiation of naïve T 
cells to Treg cells by either CD28 or ICAM-1 costimulation in the absence of exogenous 
cytokines.  Human naïve CD4+ T cells stimulated for 7 or 10 days with anti-CD3+anti-CD28, 
anti-CD3+anti-CD28+anti-CD23, anti-CD3+anti-ICAM-1 or anti-CD3+anti-ICAM-1+anti-
CD23 were stained for CD25 and strong Foxp3 expression and analyzed by flow cytometry.  
Representative of 3 (CD28) or 4 (ICAM-1) experiments.  Fig. 4.31, average number of Treg 
cells ± SEM at day 7.  Fig. 4.32, average percentage of Treg cells ± SEM at day 7.  
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Fig. 4.33 
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Figure 4.33.  Stimulation through CD23 may induce Treg differentiation in the presence of 
high levels of IL-4.  Human naïve CD4+ T cells stimulated for 7 days with anti-CD3+anti-
CD28, anti-CD3+anti-CD28+anti-CD23, anti-CD3+anti-ICAM-1 or anti-CD3+anti-ICAM-
1+anti-CD23 in the presence of absence of IL-4 (1 ng/ml).  On day 7, cells were stained for 
CD25 and strong Foxp3 expression and analyzed by flow cytometry.  Representative of 2 
experiments.  Percentage of Treg cells indicated with Treg numbers parenthetically. 
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Fig. 4.34 
 
 
 
 
 
 
Fig. 4.35 
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Figure 4.34-4.36. Treg expansion induced by classical polarizing conditions did not yield 
CD23+ or IL-4R+ cells.  E-rosetted peripheral T cells were stimulated for 48 hours with either 
anti-CD3+anti-CD28 or anti-CD3+anti-ICAM-1 in the presence of exogenous IL-2 (10 U/ml) 
and TGF-β (10 ng/ml) to expand the Treg population.  At 48 hours, cells stained for CD25, 
CD23, IL-4R and strong Foxp3 expression were analyzed by flow cytometry.  Representative of 
1 experiment.  Fig. 4.34, Number of Treg cells with cell numbers indicated.  Fig. 4.35, Number 
of Foxp3hiCD23(-) T cells (upper left quadrant), Foxp3hiCD23+ T cells (upper right quadrant), or 
Foxp3lo-intermediateCD23+ T cells (lower right quadrant).  Fig. 4.36, Dot plot of CD25 vs. IL-4R 
expression.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   221	  
presence of exogenous IL-2 and TGF-β did not generate CD23+ or IL-4R+ T cells in the Treg or 
total T cell population (Fig. 4.34-4.36).  
 
Signaling through CD23 may induce a transient activation of ERK in cells costimulated through 
ICAM-1 
 We examined whether early signaling events were affected by stimulation through CD23 
and may account for the differential effects on differentiation outcome observed between CD28 
and ICAM-1 costimulation.  Phosphorylation of ERK was determined at 5, 10, 30, and 60 
minutes of stimulation with and without anti-CD23.  CD23 did not alter phosphorylation events 
induced by CD28 (Fig. 4.37-4.39).  In contrast, combined with costimulation through ICAM-1, 
CD23 stimulated an increase in ERK activation at 30 minutes and possibly a modest increase at 5 
minutes (Fig. 4.37-4.39).  Repeated studies will determine whether this is a consistent finding, 
but the increase in phosphorylation of ERK in cells costimulated through CD3+ICAM-1+CD23 
is consistent with the supportive role of CD23 in ICAM-1 costimulation observed in other 
experiments.     
 
CD23 was expressed by both CD45RA and CD45RA(-) T cell populations through 7-10 days of 
stimulation 
 We examined the expression of CD23 and the CD45 isoforms, CD45RO (mature T cells) 
and CD45RA (naïve T cells), to determine what type of cells may be responding to stimulation 
through CD23 in our differentiation model.  CD45RA+CD23+ and CD45RA(-)CD23+ T cells 
were determined at 3, 4, 5, 7, and 10 days of stimulation in the presence and absence of 
exogenous IL-4 (Fig. 4.40-4.42).  CD23+ T cells included both CD45RA+ and CD45RA(-)  
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Fig. 4.37 
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Fig. 4.38 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.39 
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Figures 4.37-4.39.  Signaling through CD23 may induce a transient activation of cells 
costimulated through ICAM-1 by the phosphorylation of ERK. 
Human naïve CD4+ T cells stimulated for 5, 10, 30 or 60 minutes with anti-CD3+anti-CD28, 
anti-CD3+anti-CD28+anti-CD23, anti-CD3+anti-ICAM-1, anti-CD3+anti-ICAM-1+anti-CD23, 
anti-CD3 or anti-CD3+anti-CD23 were analyzed for phosphorylated ERK.  Cells were also 
analyzed at 0 minutes before stimulations began (MFI: 515).  Representative of 1 experiment.  
Fig. 4.37, histogram plots of phosphorylated ERK at 5, 10, 30 or 60 minutes of cells stimulated 
through CD3+CD28, CD3+ICAM-1 or CD3 (black lines) or CD3+CD28+CD23, CD3+ICAM-
1+CD23 or CD3+CD23 (red lines).  MFI for cells stimulated through CD23 are indicated in red 
and those not stimulated through CD23 are indicated in black.  Fig. 4.38, MFI of phosphorylated 
ERK in cells with each costimulatory regimen.  Fig. 4.39, Percentage of cells containing 
phosphorylated ERK with each costimulatory regimen. 
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Fig. 4.40 
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Fig. 4.41 
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Figures 4.40-4.42.  Both CD45RA+ and CD45RA(-) T cells expressed CD23 with peak 
expression for both populations on day 7.  Human naïve CD4+ T cells stimulated for 3, 4, 5, 7 
or 10 days with anti-CD3+anti-CD28 or anti-CD3+anti-ICAM-1 in the presence or absence of 
IL-4 (1 ng/ml) were analyzed for expression of CD23 and CD45RA.  Cells were also analyzed at 
day 0 for CD23 expression before stimulations began.  Representative of 3-7 independent 
experiments.  Fig. 3.40, number of CD4+CD23+CD45RA+ (upper right quadrant and 
CD4+CD23+CD45RA(-) (lower right quadrant) T cells at day 5 with each costimulatory 
regimen.  Fig., 4.41, average number ± SEM of CD4+CD23+CD45RA+ cells (open bars) and 
CD4+CD23+CD45RA(-) cells (closed bars) generated with stimulation through CD3+CD28 or 
CD3+ICAM-1.  Fig. 4.42, average number ± SEM of CD4+CD23+CD45RA+ cells (open bars) 
and CD4+CD23+CD45RA(-) cells (closed bars) generated with stimulation through CD3+CD28 
or CD3+ICAM-1 in the presence of IL-4 (1 ng/ml). 
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populations (Fig. 4.40) that increased over time peaking at day 7 (Fig. 4.41-4.42).  The peak in 
CD23+ T cells at day 7 is consistent with our observations of MFI expression at day 7 (Fig. 4.5-
4.6).  Cells costimulated through ICAM-1 did not induce sizeable CD23+ populations unless 
exogenous IL-4 was added (Fig. 4.41-4.42).  Costimulation through CD28 regardless of 
exogenous IL-4 induced more CD23+ T cells than ICAM-1.  Differences in the number 
CD45RA(-)CD23+ T cells generated by these costimulatory proteins were more dramatic.  
Stimulation through CD3+CD28 and CD3+ICAM-1 generated 4,963 and 399 CD45RA(-
)CD23+ T cells in the absence of exogenous IL-4 and 16,250 and 3,958 CD45RA(-)CD23+ T 
cells in the presence of exogenous IL-4, respectively (Fig. 4.42).  Thus, costimulation through 
CD28 generated at the least 2.5-fold and at the most 12-fold greater numbers of CD23+ T cells 
than costimulation through ICAM-1 which may account for some of the differences in CD23 
regulation of these costimulatory proteins.   
 
Characterization of CD23+ T cells 
 One of our goals was to characterize the phenotype of CD23+ T cells observed in our 
differentiation studies, which may assist in determining the role of CD23 function in T cells.  
Expression of Gata3 (Th2), Tbet (Th1), Foxp3 (Treg), and IL-4R (IL-4 receptor) was determined 
in the context of CD23 expression.  Although all data are preliminary, it appears the CD23+ T 
cells express intermediate and high levels of Gata3 (Th2) and Foxp3 (Treg) and high levels of 
Tbet (Th1) and IL-4R (Fig. 4.43).  The CD23+ population predominantly expresses intermediate 
levels of Foxp3 represents the activated T cell population (middle right panel, Fig. 4.43).  We 
also tested whether CD23+ T cells proliferate.  As seen in the bottom panel of Fig. 4.43, cells 
that express CD23 undergo multiple rounds of    
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Fig. 4.43 
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Figure 4.43.  Characterization of CD23+ T cells.  Human naïve CD4+ T cells stimulated for 7 
or 10 days with anti-CD3+anti-CD28 or anti-CD3+anti-ICAM-1 in the presence or absence of 
IL-4 (1 ng/ml) were analyzed for expression of CD23 and coexpression of Gata3, Tbet, IL-4R, or 
Foxp3.  CD23 and dilution of CFSE was also determined on day 7.  Top left panel, CD23+ cells 
are found on Gata3+ and Gata3(-) T cells (upper left panel), representative of 3 experiments.  
Top right panel Tbet+ T cells express CD23.  Representative of 3 experiments.  Middle left 
panel, CD23+ T cells express higher MFI for IL-4R.  Representative of 1 experiment.  Middle 
right panel, Foxp3hi and Foxp3intermediate T cells express CD23.  Representative of 1 experiment.  
Bottom panel, CD23+ T cells at day 7 have undergone multiple cellular divisions. 
Representative of 1 experiment. 
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division.  The functional consequences of the expression profile by CD23+ T cells remains to be 
determined.  
 
Mature (CD45RO+) T cells from healthy subjects did not increase expression of CD23 in 
response to IL-4 
 We have found that naive and mature T cells do not always respond similarly in our in 
vitro system of stimulation (21, 22), and it is well recognized that there are many functional 
differences in the responses of these populations in vivo.  Therefore, we also examined the 
expression and function of CD23 in mature (differentiated) T cells as seen by expression of 
CD45RO.  E-rosetted T cells were negatively selected for CD45RO expression.  Isolated mature 
T cells averaged 100%, 89%, 12%, and 97% for CD3, CD4, CD8 and CD45RO expression (data 
not shown).  Average MFI of CD23 in this population prior to stimulation was 1,219 (with a 
variable range of 560 to 2,507 depending on the donor), and intracellular CD23 was not detected.  
Cells were stimulated through CD3, CD3+CD28, or CD3+ICAM-1 in the absence or presence of 
exogenous IL-4 and analyzed for expression of CD23.  The addition of IL-4 did not enhance 
CD23 expression as observed in the naïve CD4+ T cell population (Fig. 4.44-4.46).  The 
increase at 48 hours in cells costimulated through CD3+CD28 occurred in one of the two 
experiments performed so it remains to be determined if this is a consistent finding (Fig. 4.44).   
 
Simulation of human CD45RO+ T cells through CD23 did not influence expression of Gata3 
 We observed that stimulation through CD23 when combined with costimulation through 
CD28 but not ICAM-1 inhibited differentiation and decreased both Gata3 (Th2) and Tbet (Th1)  
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Fig. 4.44 
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Figures 4.44-4.46.  IL-4 did not induce CD23 expression in mature CD45RO+ T cells.  
CD45RO expressing T cells stimulated with anti-CD3, anti-CD3+anti-CD28 or anti-CD3+anti-
ICAM-1 in the presence or absence of IL-4 (1 ng/ml) were analyzed for expression of CD23.  
Representative of 1 or 2 experiments.  Fig. 4.44, average MFI of CD23 ± SEM comparing 
stimulation through CD3+CD28 with or without exogenous IL-4. Fig. 4.45, average MFI of 
CD23 ± SEM comparing stimulation through CD3+ICAM-1 with or without exogenous IL-4. 
Fig. 4.46, average MFI of CD23 ± SEM comparing stimulation through CD3 with or without 
exogenous IL-4. 
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expression in naïve CD4+ T cells.  We examined whether stimulation through CD23 could also 
modulate Th1 and Th2 responses in mature T cells.  Overall stimulation of CD45RO+ T cells 
through CD23 did not influence expression of Gata3 (Fig. 4.47-4.49).  Thus, CD23 does not 
seem to activate or inhibit the Th2 response of mature T cell populations.   
 
Stimulation of human mature CD45RO+ T cells through CD23 differentially influenced 
activation and expression of Tbet 
 We tested the effect of stimulation through CD23 on the activation of T cells and 
expression of Tbet.  In contrast to naïve T cell responses, addition of CD23 stimulation to mature 
T cells costimulated through CD28 augmented the percentage of activated cells from 41% to 
74% (p < 0.01) (Fig. 4.50) with a concomitant increase in the percentage of CD25+Tbet+ T cells 
(30% to 53%, p <0.05) (Fig. 4.51).  Cells costimulated through ICAM-1 were unaffected by the 
additional CD23 stimulus.  Stimulation through CD3 and CD23 impaired the percentage of 
CD25+Tbet+ T cells compared to stimulating mature T cells through only the TCR (p < 0.01) 
(Fig. 4.51).  Thus, the function of CD23 in mature T cells may differ from its function in naïve 
CD4+ T cells. 
 
The data from Part I of this chapter are summarized in Table 4.1. 
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Fig. 4.47 
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Figures 4.47-4.49. Simulation of human mature CD45RO+ T cells through CD23 did not 
influence expression of Gata3.  CD45RO+ T cells stimulated with anti-CD3, anti-CD3+anti-
CD23, anti-CD3+anti-CD28, anti-CD3+anti-CD28+anti-CD23, anti-CD3+anti-ICAM-1 or anti-
CD3+anti-ICAM-1+anti-CD23 were analyzed for expression of Gata3 by flow cytometry.  
Representative of 1 (day 5 and 7) or 2 experiments (18, 24, and 48 hours).  Fig. 4.47, average 
MFI of Gata3 ± SEM comparing stimulation through CD3+CD28 and CD3+CD28+CD23. Fig. 
4.48, average MFI of Gata3 ± SEM comparing stimulation through CD3+ICAM-1 and 
CD3+ICAM-1+CD23. Fig. 4.49, average MFI of Gata3 ± SEM comparing stimulation through 
CD3 and CD3+CD23. 
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Fig. 4.50 
 
 
 
 
 
 
 
 
 
Fig. 4.51 
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Figures 4.50-4.51.  Stimulation through CD23 enhanced activation and Tbet expression in 
mature cells costimulated through CD28.  Mature CD45RO+ T cells stimulated through anti-
CD3, anti-CD3+anti-CD23, anti-CD3+anti-CD28, anti-CD3+anti-CD28+anti-CD23, anti-
CD3+anti-ICAM-1 or anti-CD3+anti-ICAM-1+anti-CD23 were analyzed for expression of 
CD25 and Tbet on day 7.  Representative of 2 experiments.  Fig. 4.50, average percentage 
CD25% T cells ± SEM.  Fig. 4.51, average percentage of CD25+Tbet+ T cells ± SEM.  
* p < 0.05, ** p < 0.01 
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Table 4.1 
Naïve CD4+ T Cells (Healthy subjects)         Mature (CD45RO+) T cells 
 CD3+CD28 (+CD23) 
CD3+ICAM-1 
(+CD23)  
CD3+CD28 
(+CD23) 
CD3+ICAM-1 
(+CD23) 
Proliferation 
 No effect ! 
Th1 
function 
 
! No effect 
Protection 
from 
apoptosis 
 
No Yes 
Th2 
function 
 No effect No effect 
Memory T cell  
Differentiation 
 " No effect 
Activation  
(CD25  
expression) 
 
! No effect 
Effector T cell  
Differentiation 
 
" No effect 
Differentiation 
 to Th1 cells 
 
" No effect 
Differentiation 
to Th2 cells 
 
" No effect 
Differentiation 
to Treg cells 
 
No effect ! 
+ IL-4: 
 
Differentiation 
to Treg cells  
 
! " 
+ IL-2&TGF-
β: 
 
Differentiation 
to Treg cells 
 
No effect No effect 
Activation of  
ERK 
 
No effect ! 
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Table 4.1.  Summarized results of addition of anti-CD23 to costimulation through CD28 or 
ICAM-1 on naïve CD4+ T cells (left) or mature (CD45RO+)  T cells (right) from healthy 
individuals.   
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Part II- Characterization and function of CD23 in naïve CD4+ T cells from subjects with 
allergic asthma 
 Our original hypothesis regarding CD23 function in atopic (allergic) individuals is that 
stimulation through CD23 during an allergic reaction would exacerbate Th2 responses.  
However, our studies of naïve CD4+ T cells from healthy subjects indicate that CD23 normally 
does not support Th2 function; in fact, CD23 may be inhibitory and downregulate T cell 
responses, particularly those mediated through CD28 costimulation.  Therefore, we modified our 
hypothesis and proposed that the natural function of CD23 in T cells may be impaired or altered 
in allergic asthmatics resulting in less inhibition of T cell responses during an allergic response 
and thus, a heightened Th2 response.  First we characterized the expression of CD23 and then the 
functional sequelae of stimulating naïve T cells through CD23 in these allergic patients. 
 
Expression of CD23 by naïve CD4+ T cells from allergic asthmatics was detected earlier after 
stimulation than cells from healthy subjects 
 Naïve CD4+ T cells from subjects with allergic asthma were routinely ≥98% pure 
[CD45RO(-)CD11aloCD27+] and did not express IL-4R or CD23 (data not shown).  Our results 
from healthy subjects were that expression of CD23 peaked at day 7, was enhanced by 
exogenous IL-4, and was higher in cells costimulated through CD28 than ICAM-1.  So we next 
examined expression of CD23 at days 5 and 7 on naïve CD4+ T cells from allergic asthmatics.  
Expression of CD23 by naïve CD4+ T cells from allergic asthmatics peaked earlier, at day 5 
instead of day 7 (Fig. 4.52-4.53).   Exogenous IL-4 only enhanced the CD23 expression in cells 
costimulated through CD28 and only on day 5 (Fig. 4.52).  As seen in Fig. 4.54, stimulation  
 
	   242	  
Fig. 4.52 
 
 
 
 
 
 
 
 
Fig. 4.53 
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Figures 4.52-4.53. Expression of CD23 by naïve CD4+ T cells from allergic asthmatics was 
detected earlier after stimulation than cells from healthy subjects.  Human naïve CD4+ T 
cells stimulated for 5 or 7 days with anti-CD3+anti-CD28 or anti-CD3+anti-ICAM-1 in the 
presence of absence of IL-4 (1 ng/ml) were stained for CD23 and analyzed by flow cytometry.  
Representative of 2 experiments.  Fig. 4.52, Average MFI of CD23 ± SEM on day 5.  Fig. 4.53, 
Average MFI of CD23 ± SEM on day 7. 
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Fig. 4.54  
   Day 5 
 
 
 
 
 
 
 
 
 
Fig. 4.55 
         Day 5 
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Fig. 4.56 
 
 
 
 
 
Fig. 4.57 
 
 
 
 
 
 
Fig. 4.58 
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Figures 4.54-4.58. Exogenous IL-4 enhanced expression of CD23 by naïve CD4+ T cells 
from allergic asthmatics on day 5.  Human naïve CD4+ T cells stimulated for 5 or 7 days with 
anti-CD3+anti-CD2 or anti-CD3+anti-ICAM-1 in the presence or absence of IL-4 (1 ng/ml) were 
stained for expression of CD23, CD45RA, and Gata3 (Th2) and analyzed by flow cytometry.  
Representative of 2 experiments.  Fig. 4.54, Number of CD45RA+CD23+ T cells (upper right 
quadrant, top panels), CD45RA(-)CD23+ T cells (lower right quadrant, top panels), or 
Gata3+CD23+ T cells (upper right quadrant, bottom panels) generated by CD3+ICAM-1 ± IL-4 
on day 5.  Fig. 4.55, Number of CD45RA+CD23+ T cells (upper right quadrant, top panels), 
CD45RA(-)CD23+ T cells (lower right quadrant, top panels), or Gata3+CD23+ T cells (upper 
right quadrant, bottom panels) generated by CD3+CD28 ± IL-4  on day 5.  Fig. 4.56, Average 
number of CD45RA+CD23+ T cells ± SEM.  Fig. 4.57, Average number of CD45RA(-)CD23+ 
T cells ± SEM.  Fig. 4.58, Average number of Gata3+CD23+ Th2 cells ± SEM. 
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through CD3+ICAM-1 with or without IL-4 did not activate differentiation of naïve T cells from 
these atopic subjects.  Addition of IL-4 to cultures costimulated through CD28 enhanced the 
number of both CD45RA+CD23+ T cells and CD45RA(-)CD23+ T cells by approximately two-
fold (Fig. 4.55-4.57) and enhanced the number of CD23+ cells expressing Gata3 (Th2 cells) by 
nearly four-fold (Fig. 4.58) on day 5.    
 
Stimulation through CD23 may have supported the differentiation of naïve T cells to Treg cells 
in allergic patients 
 In healthy subjects, stimulation through CD23 may induce Treg cells by working in 
concert with exogenous IL-4 depending on the other costimulatory protein engaged during naïve 
T cell activation.  We tested whether CD23 would also enhance differentiation to Treg cells in 
atopic donor cells.  In healthy subjects, costimulation through ICAM-1 but not CD28 stimulates 
naïve CD4+ T cells to differentiate to regulatory T cells (17).  Unfortunately, cells from subjects 
with allergic asthma did not stimulate through CD3+ICAM-1 so we could not assay the effect on 
Treg induction by ICAM-1.  However, we observed (Fig. 4.59-4.60) that the addition of anti-
CD23 or the combination of anti-CD23 and exogenous IL-4 induced Treg differentiation in cells 
stimulated through CD3+CD28.  CD25+Foxp3hi T cells increased, and the level of CD25 
expression (MFI) was higher in cells stimulated through CD3+CD28+CD23 with or without IL-4 
Thus, naïve T cells from either healthy or allergic subjects seem to respond to stimulation 
through CD23 in the presence of IL-4 to induce Treg cells.   
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Fig. 4.59 
 
 
 
 
 
 
Fig. 4.60  
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Figures 4.59-4.60.  Stimulation through CD23 seemed to induce differentiation of naïve 
CD4+ T cells from allergic patients to regulatory T cells.  Human naïve CD4+ T cells 
stimulated for 7 days with anti-CD3+anti-CD28, anti-CD3+anti-CD28+anti-CD23, anti-
CD3+anti-ICAM-1 or anti-CD3+anti-ICAM-1+anti-CD23 in the presence or absence of IL-4 (1 
ng/ml) were stained for CD25 and strong Foxp3 expression and analyzed by flow cytometry.  
Representative of 1 experiment.  Fig. 4.59, Percentage of Treg cells indicated with numbers of 
Treg cells parenthetically.  Fig. 4.60, MFI of CD25 indicated for each stimulation. 
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Regulation of effector and memory differentiation by CD23 may vary among subjects with 
allergic asthma 
In our studies of human naïve T cells from healthy subjects, stimulation through CD23 
reduced the number of effector and memory T cells induced by costimulation through CD28 but  
not ICAM-1.  We tested whether CD23 would do the same thing in naïve T cells from allergic 
asthmatics.  Naïve CD4+ T cells from all three subjects with allergic asthma did not stimulate 
well through CD3+ICAM-1 and thus, failed to differentiate to effector or memory cells (Fig. 
4.61, bottom panels).  The cells from one of these subjects also did not stimulate through CD28 
and was excluded from the final analysis.  Fig. 4.61 shows the expression of CD11a and CD27 
on day 7 from the two subjects that were stimulated either through CD3+CD28 or 
CD3+CD28+CD23.   The results of CD23 stimulation on effector and memory differentiation in 
these two experiments conflict.  Addition of anti-CD23 to stimulation through CD3+CD28 
inhibited differentiation to effector and memory cells in donor 1 but enhanced differentiation to 
effector and memory cells in donor 2 (Fig. 4.61).  We are unable to conclude the effect of CD23 
stimulation on effector and memory differentiation.  It is possible that with more experiments, 
we may notice two distinct groups of patients with allergic asthma based on their response to 
stimulation through CD23.   
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Fig. 4.61  
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Figure 4.61.  Regulation of effector and memory differentiation by CD23 seemed to vary 
among subjects with allergic asthma.  Human naïve CD4+ T cells stimulated for 7 days with 
anti-CD3+anti-CD28, anti-CD3+anti-CD28+anti-CD23, anti-CD3+anti-ICAM-1 or anti-
CD3+anti-ICAM-1+anti-CD23 were stained for expression of CD45RO, CD27 and CD11a and 
analyzed by flow cytometry.  Representative of 2 experiments.  The plots are gated on the live 
population rather than the CD45RO+ T cell population typical for effector and memory dot plots 
so that the naïve T cell population (upper left quadrant) can be visualized.  Upper right quadrants 
identify the percentage of effector T cells with cell numbers parenthetically.  Lower right 
quadrants identify the percentage of memory T cells with cell numbers parenthetically.   
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Naïve CD4+ T cells from allergic asthmatics upregulated expression of ICAM-1 after 
stimulation through the TCR at 24 hours but did not sustain expression of ICAM-1 at 48-72 
hours 
 Normally, stimulation of human naïve CD4+ T cells through the TCR increases the 
existing level of expression of ICAM-1 within 24-48 hours, peaking at 72 hours (Chapter 2).  We 
hypothesized that the naïve T cells from these atopic individuals may not have responded to  
stimulation through ICAM-1 because of a failure to upregulate expression of ICAM-1 within the 
first few days of stimulation.  TCR stimulation upregulated ICAM-1 expression at 24 hours (MFI 
of 447) by 15% (Fig. 4.62) but did not continue to sustain expression, returning to baseline levels 
(day 0, MFI of 388) at 48 and 72 hours (MFI of 371 and 381, respectively).  This expression 
pattern of ICAM-1 in allergic asthmatics differs from what we observed in our other studies of 
naïve T cells from healthy subjects (Chapter 2) where peak expression of ICAM-1 is seen at 72 
hours of stimulation by all stimuli including stimulation through the TCR.  The failure of these 
naïve T cells to sustain ICAM-1 expression past 24 hours after activation may account for the 
inability of costimulation through ICAM-1 to induce differentiation.  We also stained naïve 
CD4+ T cells for CD28 prior to stimulation and then at 24, 48, and 72 hours of stimulation.  
High levels of CD28 were expressed by cells at all timepoints (data not shown) as expected.   
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Fig. 4.62 
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Figure 4.62.  TCR stimulation of naïve CD4+ T cells from allergic individuals upregulated 
expression of ICAM-1 at 24 hours but not 48 or 72 hours.  Human naïve CD4+ T cells from 
allergic subjects stimulated with anti-CD3 for 24, 48 or 72 hours were stained for ICAM-1 
expression and analyzed by flow cytometry.  Representative of 1 experiment.  MFI of ICAM-1 
expression is indicated before stimulation began on day 0 (black lines) or 24, 48 or 72 hours of 
stimulation through CD3 (red lines). 
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Discussion 
Expression of CD23 in T cells from healthy subjects 
 Our goals for this project included determining the expression of CD23 in mature and 
naïve T cells and the phenotype of cells that express CD23.  Stimulation induced greater 
expression of CD23 in naïve T cells than in mature T cells regardless of the type of stimulus.  
Naïve CD4+ T cells also responded to IL-4 by upregulating CD23 in contrast to mature T cells 
that were mostly unresponsive to the addition of exogenous IL-4.  This suggests that CD23 may 
function to regulate the activation and differentiation of naïve T cells more than the responses of 
mature T cells.   
The phenotype of CD23+ cells generated from the naïve CD4+ T cell population is 
variable, and CD23 can be detected on many T cell subsets.  CD23 was detected on both 
CD45RA+ (mostly naïve) and CD45RA(-) (mature) T cells.  Also, activated T cells (based on 
CD25 and the intermediate levels of Foxp3 and Tbet expression) may express CD23 more 
frequently than other populations.  This suggests that CD23 expression and thus, function, may 
be relevant in transiently activated T cells, possibly influencing the differentiation of naïve T 
cells and responses of T helper cells during a primary immune response.   
 
Functional outcomes of CD23 stimulation of T cells from healthy subjects differed between naïve 
and mature subsets and between ICAM-1 and CD28 costimulation 
 Stimulation through CD23 models a situation where a T cell receives a signal through 
resident CD23 with a captured IgE Ab that is engaging its cognate Ag.  We examined potential 
ramifications of this in combination with other signals on T cell subsets.   
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Naïve CD4+ T cells 
CD23 did not function as an independent costimulatory protein to induce differentiation 
of naïve CD4+ T cells.  Thus, any positive function of CD23 on naïve T cells appears to be 
limited to situations in which another costimulatory protein such as CD28 or ICAM-1 cooperates 
with Ag stimulation through TCR(CD3) 
 
Mature T cells 
Stimulation of mature T cells through CD3+CD23 was inhibitory compared to 
stimulation through only CD3.  However, CD23 stimulation enhanced activation and the 
percentage of Tbet+ cells when combined with stimulation through CD28, suggesting that CD23 
stimulation of mature T cells may enhance Th1 function in the presence of CD28 signaling.  
Consistent with naïve T cells, cells costimulated through ICAM-1 were less responsive to the 
effects of CD23 stimulation.  
 
Overall Function of CD23 
Our hypothesis prior to beginning this project was that CD23 regulates T helper 
responses through supporting the generation and function of Th2 cells.  However, our data 
suggest a different role for CD23 as a negative regulator of Th2 responses.  Th1 cells oppose Th2 
cells by directly inhibiting Th2 cell differentiation or function by cytokine secretion.  In mature T 
cells, CD23 may oppose Th2 function by supporting the expansion of activated, Th1 cells that 
can suppress Th2 cells.  In naïve T cells, the effect of CD23 depended on the traditional 
costimulatory molecule that also was engaged.  In cells costimulated through ICAM-1, CD23 
enhanced activation of ERK and proliferation and modestly enhanced differentiation to Treg 
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cells.  Stimulation through CD3+CD28+CD23 compared to CD3+CD28 resulted in fewer 
activated, effector and memory cells and reduced expression of Gata3 (Th2) and Tbet (Th1).  
The effects of stimulation through CD23 on naïve T cells and mature T cells when combined 
with CD3+CD28 differed.  CD23 inhibited naïve T cells and activated mature T cells.  Overall, 
though, these effects on naïve and mature populations are consistent with a role for CD23 as a 
negative regulator of Th2 responses because it suppressed Th2 function (naïve T cells) and 
supported Th1 function (mature T cells).  Th1 and Th2 cells suppress each other; by enhancing 
Th1 function in mature T cells, the Th2 response is likely to be inhibited.  Costimulation through 
CD28 but not ICAM-1 generates Th2 cells (17-19).  Therefore, it seems reasonable that 
costimulation through CD28 but not ICAM-1 would be inhibited by CD23 based on the proposed 
inhibition of Th2 responses by CD23.  In mature T cells, CD23 promoted Th1 cell expansion. 
 
CD23 expression and functional outcomes of CD23 stimulation in subjects with allergic asthma 
 Conclusions herein regarding CD23 expression and function in allergic asthmatics are 
based on preliminary data with the hope that the project continues.  Experiments from only two 
of the three subjects were usable so continued studies are certainly needed.  Similar to naïve T 
cells from healthy subjects, costimulation through CD28 plus exogenous IL-4 induced higher 
levels of CD23 expression in cells from allergic asthmatics.  However, the peak of CD23 
expression in the donor cells from these atopic individuals peaked two days earlier than in cells 
from non-atopic individuals.  Differences in gene regulation between day 5 and 7 in these 
activating naïve T cells may result in different functional outcomes when CD23 is engaged.  
Stimulation of naïve CD4+ T cells through CD3+ICAM-1 did not induce differentiation in the 
cells from allergic asthmatics, but expression of ICAM-1 was also lower at 48-72 hours 
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compared to naïve T cells from healthy subject.  This reduced expression of ICAM-1 may limit 
the amount of ICAM-1 signaling received by these cells.  This may suggest that expression and 
participation of costimulatory proteins such as ICAM-1 in allergic asthmatics may differ from 
the general population.  The ability of CD23 stimulation to induce Treg differentiation was 
consistent, though, between cells from allergic and healthy subjects in the presence or absence of 
IL-4.  It appears that contrary to our hypothesis, CD23 may function in allergic asthmatics and 
healthy individuals in a similar manner.  Whether CD23 also promotes Th1 expansion from a 
mature T cell population in these patients remains to be determined.   
 
Proposed hypothesis for function of CD23 in vivo (both healthy and allergic individuals) 
We propose an in vivo function for CD23 during an elevated Th2-driven immune 
response based on our data from both healthy and allergic subjects.  CD23 binds to IgE and 
IgE:Ag complexes one-tenth of the affinity of the high affinity receptor (4).  CD23 may not be 
engaged and regulate T cell responses when IgE levels are low to moderate depending on the 
expression of the high affinity IgE receptor in the microenvironment.  Under conditions in which 
IgE levels are high such as during a parasitic infection or allergic response, sufficient IgE is 
available to maintain binding to the low affinity receptor which serves as a sensor to the 
heightened Th2 response.  CD23, therefore, seems to function to balance the immune response 
by inducing differentiation of naïve T cells to Treg cells, inhibiting differentiation of naïve T 
cells to Th2 cells, and promoting Th1 expansion of mature T cells.  
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Summary 
 Thus far, we have characterized the expression and function of CD23 in naïve CD4+ T 
cells from healthy subjects and plan to continue these studies using subjects with allergic asthma.  
We have preliminary evidence regarding the function and expression of CD23 in mature T cells 
from healthy individuals.  In future studies, we will examine the function of CD23 in mature T 
cells from allergic asthmatics and determine whether the function of CD23 differs between 
allergic asthmatics with or without the R62W SNP mutation in CD23.  Overall, our data refute 
our original hypothesis for increased Th2 function and have led to the development of a new 
proposal in which CD23 functions as a negative regulator of Th2 responses.    
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Chapter 5  
Oxidized low density lipoprotein (oxLDL) promotes human naïve CD4+ T cell 
differentiation to Th1 cells: a novel mechanism to exacerbate atherosclerosis.   
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Introduction 
Atherosclerosis, a chronic inflammatory condition of the major arteries, contributes 
significantly to cardiovascular disease, the leading cause of death worldwide (1).  Oxidized low-
density lipoprotein (oxLDL) promotes atherogenesis through several known mechanisms 
whereas high-density lipoprotein (HDL) opposes atherogenesis.  Pathogenic Th1 cells represent 
a major cell population within atherosclerotic plaque.  We investigated the hypothesis that 
selective influence on naïve T cell differentiation by oxLDL and HDL may identify novel 
mechanisms by which oxLDL promotes and HDL inhibits atherosclerosis.   
 
LDL, HDL and the immune response in atherosclerotic plaque  
It is widely theorized that insult to the endothelium, which can be physical, immune-
related or both, initiates atherogenesis.  Atherosclerotic lesion formation typically occurs at sites 
where the arteries bifurcate causing a greater fluid shear force on the endothelial cells and 
increasing their permeability to LDL (2).  Accumulation of LDL in the arterial wall is 
accompanied by oxidation to oxLDL, which is atherogenic.  OxLDL induces vascular 
endothelial cells to express adhesion molecules and secrete cytokines and chemokines that attract 
immune cells (3-7).  Activated macrophages ingest oxLDL to become lipid rich foam cells, 
release proinflammatory cytokines and contribute to the necrotic core of the lesion (8-10).  In 
addition, platelets activated by oxLDL adhere to the lesion and promote thrombus formation (11, 
12).  HDL opposes atherogenesis by inhibiting LDL oxidation, endothelium activation, 
macrophage activation, and platelet aggregation (13-17) and by removing cholesterol from 
existing plaque (13).   
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T cells in atherosclerosis  
T cells comprise 10-20% of cells in early atherosclerotic plaque and continue to be found 
in lesions throughout plaque development (18-20).  However, the mechanisms by which 
pathogenic T cells participate in atherogenesis have not been fully elucidated.  In the absence of 
T cells, atherosclerotic plaque develops less efficiently reaching 10% of potential size, and 
adoptive transfer of CD4+ T cells into ApoE(-/-) scid/scid mice accelerates lesion development 
(21-27).  T cells resident in plaque predominantly exhibit a Th1 phenotype secreting IFN-γ (19, 
20, 28, 29).  Deficiency in expression of the IFN-γ receptor and reduced production of IFN-γ 
diminish plaque development, whereas exogenously added IFN-γ exacerbates lesion 
development (30, 31).  Thus, Th1 cells contribute to plaque evolution.  A subset of mature 
effector T cells recognizes modified LDL using the T cell antigen receptor (25-27).  In addition 
to this mature T cell antigen response, we hypothesize that oxLDL interacts with specific LDL 
receptors on immature naïve T cells to promote selective differentiation that favors 
atherosclerosis.  We also hypothesize that HDL opposes the proposed oxLDL effect on naïve T 
cell differentiation. 
 
Naïve T cell differentiation in plaque  
Naïve T cells have emigrated recently from the thymus carrying a half-life of 6 weeks 
and requiring engagement with cognate antigen to stimulate activation and differentiation 
leading to effector T cells, and to the increased longevity of memory T cells.  Naïve T cells are 
not limited to the lymph node as a site of differentiation. Under chronic inflammatory conditions, 
naïve T cells can migrate, activate, and proliferate in lymph node-like aggregates within non-
lymphoid tissues (32-35).  Perhaps the most notable alternative site described thus far is the islets 
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of Langerhans in developing diabetes.  The chronic inflammatory conditions prevailing in plaque 
seem likely to provide a hospitable microenvironment for extra-lymphoid activation of naïve T 
cells.  Although not as abundant as in peripheral blood, CD45RA expressing T (naïve) cells have 
been found in human atherosclerotic plaque (36, 37), suggesting that naïve T cells can migrate to 
plaque and once there, may become activated by a number of cells that express HLA Class II 
(HLA II).  Dendritic cells are found at very early stages of lesion development and co-localize 
with T cells in atherosclerotic plaque (20-22).  Activated macrophages populate plaque, and 
smooth muscle cells and CD8+ T cells in these atherosclerotic lesions also express HLA Class II 
(37, 38).  All these cell types are capable of activating naïve CD4+ T cells.   
 
Model Differentiation System   
Previously we reported different effects of HDL and oxLDL on peripheral blood-derived 
total T cell proliferation, cell death, and cytokine secretion (39) using a mixed population of 
naïve and mature, differentiated T cells.  Here, we examined whether the lipoproteins could 
affect human naïve CD4+ T cell differentiation in response to different cellular 
microenvironments.  Because intercellular interactions engage dozens of T cell surface counter 
receptors, we use antibodies to stimulate only through surface proteins of interest in a 
reductionist approach to model specific events (40, 41) that participate individually.  This 
approach has the added benefit of limiting control of differentiation to a targeted 
microenvironment.  Thus it involves cytokines created only by the differentiating naïve T cells 
without the classic addition of polarizing cytokines provided by other cells, for example, in the 
lymph node.  We compared (40-43) classic costimulation through the T cell antigen receptor, 
TCR(CD3)+CD28 with less well-studied costimulation through CD3+ICAM-1 and CD3+CTLA-
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4.  We have observed that costimulation through CD3+CD28 induces human naïve CD4+ T cells 
to differentiate to Th1 and Th2 effector and memory cells in our system but not to become 
regulatory T cells (Treg cells) without exogenously added cytokines.  In contrast, costimulation 
through CD3+ICAM-1 induces the same naïve CD4+ T cell population to differentiate to 
effector and memory Th1 cells and to Treg cells without exogenously added cytokines but not to 
become Th2 cells.  CD3+CTLA-4 induces differentiation of naïve T cells to effector, memory 
and regulatory T cells (See Chapter 2).  Here, we compared effects of oxLDL and HDL on 
human naïve T cell differentiation in the context of our three different, modeled 
microenvironments.   
 
Hypotheses examined 
The working hypothesis was that oxLDL promotes differentiation of human naïve CD4+ 
T cells to plaque-favoring effector cells and that HDL opposes this process.  On any day, the 
percentage of naïve T cells with specificity for a particular antigen is expected to be very low.  
Hence, use of naïve T cells here assures us that any reasonably robust response to LDL or HDL 
would be due to non-TCR mediated interaction.  In support of the hypotheses, oxLDL promoted 
human naive CD4+ T cell differentiation and survival of activated, effector T cells with a Th1 
activity, suggesting a novel mechanism by which oxLDL could enhance atherogenesis. In 
contrast, HDL inhibited proliferation and decreased cell survival suggesting opposition to 
atherogenesis at the level where naïve T cells differentiate. 
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Materials and methods 
Antibodies and reagents 
Antibodies used to stain cells for flow cytometry were: anti-CD11a-FITC (clone: G43-
25B, BD Biosciences, San Jose, CA), anti-CD27-PE (clone: CLB-27/1, Invitrogen, Carlsbad, 
CA), anti-CD27-PECy5 (clone: 0323, eBioscience, San Diego, CA), anti-CD45RO-APC (clone: 
UCHL1, Invitrogen), anti-CD45RO-PerCP (clone: UCHL1, Invitrogen), anti-Foxp3-PE (clone: 
3G3, Miltenyi Biotec, Auburn, CA), and anti-CD25-Tri Color (clone: 3G10, Invitrogen).  
Intracellular staining of Foxp3, CFSE staining and flow cytometry analysis were performed as 
describe in Chapter 2.  
 
Human Subjects 
Peripheral blood (240 ml into heparin) was obtained after informed consent from healthy 
adult volunteers of both genders, ages between 20 and 30y, who had been free of infection for 14 
days.  No other information was collected. Procedures were approved by the University of 
Kansas Institutional Review Board. 
 
Human naïve CD4+ T cell purification 
Human naïve CD4+ T cells were isolated as described in Chapter 2.  
 
Naïve CD4+ T cell stimulation 
Human naïve CD4+ T cells were stimulated using plate-bound antibodies as we have 
described (40).  Clones and concentrations of Ab were used as describe in Chapter 2.  Either 
HDL (200 µg/ml) or oxLDL (25 µg/ml) from Intracel (Frederick, MD) was added immediately 
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after plating cells.  Concentrations of lipoproteins were based on our previously published work 
(39) and attained roughly equivalent molar concentrations between the largely disparate 
molecular masses of these lipoproteins (45).   
 
ELISA 
Supernate from stimulated cells was collected at day 4 or 7 and stored at -70°C until analysis 
of IL-2, IFN-γ, and IL-4 production using Quantikine Colorimetric Sandwich ELISA kits (R&D 
Systems, Minneapolis, MN) and The Ready-Set-Go! ELISA kit (eBioscience) for IL-17A.  
Assays were performed in duplicate.  Plates were washed with the ELx50 Auto Strip Washer 
(Bio-Tek Instruments Inc., Winooski, VT) and read at 450 nm using an EL311 Microplate 
Autoreader (Bio-Tek Instruments Inc.).   
 
Migration Assay 
 400 µl serum-free RPMI 1640 was added to the wells of 24-transwell plates with a pore 
size of 5 µm.  OxLDL (25 µg/ml), LDL (25 µg/ml), HDL (200 µg/ml) were added to the wells 
and mixed prior to securing transwell inserts.  200 µl freshly isolated human naïve CD4+ T cells 
were plated at 5 x 106 cells/ml in the inserts and allowed to migrated for 5 hr at 37°C.  Inserts 
were removed, and migrated cells collected and analyzed by flow cytometry.   
 
Statistical Analysis 
The one-way A was used to determine statistical confidence for all analyses except 
analysis of IFN-γ and IL-17A ELISA data for which the two-way ANOVA was performed.  All 
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statistical analysis was performed using GraphPad Prism (GraphPad Software Inc., La Jolla, 
CA).  
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Results 
 
Phenotypic characterization of naïve, effector, and memory T cell populations 
Throughout this work, naïve T cells were CD4+CD45RA+CD45RO(-)CD11aloCD27+ 
and averaged 98% purity as we have observed many times (40, 41) and as seen in Fig. 5.1A.  
Because a subpopulation of effector T cells recognizes modified LDL using the TCR (25-27), 
use of naïve T cells reduces the probability that oxLDL-specific cells will represent a significant 
population of responding cells and allows study of more direct effects on cell differentiation 
induced by oxLDL or HDL.  Figures 5.2-5.5 ask whether a microenvironment rich in 
lipoproteins relevant to atherosclerosis might influence differentiation of human naïve CD4+ T 
cells.  Human T cells were defined phenotypically some time ago by others (44), and we verified 
these observations (40) in our own system.  Effector T cells reside in the upper right quadrant of 
the flow dot plots as diagrammed in Fig. 5.1B and memory T cells in the lower right quadrant.  
The memory CD4+ T cells observed here as CD45RA(-)CD45RO+CD11ahiCD27(-) cells (lower 
right quadrant) routinely respond to suboptimal TCR stimulation (alone) with more robust 
proliferation and higher Th1 cytokine secretion than naïve T cells from the same individual (40).  
Thus, these phenotypic distinctions were used to study the influence on differentiation to 
memory and effector T cells.   
 
oxLDL augmented differentiation of human naïve CD4+ T cells to T effector cells 
As we observed previously (40), the majority of human naïve CD4+ T cells costimulated 
through CD3+CD28 (Fig. 5.2-5.3) shifted to the upper right quadrant and thus differentiated to 
an effector cell phenotype [CD45RA(-)CD45RO+, CD11ahi, CD27hi].  Addition of oxLDL (third 
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column) significantly increased the percentage of effector cells regardless of the choice of 
costimulatory molecule or timepoint of differentiation (representative figures in Fig. 5.2-5.3, 
summarized in Fig. 5.4).  OxLDL caused effector T cells induced by stimulation through 
CD3+CD28 to increase from 63 ± 3% to 79 ± 3% (p < 0.005) at day 7 and from 62 ± 8% to 80 ± 
4% (p < 0.05) at day 14 (Fig. 5.4).  Differentiation to effector cells by costimulation through 
CD3+ICAM-1 or CD3+CTLA-4 was affected in a similar manner by oxLDL.  With ICAM-1 
costimulation, oxLDL enhanced differentiation to effector T cells from 34 ± 6% to 58 ± 4% (p < 
0.005) at day 7 and from 38 ± 5% to 66 ± 4% (p < 0.005) at day 14.  The effector T cell 
population generated through CD3+CTLA-4 also increased from 34 ± 8% to 65% ± 6% at day 7 
and from 51% ± 7% to 76 ± 4% at day 14.  Overall, oxLDL augmented the effector T cell 
population in all stimuli.  In contrast, HDL (column 2) exerted no consistent effect on 
differentiation of naïve CD4+ T cells to effector cells with any costimulatory regimen. 
 
oxLDL suppressed differentiation to memory T cells 
Human naïve CD4+ T cells differentiated to memory T cells in response to all costimuli 
as expected (36, 37 and Chapter 2).  The relative kinetics and memory cell numbers were 
consistent with our previous (30) parameters (Fig. 5.2-5.3 summarized in Fig. 5.5).  OxLDL 
inhibited differentiation to memory phenotype by the naïve CD4+ T cells regardless of the 
costimulation.  On day 7, memory T cells arising from CD28 costimulation decreased from 13 ± 
2% to 6 ± 1% (p < 0.005) (summarized in Fig. 5.5), and by 14 days the difference with or 
without oxLDL was no longer detectable. ICAM-1 and CTLA-4 costimulated cells demonstrated 
a similar response to oxLDL except the decrease in memory cells was delayed to day 14 (from  
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Figure 5.1  
    A     B 
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Figure 5.1A-B. Highly pure populations of naïve CD4+ T cells are used in the in vitro 
differentiation studies.  Fig. 5.1A, Representative dot plot of naïve T cell purity, gated on 
CD4+CD45RA+CD45RO(-) population.  Fig. 5.1B, Diagram indicating location of naïve 
[CD45RA+CD45RO(-)], effector and memory T cell populations [CD45RA(-)CD45RO+].  
Effector (upper quadrant) and memory (lower quadrant) populations are gated on the 
CD4+CD45RA(-)CD45RO+ population.  
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Figure 5.2 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 
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Figures 5.2-5.3. OxLDL augmented T cell differentiation to effector T cells but not memory 
cells.  Human naïve CD4+ T cells stimulated for 7 or 14 days using anti-CD3+anti-CD28, anti-
CD3+anti-ICAM-1 or anti-CD3+anti-CTLA-4 were analyzed for CD45RO, CD27, and CD11a 
expression by flow cytometry.  HDL (200 µg/ml) or oxLDL (25 µg/ml) was added on day 0.  
Dot plots were gated on the CD45RO+ population.  Effector T cells are defined as 
CD45RO+CD11ahiCD27hi and memory T cells as CD45RO+CD11ahiCD27lo.  Effector (upper 
right quadrant) and memory (lower right quadrant) T cell populations after 7 days (Fig. 5.2) and 
14 days (Fig. 5.3) of stimulation through CD3+CD28 (upper panels), CD3+ICAM-1 (middle 
panels), or CD3+CTLA-4 (lower panels).  Additions: medium (column 1), HDL (column 2), or 
oxLDL (column 3). Percentage of each is indicated, with cell numbers parenthetically.  
Representative of eight (CD3+CD28, 7d and 14d), eight (CD3+ICAM-1, 7d), nine (CD3+ICAM-
1, 14d), seven (CD3+CTLA-4, 7d) or eight (CD3+CTLA-4, 14d) separate experiments.  
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Figure 5.4 
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Figures 5.4. OxLDL augmented T cell differentiation to effector T cells.  Human naïve CD4+ 
T cells stimulated for 7 or 14 days using anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1 or anti-
CD3+anti-CTLA-4 were analyzed for CD45RO, CD27, and CD11a expression by flow 
cytometry.  HDL (200 µg/ml) or oxLDL (25 µg/ml) was added on day 0.  Effector T cells are 
defined as CD45RO+CD11ahiCD27hi.  Fig. 5.4, Average percentage of 
CD4+CD45RO+CD11ahiCD27hi cells (effector cells) ± SEM at 7d and 14d with each 
costimulatory regimen (open bars) and costimulation plus HDL (closed bars) or oxLDL (striped 
bars).  
* p < 0.05, ** p < 0.01, *** p < 0.001. 
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Figure 5.5 
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Fig. 5.5. OxLDL suppressed differentiation to memory T cells.  Human naïve CD4+ T cells 
stimulated for 7 or 14 days using anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1 or anti-
CD3+anti-CTLA-4 were analyzed for CD45RO, CD27, and CD11a expression by flow 
cytometry.  HDL (200 µg/ml) or oxLDL (25 µg/ml) was added on day 0.  Memory T cells are 
defined as CD45RO+CD11ahiCD27lo.  Fig. 5.5, Average percentage of 
CD4+CD45RO+CD11ahiCD27lo cells (memory cells) ± SEM at 7 and 14d with each 
costimulatory regimen and indicated lipoprotein. Representative of eight (CD3+CD28, 7d and 
14d), eight (CD3+ICAM-1, 7d), nine (CD3+ICAM-1, 14d), seven (CD3+CTLA-4, 7d) or eight 
(CD3+CTLA-4, 14d) separate experiments.  
* p < 0.05, ** p < 0.01, *** p < 0.001. 
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38 ± 3% to 19 ± 4% with ICAM-1 and from 32 ± 6% to 14 ± 3% with CTLA-4; p < 0.001 and p 
< 0.01) (Fig. 5.5).  HDL either had little effect on differentiation to memory cells or favored an 
increase in memory (day 14, CD3+CD28 and CD3+CTLA-4) over several experiments.  As seen 
in Fig. 5.3, the percentage of memory T cells (lower right quadrant) produced by CTLA-4 
costimulation in the presence of HDL is high, 73%, but the number of cells is considerably low.  
Although statistically significant, the increase in the percentage of memory cells by HDL was  
likely the result of either a decrease in cell viability or proliferation because we often observed 
fewer cells in the presence of HDL as will be discussed later in Chapter 5.   
In support of the working hypothesis, a cellular microenvironment providing elevated 
oxLDL during costimulation through CD3+CD28, CD3+ICAM-1 or CD3+CTLA-4 favored 
increased effector T cells capable of causing damage.  In contrast, elevated HDL favored no 
increase in effector cells and a possible increase in memory T cells. 
 
oxLDL and HDL did not alter expression of CD45RO 
During activation, naïve T cells upregulate CD45RO and typically downregulate 
CD45RA as they differentiate (54-56).  To verify that oxLDL induced a shift in favor of effector 
but not memory T cell differentiation, we assessed the percentage of total CD4+CD45RO+ cells 
at days 7 and 14.  Neither oxLDL nor HDL altered the percentage of CD45RO+ cells at either 
timepoint through any of the costimulatory regimen (representative plots in Fig. 5.6-5.7, 
summarized in Fig. 5.8).  However, the addition of HDL resulted in fewer CD45RO+ cells for all 
costimuli (Fig. 5.6-5.7, middle columns), suggesting a generalized suppressive effect on 
differentiation by HDL.  Possible explanations for this observation may be inhibition of 
proliferation or cell viability by HDL.  Thus, the increase in the effector T cell population and  
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Figure 5.6 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 
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Figure 5.8 
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Figures 5.6-5.8.  Lipoproteins did not alter the percentage of cells expressing CD45RO.  
Human naïve CD4+ T cells stimulated for 7 or 14 days using anti-CD3+anti-CD28, anti-
CD3+anti-ICAM-1 or anti-CD3+anti-CTLA-4 were analyzed for CD45RO expression by flow 
cytometry.  HDL (200 µg/ml) or oxLDL (25 µg/ml) was added on day 0.  Representative 
histogram plots are shown for day 7 (Fig. 5.6) and day 14 (Fig. 5.7) of stimulation through 
CD3+CD28 (upper panels), CD3+ICAM-1 (middle panels), or CD3+CTLA-4 (lower panels).  
Additions: medium (column 1), HDL (column 2), or oxLDL (column 3).  Percentage of each is 
indicated, with cell numbers parenthetically.  Fig. 5.8, Fig. 5.5, Average percentage of 
CD4+CD45RO+ cells ± SEM at 7 and 14d with each costimulatory regimen and indicated 
lipoprotein.  Representative of eight (CD3+CD28, 7d and 14d), eight (CD3+ICAM-1, 7d), nine 
(CD3+ICAM-1, 14d), seven (CD3+CTLA-4, 7d) or eight (CD3+CTLA-4, 14d) separate 
experiments.  
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decrease in memory T cell population is a result of oxLDL shifting naïve T cell differentiation to 
effector cells.  The increase in the memory population by HDL (CD28 and CTLA-4 
costimulations, 14d) may be a result of analyzing a smaller sample size which can readily skew 
percentages. 
 
Effector T cells generated in the presence of oxLDL exhibited a Th1 phenotype 
We investigated whether oxLDL promoted differentiation to a particular T helper subset. 
Th1 or Th17 were likely candidates since they foster cell mediated immunity and inflammatory 
conditions (57, 58).  Effector T cell functions were assessed by determining secretion of IFN-γ 
and IL-2 (Th1), IL-4 (Th2), and IL-17A (Th17) using ELISA.  On day 4 or 7, neither lipoprotein 
altered secretion of IL-2 with any stimulus (not shown).  As seen in Fig. 5.9, oxLDL had little 
effect on secretion of IFN-γ by cells costimulated through CD28 at day 4, but enhanced secretion 
from 273 ± 127 pg/ml to 844 ± 317 pg/ml by day 7 (p < 0.001).  With ICAM-1 costimulation, 
oxLDL enhanced IFN-γ production (Fig. 5.9) at day 4 from 21 ± 21 pg/ml to 1,251 ± 625 pg/ml 
(p < 0.001) fully a 60 fold increase that had diminished by day 7.  There was no increase in IFN-
γ production by cells costimulated through CTLA-4 at day 7; however, there was great variation 
(up to 500 fold for the same experimental condition) among the three samples analyzed, and no 
other days or other cytokines were examined for this costimulus.  Thus, oxLDL (striped bars) 
caused an increase in the Th1 cytokine (IFN-γ) with either CD28 or ICAM-1 costimulation, 
although the timing was consistently different.  In contrast, HDL (closed bars) had no effect on 
IFN-γ secretion by the differentiating cultures. 
Secretion of the Th2 cytokine IL-4 by CD28-costimulated cells (Fig. 5.10) decreased from 
639 ± 173 pg/ml to 148 ± 45 pg/ml on day 7 in the presence of oxLDL (p < 0.05).  
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Figure 5.9 
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Figure 5.10 
 
 
 
 
 
 
 
 
Figure 5.11 
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Figures 5.9-5.11. OxLDL enhanced Th1 function, modestly increased Th17 activity and 
impaired Th2.  Supernates collected from human naive CD4+ T cells stimulated for 4 or 7d 
with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1 or anti-CD3+anti-CTLA-4 in medium alone 
(open bars), medium+HDL (closed bars), or medium+oxLDL (striped bars).  Secretion of IFN-γ, 
IL-4, or IL-17 was determined by ELISA.  Fig. 5.9, Average IFN-γ secretion ± SEM on 4 and 
7d.  Representative of five (CD3+CD28 and CD3+ICAM-1) or three (CD3+CTLA-4) 
experiments, each conducted in duplicate.  Fig. 5.10, Average IL-4 secretion ± SEM on day 7.  
Representative of five experiments each conducted in duplicate.  Fig. 5.11, Average IL-17 
secretion ± SEM on day 7.  Representative of four (CD3+CD28) or six experiments 
(CD3+ICAM-1) each in duplicate.  
* p < 0.05, *** p < 0.001 
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Interestingly, HDL exerted a similar effect. When applied to cells undergoing ICAM-1 
costimulation, oxLDL had no effect on IL-4 production on day 7 (Fig. 5.10) and HDL exerted 
the same lack of effect.  So neither lipoprotein favored differentiation to Th2 cells, and both 
reduced the Th2 cytokine activity induced by costimulation through CD28.  
Human naïve T cells costimulated through CD3+CD28 or CD3+ICAM-1 produce 
minimal differentiation to Th17 cells in the absence of exogenous cytokines (A. Newton, 
unpublished).  However, whether the two lipoproteins could directly influence differentiation to 
a Th17 phenotype has not been tested.  Neither lipoprotein affected production of IL-17A by 
cells costimulated through CD3+CD28 (Fig. 5.11).  Cells stimulated through CD3+ICAM-1 
demonstrated a modest increase in IL-17A production from 9 ± 8 pg/ml to 23 ± 6 pg/ml in the 
presence of oxLDL (p < 0.001) but not HDL.   
Thus, oxLDL augmented Th1 effector function while inhibiting Th2 effector function 
during CD28 costimulation.  With ICAM-1 costimulation, oxLDL promoted Th1 effector 
function and slightly augmented Th17 effector function.   
 
oxLDL enhanced activation of naïve CD4+ T cells 
When naïve T cells encounter appropriately presented cognate antigen, they undergo 
activation prior to differentiation.  The alpha subunit (CD25) of the IL-2 receptor is expressed by 
activated T cells, and by regulatory T cells (59-61). CD25 expression was assessed to learn  
whether oxLDL or HDL influenced the normal activation of naïve T cells induced by the three 
types of costimulation.  In the representative experiment, (Fig. 5.12) 41% (~37,000 cells) of 
CD28 costimulated cells expressed CD25 and addition of oxLDL increased this to 73% (~60,000 
cells).  Results were similar in the representative experiment either using ICAM-1 or CTLA-4 
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costimulated cells.  Several experiments are summarized in Fig. 5.13.  In comparison with CD28 
costimulation (open bars), oxLDL (striped bars) increased the expression of CD25 from 44 ± 3% 
to 63 ± 5% (p < 0.005).  Cells stimulated through CD3+ICAM-1 in the presence of oxLDL 
demonstrated a statistically non-supported trend increasing from 33 ± 8% to 53 ± 9% (p = 0.058) 
on day 7 as did cells stimulated through CD3+CTLA-4 with an increase from 27 ± 7% to 41 ± 
8% (p = 0.07).  Thus, oxLDL seemed to augment the percentage of activated CD4+ T cells with 
all sets of costimuli.  HDL (closed bars) did not affect the percentage of activated CD4+ T cells 
with either CD28 or ICAM-1 costimulation, but overall cell numbers were reduced (Fig. 5.12) 
consistent with earlier observations of decreased cell numbers involving CD45RO+ and memory 
cells (Fig. 5.2, 5.3, 5.6, 5.7).  Although not statistically significant (p = 0.055), HDL seemed to 
reduce the percentage of activated CD4+ T cells in cells costimulated through CTLA-4 from 27 
± 7% to 14 ± 5%.   
CD25 also functions as a Treg cell (regulatory T cell) marker.  We recently observed that 
in vitro stimulation of human naïve CD4+ T cells through CD3+ICAM-1 (41) or CD3+CTLA-4 
(See Chapter 2) generated a functionally inhibitory inducible Treg (Treg) cell population in the 
absence of exogenously added cytokines, and this was in contrast to CD28 costimulation where 
no Treg cells were observed.  We next asked whether the increased CD4+CD25+ T cells in Fig. 
5.13, was an effect on the Treg cell population.  Cells were assessed for CD25 plus strong Foxp3 
expression at day 7 (summarized in Fig. 5.14).  Neither lipoprotein altered the percentage of 
CD4+CD25+Foxp3hi T (Treg) cells with CD28 or ICAM-1 costimulation.  Interestingly, HDL 
reduced the percentage of Treg cells generated through CTLA-4 costimulation, and oxLDL 
exerted no consistent effect.  Thus, the increase in CD4+CD25+ T cells caused by the addition of 
oxLDL represent activated T cells and not an inducible Treg cell population and further supports  
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Figure 5.12 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 
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Figure 5.14 
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Figures 5.12-5.14. OxLDL enhanced T cell activation without expanding the Treg 
population.  Human naïve CD4+T cells stimulated for 7 days with anti-CD3+anti-CD28, anti-
CD3+anti-ICAM-1, or anti-CD3+anti-CTLA-4 were analyzed for CD25 or strong Foxp3 
expression by flow cytometry.  Medium (none added), oxLDL or HDL was added on day 0.  Fig. 
5.12, Representative figure, cells stimulated through CD3+CD28 (upper panels), CD3+ICAM-1 
(middle panels), or CD3+CTLA-4 (lower panels).  Percentages of CD4+CD25+ T cells at 7d are 
indicated, with cell numbers in parentheses.  Fig. 5.13, Average percentage of CD4+CD25+ T 
cells (activated cells) ± SEM at day 7, with medium (open bars), HDL (closed bars) or oxLDL 
(striped bars).  Representative of eight (CD3+CD28), or seven (CD3+ICAM-1 and CD3+CTLA-
4) experiments.  Fig. 5.14, Percentage of CD4+CD25+Foxp3hi T cells (Treg cells) ± SEM at day 
7.  Representative of seven experiments. 
* p < 0.05 
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the earlier observation that oxLDL augments differentiation to effector cells, a highly activated 
(CD25+) population. 
 
oxLDL supported T cell proliferation whereas HDL inhibited proliferation  
As demonstrated in Fig. 5.4, oxLDL increased the number of effector cells in our cell 
culture model of differentiation for all three stimuli.  Increased effector cell numbers could be 
explained by increased differentiation of naïve T cells, by increased proliferation of newly 
differentiating effector cells or by decreased death rates of effector T cells in the population.  As 
previously discussed, the percentage of overall differentiation did not change with the addition of 
either lipoprotein (Fig. 5.8).  In Fig. 5.15, human naïve CD4+ T cells were stimulated through 
either CD3+CD28, CD3+ICAM-1, or CD3+CTLA-4 in the absence or presence of HDL or 
oxLDL and assessed for proliferation on day 7 using CFSE dilution.  The percentage of T cells 
with at least one division did not change with addition of oxLDL to either CD28-, or ICAM-1-
costimulated cells (representative data in Fig. 5.15, summarized in Fig. 5.16).  In addition, the 
form and number of cell divisions remained essentially the same with oxLDL for each of these 
costimulatory regimens, as did the overall numbers of dividing cells (parenthetically in Fig. 
5.15).  However, oxLDL did enhance proliferation of cells stimulated through CD3+CTLA-4 
from 25 ± 11% to 56% ± 9%  (p < 0.01) as well as the number of dividing cells, suggesting a 
possible mechanism by which oxLDL enhances differentiation of naïve T cells stimulated 
through CD3+CTLA-4 to activated, effector cells.   
HDL inhibited proliferation from 75 ± 4% to 57 ± 10% (p < 0.05) during costimulation 
through CD3+CD28 and from 48 ± 7% to 26 ± 8% (p < 0.05) during differentiation with 
CD3+ICAM-1 (Fig. 5.16). The form and number of divisions remained similar, but the number  
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Figure 5.15 
 
 
 
 
 
 
 
 
 
 
Figure 5.16 
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Figures 5.15-5.16. OxLDL allowed or enhanced while HDL suppressed naïve T cell 
proliferation.  Naïve CD4+ T cells stained with 2.5 µM CFSE at day 0 were analyzed for CFSE 
dilution after stimulation for 7 days with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, or anti-
CD3+anti-CTLA-4, in medium, oxLDL or HDL.  Representative of seven (CD3+CD28 and 
CD3+ICAM-1) or five (CD3+CTLA-4) experiments.  Fig. 5.15. Cells costimulated through 
CD3+CD28 (upper panels), CD3+ICAM-1 (middle panels), or CD3+CTLA-4 (lower panels).  
Histogram plots indicate total percentage of divided cells with number of cells in parentheses.  
Fig. 5.16. Average percentage of total divided T cells ± SEM at day 7 with added medium (open 
bars) or HDL (closed bars) or oxLDL (striped bars). 
* p < 0.05, ** p < 0.01 
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of participating cells was decreased.  HDL did not inhibit the overall percentage of proliferated 
cells through CTLA-4 costimulation, but reduced cell numbers were observed (Fig. 5.15).  
Hence, depending on the choice of costimulation, oxLDL either had no effect on proliferation 
(CD28 and ICAM-1) or enhanced proliferation (CTLA-4) of naïve CD4+ T cells.  HDL reduced 
division and resulted in fewer cells at day 7 for all costimuli. 
 
oxLDL and HDL exerted opposing and differential effects on cell death depending on the choice 
of costimulatory molecule 
Thus far, oxLDL led to increased T effector cells without increasing proliferation in 
CD28 and ICAM-1 costimulated cells.  One possible explanation was that oxLDL decreased the 
rate of cell death.  Similarly, HDL reduced proliferation and the number of proliferating cells 
undergoing differentiation.  A possible additional explanation is that HDL increased cell death 
rates, and this contributed to decreased T cells in the differentiating populations.  We analyzed 
effects of the lipoproteins on the moderate level of cell death that is common in this model of cell 
differentiation.  Costimulated cells were stained for Annexin V and 7-AAD and different effects 
of the lipoproteins were observed based on the costimulatory molecule used.  In cells 
costimulated through CD3+CD28, oxLDL inhibited the percentage of Annexin V+,7-AAD+ 
dying cells at day 7 from 29 ± 4% to 10 ± 2% (p < 0.0001).  Representative data are in Fig. 5.17 
and data are summarized in Fig. 5.18.  Inhibition of cell death would help explain an increase in 
viable cells. The baseline level of death was lower in cells costimulated through CD3+ICAM-1 
than CD3+CD28, and oxLDL (striped bars) did not inhibit cell death as it did with CD28  
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Figure 5.17 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18 
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Figures 5.17-5.18.  OxLDL decreased cell death whereas HDL enhanced cell death.  Naïve 
CD4+ T cells stimulated for 7 days with anti-CD3+anti-CD28, anti-CD3+anti-ICAM-1, or anti-
CD3+anti-CTLA-4, in medium, or with added oxLDL, or HDL, were analyzed for expression of 
Annexin V and 7AAD by flow cytometry.  Fig. 5.17, Cells stimulated through CD3+CD28 
(upper panels), CD3+ICAM-1 (middle panels), or CD3+CTLA-4 (lower panels).  Upper right 
quadrant identifies the percentage of Annexin V+, 7AAD+ cells (percentage of cell death). Fig. 
5.18, Average percentages of Annexin V+, 7AAD+ T cells ± SEM (day 7) with added medium 
(open bars), HDL (closed bars) or oxLDL (striped bars). Representative of ten (CD3+CD28 and 
CD3+ICAM-1) or eight (CD3+CTLA-4) separate experiments.  
** p < 0.01, *** p < 0.001.   
 
 
 
 
 
 
 
 
 
 
 
 
 
	   301	  
costimulation nor did it in cells undergoing CTLA-4 costimulation (Fig. 5.18).  Due to the robust 
effects observed with oxLDL, we tested whether oxLDL could induce activation and 
differentiation of naïve T cells in the absence of TCR or costimulatory protein signaling (Fig. 
5.19).  OxLDL did not induce proliferation or differentiation to effector, memory or regulatory T 
cells.  As shown in Fig. 5.19, stimulating through the TCR in the presence of oxLDL did not 
generate effector or memory cells at day 7 or day 14.  This lack of effect was also observed when 
proliferation and differentiation to regulatory T cells was assessed at day 7 (not shown).   
HDL (closed bars) exerted no effect on cell death in cells costimulated through CD3+CD28 (Fig. 
5.18).  However, HDL enhanced the percentage of Annexin V+,7-AAD+ cells from 15 ± 2% to 
28 ± 4% (p < 0.01) in cells costimulated through CD3+ICAM-1 and from 17 ± 3% to 37 ± 7% (p 
< 0.01) in cells costimulated through CD3+CTLA-4.  Overall, these data suggest that oxLDL can 
enhance CD4+ T cell survival whereas HDL reduces CD4+ T cell survival under certain 
circumstances.  OxLDL-induced survival of T effector cells is consonant with the hypothesis that 
increased activity of effector T cells promotes atherosclerosis.  Increased death of T effector cells 
in the presence of HDL agrees with the hypothesis that HDL inhibits atherosclerosis in part by 
decreasing the function of attacking T cells.  
 
oxLDL and HDL induced migration of naïve T cells more strongly than native LDL 
 To determine whether freshly isolated human naïve CD4+ T cells could migrate in 
response to the presence of the lipoproteins examined in the differentiation studies, we assessed 
the number of naïve T cells that migrated within 5 hours in response to medium only and 
medium supplemented with oxLDL (25 µg/ml), LDL (25 µg/ml) or HDL (200 µg/ml) (Fig. 
5.20).  Although all lipoproteins induced migration of naïve T cells, oxLDL and HDL caused  
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Figure 5.19 
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Figures 5.19. OxLDL did not induce differentiation of naïve T cells in the absence of a 
second signal through a costimulatory molecule.  Human naïve CD4+ T cells were stimulated 
for 7 days using anti-CD3 in the presence or absence of oxLDL (25 µg/ml) or alternatively, were 
exposed to oxLDL in the absence of any stimulation through the TCR.   Cells were analyzed for 
expression of CD45RO, CD27, and CD11a by flow cytometry.  Representative of three separate 
experiments. 
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Figure 5.20 
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Figure 5.20.  OxLDL and HDL induced migration of naïve T cells more strongly than 
native LDL.  Freshly isolated human naïve CD4+ T cells were added to inserts of 24 transwell 
plates at 5 x 106 cells/ml in serum-free RPMI 1640 exposed to medium only, oxLDL (25 µg/ml), 
LDL (25 µg/ml) or HDL (200 µg/ml) and allowed to migrate at 37°C for 5 hr.  Representative of 
one experiment performed in duplicate.   
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nearly a 2-fold increase in migrated cells beyond that induced by native LDL (Fig. 5.20).  This 
suggests that both HDL and oxLDL can attract naïve CD4+ T cells and may compete for 
regulation of T cell processes in atherosclerosis. 
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Discussion 
Elevated LDL and lower HDL levels increase the risk of cardiovascular disease.  As LDL 
accumulates within the arterial wall, it is oxidized to oxLDL, recruiting monocytes and T cells, 
generating pro-inflammatory foam cells, and activating platelets, endothelial cells, and 
macrophages (3-6, 9, 10) exacerbating lesion development.  HDL opposes atherogenesis, 
inhibiting plaque development and progression (13-17).  Macrophages in atherosclerotic lesions 
have been well studied, but although T cells have been established as important for 
atherogenesis, mechanisms of T cell function in atherogenesis are still being defined.  Mature T 
cells participate in perpetuation and development of atherosclerotic plaque and can specifically 
recognize by TCR plaque related antigens including oxLDL.  Participating T cells are 
predominantly Th1 cells that produce IFN-γ and promote inflammation.  Whether naïve T cells 
might participate early in the process is not as clear.  For example, it has not been addressed 
whether a microenvironment rich in LDL can influence the ability of naïve T cells to 
differentiate in favor of atherogenic phenotypes such as Th1 or Th17.  Here we used a model 
system for differentiation of human naïve CD4+ T cells to demonstrate for the first time that 
oxidized LDL can influence naïve cell differentiation to Th1.  The data suggest a novel 
mechanism in which oxLDL can perpetuate atherogenesis by tuning the differentiation process to 
favor Th1 cells.  In analogous experiments, HDL opposes the activity of oxLDL on human naïve 
T cell differentiation.   
 
Effects of oxLDL  
Here, oxLDL promoted naïve CD4+ T cell differentiation to effector cells, augmented 
secretion of Th1 derived IFN-γ and inhibited appearance of memory T cells.  OxLDL inhibited 
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Th2 function, reducing secretion of IL-4 by cells differentiating in response to CD28 
costimulation.  Th2 differentiation is not usually observed with ICAM-1 costimulation in this 
system and the lipoproteins did not alter this result.  The role of CTLA-4 as a costimulatory 
molecule in guiding human naïve T cell differentiation is still being defined (See Chapter 2), and 
further studies are needed to determine how costimulation through CTLA-4 influences T helper 
function.  Th17 function was modestly enhanced by oxLDL in cells costimulated through ICAM-
1.  Thus, in general, oxLDL promoted Th1 but not Th2 during differentiation, and suppressed 
appearance of memory T cells.  A decrease in memory T cells plus increased Th1 and Th17 
function support the hypothesis that oxLDL promotes generation of pathogenic Th1 cells capable 
of exacerbating plaque progression. 
Effector T cells have a shorter lifespan and higher rates of apoptosis than resting memory 
T cells.  After clonal expansion, 90% or more of the effector population undergoes apoptosis 
resulting in effector T cells only living a few days as opposed to the decades that memory T cells 
survive in vivo (62, 63).  Th1 effector cells exhibit a higher rate of apoptosis and begin undergo 
AICD (activation-induced cell death) 3-5 days earlier than other subsets such as Th2 cells (64, 
65).  The increase in T cell activation and differentiation of naive T cells to Th1 cells by oxLDL 
was not accompanied with higher rates of cell death as may be expected with expansion of Th1 
effector cells.  In fact, in cells costimulated through CD28, oxLDL actually improved cell 
viability.  This protection by oxLDL from cell death is evident even at 14 days of in vitro 
stimulation when the effector population is expected to contract as we have previously observed 
(41, See Chapter 2).  In the microenvironment of atherosclerotic plaque, naïve T cell 
differentiation to Th1 cells that are resistant to apoptosis and thus, may persist much longer than 
a few days, may exacerbate and prolong inflammatory processes.  The present data suggest a 
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novel mechanism by which oxLDL may increase the number of pathogenic T cells within plaque 
by favoring differentiation of naïve T cells into Th1 cells and by enhancing activation and 
reducing the rate of death as modeled in Fig. 5.21.  Consistent with its other roles in   
atherogenesis, this would provide an additional avenue by which oxLDL may promote 
atherosclerosis.   
 
Effects of HDL   
HDL exerted little effect on activation or differentiation of human naïve CD4+ T cells in 
the various costimulatory systems.  HDL did decrease proliferation and survival of potentially 
pathogenic cells.  Memory T cells generated in the presence of HDL differed according to 
costimulatory regimen where increase was observed with costimulation through CD3+CD28 and 
CD3+CTLA-4 at day 14 but not through CD3+ICAM-1.  However, overall there were fewer 
CD45RO+, CD25+ cells, memory and regulatory T cells, indicating an overall inhibition of 
proliferation or viability rather than a favored induction of memory differentiation by HDL. We 
have often observed a similar effect when naïve T cells are stimulated through only CD3 (TCR), 
which does not induce differentiation or proliferation.  The decrease in cell viability and 
proliferation by HDL was limited to naïve CD4+ T cells and was not detected in our previous 
work using mature peripheral blood T cells (39).  Although HDL decreased proliferation with all 
costimulatory regimens, it selectively decreased survival in both ICAM-1 and CTLA-4 
costimulated cells but not CD28-costimulated cells.  As mentioned previously, ICAM-1 or 
CTLA-4 costimulation induce differentiation to Treg cells which can suppress T cell responses 
such as inducing apoptosis.  The presence of regulatory T cells in these populations may have 
influenced the ability of HDL to induce higher rates of cell death, and in fact, there was a slight 
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increase in Treg cells generated by stimulation through CD3+ICAM-1.  However, HDL reduced 
the percentage of Treg cells induced by CTLA-4 warranting a different explanation.  As 
discussed in Chapter 2, costimulation through CTLA-4 induces slightly delayed and weaker T 
cell activation and proliferation in comparison to CD28 or ICAM-1, and therefore, may exhibit 
increased sensitivity to inhibition by HDL.  Overall, HDL inhibited proliferation and 
differentiation of naïve T cells suggesting a novel mechanism in which in the context of the 
microenvironment of plaque, HDL may inhibit or slow the progression of atherosclerosis as 
modeled in Fig. 5.22.  The effects on naïve T cells by HDL and oxLDL in the present study seem 
to oppose each other and are consistent with the accepted and more general roles of these 
lipoproteins in atherosclerosis.  Interestingly, both lipoproteins induced migration of naïve T 
cells much higher than levels produced in response to native LDL.  This suggests a possible 
competition between HDL and oxLDL attracting T cells and subsequently, regulating them to 
oppose or favor atherogenesis.  
 
Differential costimulation implies influence of microenvironment.   
In our in vitro human T cell system, costimulation through CD3+CD28, CD3+ICAM-1, 
and CD3+CTLA-4 induce memory and effector differentiation (40, 43).  Costimulation through 
either CD28 or ICAM-1 induces Th1 function (40).  ICAM-1 costimulation and CTLA-4 
costimulation generate functional regulatory T cell populations in the absence of exogenous 
cytokines (41, 43), and only CD28 induces Th2 responses (40, 42).  Thus, although all 
costimulatory regimens are capable of inducing naïve T cell differentiation to mature, functional 
T cell populations, they differ in their influence on differentiation outcome.  These inherent 
distinctions may account for the variations among CD28-, ICAM-1-, and CTLA-4-costimulated 
	   311	  
cells when the lipoproteins were added and suggest that we may be modeling differential 
influence by various cellular microenvironments.   
 
Summary 
We suggest an additional mechanism by which HDL and oxLDL modulate plaque 
development (Proposed models in Fig. 5.21 and Fig. 5.22).  This is by influencing human CD4+ 
naïve T cell activation, proliferation, differentiation, or survival, depending on the nature of the 
microenvironment and the lipoprotein involved.  Consistent with its broader, more recognized 
anti-atherogenic roles, HDL may reduce disease severity by inhibiting T cell proliferation during 
differentiation, and inducing death of disease-exacerbating T cells that appear with 
differentiation.  In contrast, oxLDL may exacerbate the chronic inflammatory microenvironment 
of plaque by guiding the differentiation process to favor an effector Th1 population that provides 
IFN-γ production and experiences increased survival or proliferation. Thus, the present data 
suggest that the two opposing lipoproteins could function in opposition to regulate naïve T cell 
differentiation and survival and influence the extent of T cell participation in atherosclerosis.  
This would provide an additional and novel mechanism by which atherosclerotic plaque can be 
regulated and should provide new avenues for investigation of atherosclerotic plaque formation 
and possible therapeutic approaches. 
 
Notes 
Some data presented in this chapter are included in a paper accepted for publication: 
A.H. Newton and S.H. Benedict. Low density lipoprotein promotes human naïve T cell 
differentiation to Th1 cells. Human Immunology, 2014. 
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Fig. 5.21 
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Fig. 5.22 
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Fig. 5.21-5.22. Model of proposed hypotheses for lipoprotein regulation of naïve T cells and 
implications in the pathogenesis of atherosclerosis.  Fig. 5.21, modulation of activation, 
proliferation, survival, and differentiation of human naïve CD4+ T cells by oxLDL.  Fig. 5.22, 
modulation of proliferation and survival of human naïve CD4+ T cells by HDL. 
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Chapter 6 
 
Blocking ICAM-1:LFA-1 interactions attenuates severity of disease in a mouse model of 
emphysema that is driven by T cells  
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Introduction 
Chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and death 
worldwide.  Two major forms of COPD occur: chronic bronchitis and emphysema.  We address 
the emphysematous form here, which is characterized by a progressive decline in respiration as a 
result of destruction to the alveoli and narrowing of the airways.  Inflammatory processes 
mediated primarily by neutrophils and macrophages contribute significantly to this destruction.  
Recent evidence also supports an autoimmune component driven by lymphocytes (1, 2), but 
whether COPD can be considered an autoimmune disease remains to be determined.  Here we 
tested the ability of T cells to transfer disease in an elastase-induced model of emphysema (Part 
I) and the therapeutic treatment of elastase-induced emphysema using peptides to block ICAM-
1:LFA-1 interactions (Part II).   
While the innate immune response is recognized as an integral part of disease 
development in COPD, elucidating the role of the adaptive immune response has been more 
challenging.  Macrophages and neutrophils propagate inflammation and damage in the lungs by 
releasing various inflammatory mediators such as proteases, cytokines, chemokines, and reactive 
oxygen species (reviewed in 3).  The degree to which adaptive immune cells such as T 
lymphocytes contribute to pathogenesis has been more controversial as emphysema can be 
induced in T cell deficient mice (4).  However, elevated numbers of CD8+ and CD4+ T 
lymphocytes in the lungs and periphery of COPD patients correlate to disease severity (5-8), and 
recent studies indicate that T cells transfer disease in both immunocompetent and 
immunodeficient mice (1, 2).  Furthermore, an autoimmune model of emphysema in rats 
mediated by antigen-specific CD4+ T lymphocytes has been developed, and oligoclonal T cells 
that respond to elastin fragments have been isolated from patients with emphysema (9, 10).  
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These studies suggest that T cells may contribute to pathogenesis of COPD by directing an 
antigen-specific immune response reminiscent of an autoimmune disease.   
Animal models are essential tools in elucidating these complex mechanisms of disease 
development and progression and for testing potential therapies.  The elastase- and cigarette-
smoke-induced models are the most commonly used animal models of emphysema, each with its 
advantages and limitations (reviewed in 11, 12).  In the elastase model, elastase (commonly 
porcine pancreatic elastase or PPE) is directly introduced to the lungs to initiate pathogenesis 
resulting in robust inflammation and alveolar destruction within a few weeks.  In the cigarette-
smoke model, exposure to cigarette smoke for several months causes mild to moderate 
destruction of the lungs.  T cells from cigarette-smoke induced models of emphysema are 
capable of transferring disease (1, 2).  However, the ability of T cells from the elastase-induced 
model to transfer disease to naïve animals has not been investigated.   
Thus, in Part I of this chapter, we tested the hypothesis that T cells could transfer disease 
from mice with PPE-induced emphysema to immunodeficient mice.  SCID or NOD SCID mice 
received CD3+ T cells from wild-type mice with elastase-induced emphysema.  T cells initiated 
leukocyte infiltration in the lungs of both immunodeficient strains but the degree of leukocyte 
infiltration and alveolar destruction in the NOD SCID mice was more severe.  These data suggest 
that T cells can transfer disease using the PPE-model of emphysema, supporting to the utility of 
this model in studies of autoimmunity in emphysema.   
Because our evidence from Part I suggested autoimmune involvement in this model of 
emphysema, we tested whether a therapeutic intervention previously found to be effective in a 
treating autoimmunity (13) would attenuate disease severity here.  In this therapy, the combined 
use of two cyclic peptides block the interactions between LFA-1:ICAM-1 and have been shown 
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to inhibit homotypic adhesion and function of T cells in mixed lymphocyte reactions without 
affecting cell viability by blocking the second signal generated through costimulatory proteins on 
the T cells (14).  In our study of autoimmune diabetes using the NOD mouse, these peptides 
delayed onset of diabetes, reduced leukocyte infiltration, and suppressed antigen-specific 
responses of autoreactive T cells (13).  Because adoptively transferred T cells from mice with 
elastase-induced emphysema caused leukocyte infiltration and alveolar destruction (Part I), we 
hypothesized that these peptides would suppress disease in the elastase model of emphysema by 
inhibiting autoreactive T cells.  We demonstrate that peptide therapy attenuates severity of 
emphysema if begun by day 7 of the 21-day model but only partially inhibits infiltration, 
suggesting other possible mechanisms of action by the peptides (Part II).   
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Materials and Methods 
Part I 
Antibodies and reagents 
Antibodies used for flow cytometry were: anti-CD3ε-FITC (145-2C11, eBioscience), 
anti-CD4-PE (RM4-5, BD Biosciences), and anti-CD8α-PE-Cy5 (53.6.7, BD Biosciences).  
Flow cytometry was performed on an Accuri C6 (BD Accuri Cytometers, Ann Arbor, MI) and 
data analysis using CFlow (Accuri).  Porcine pancreatic elastase was purchased from Elastin 
Products Co. (EC134GI, Owensville, MO).  
 
Mice 
Female BALB/cByJ mice 8 weeks of age (The Jackson Laboratory, Bar Harbor, ME) 
received either saline (saline control; n = 9) or elastase (elastase/donor mice; n = 8) intratracheal 
instillations.  Female CBySmn.CB17-Prkdcscid/J (SCID; n = 8) or NOD.CB17-Prkdcscid/J (NOD 
SCID; n = 10) mice 8 weeks of age (The Jackson Laboratory) were recipients in the adoptive 
transfer experiments.  In both immunodeficients strains of mice, a genetic mutation in the prkdc 
gene that encodes the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) causes 
severe combined immunodeficiency syndrome (scid) and consequently, a lack of functional T 
and B lymphocytes (15, 16).  The SCID mice are on the BALB/cByJ background and the NOD 
(non-obese diabetic) SCID mice on the NOD/ShiLtSz background.  The University of Kansas 
Institutional Animal Review Board approved all animal experiments. 
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Intratracheal administration of PPE or saline (elastase or saline controls only) 
 Mice were anesthetized with open-drop exposure to 20% isoflurane as previously 
described (17).  Intratracheal instillations of either 25 µl sterile saline or 25 µl elastase solution 
(1 mg/ml) were introduced to the lungs of female BALB/cByJ as previously described (18, 19).  
21 days later, mice were euthanized, lungs harvested for histological analysis, and spleens 
harvested for T cell isolation.  
 
T cell isolation and adoptive transfer  
 Spleens from elastase control or saline control mice were harvested, minced and pressed 
through a sterile 70 µm nylon mesh cell strainer.  Splenocytes were incubated at room 
temperature for 5 minutes in ACK lysis buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM 
Na2EDTA, pH 7.2) to remove erythrocytes.  CD3+ T cells were negatively selected using the 
Mouse T Cell Enrichment Kit from STEMCELL Technologies (Vancouver, BC) and were 
routinely ≥97% pure.  T cells from donor mice with elastase-induced emphysema were injected 
by tail vein (5 x106 T cells/100 µl saline) into either SCID or NOD SCID mice with 2-3 
recipients per donor.  SCID and NOD SCID mice were euthanized and lungs harvested for 
histological analysis 21 days after adoptive transfer.  See Fig. 6.1 for a model of experimental 
design. 
 
Tissue processing  
 After exsanguination, the heart was perfused with saline, and lungs were inflated by 
instilling 10% neutral-buffered formalin at constant pressure.  Inflated lungs were fixed for 24 hr 
in 10% formalin at room temperature before embedding in paraffin.  
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Morphometry and imaging 
Mid-sagittal sections (6 µm) were stained with hematoxylin and eosin and photographed 
at 20X using a Zeiss Axioskop photomicroscope (Carl Zeiss Microimaging, LLC, Thornwood, 
NY).  The mean linear intercept (Lm) was determined by light microscopy as previously 
described (20) by taking 6 fields of view for each mouse, avoiding fields containing blood 
vessels or conducting airways. Mean linear intercept measurements were determined by single-
blinded investigators (D. Danahy and A. Newton).  Degree of infiltration was determined by 
counting the number of leukocytes in three separate, random fields of view for each mouse using 
a BH-2 Olympus microscope (Olympus America Inc., Center Valley, PA) by single-blinded 
investigators (M. Chan and A. Newton).   
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad Software Inc., La 
Jolla, CA).  Statistical tests and significance for individual figures are indicated in figure legends.  
Data are expressed as the mean value ± SEM. 
 
Part II 
Antibodies and reagents 
Antibodies used for flow cytometry were: anti-CD3ε-FITC (145-2C11, eBioscience), 
anti-CD4-PE (RM4-5, BD Biosciences), anti-CD8α-PE-Cy5 (53.6.7, BD Biosciences), and anti-
IFN-γ-PE (BD Biosciences).  For intracellular cytokine staining, transcription factor buffers and 
monensin from eBioscience were used.  Flow cytometry was performed on an Accuri C6 (BD 
Accuri Cytometers, Ann Arbor, MI) and data analysis using CFlow (Accuri).  Porcine pancreatic 
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elastase and murine elastin peptides were purchased from Elastin Products Co. (Owensville, 
MO).  For antigen recall assays, cells were cultured immediately at 37°C in complete RPMI 
1640 (Mediatech, Herndon, VA) plus 10% fetal bovine serum (Atlanta Biologicals, 
Lawrenceville, GA), 2 mM L-glutamine (Invitrogen), 50 units/ml penicillin, and 50 µg/ml 
streptomycin (P/S, Invitrogen).  Stimulating antibodies, anti-CD3 (500A2) and anti-CD28 
(37.51) were purchased from BD Biosciences.   
 
Mice 
Female BALB/cByJ mice 8 weeks of age (The Jackson Laboratory, Bar Harbor, ME) 
received either saline (saline control; n = 9) or elastase (elastase and peptide groups) tracheal 
instillations.  Mice were monitored weekly for changes in weight.  The University of Kansas 
Institutional Animal Review Board approved all animal experiments. 
 
Intratracheal administration of PPE or saline 
 Mice were anesthetized with open-drop exposure to 20% isoflurane as previously 
described (17).  Intratracheal instillations of either 25 µl sterile saline (saline control) or 25 µl 
elastase solution (1 mg/ml) (all other treatment groups) were introduced to the lungs of female 
BALB/cByJ as previously described (18, 19).  21 days later, mice were euthanized, lungs 
harvested for histological analysis, and spleens harvested for T cell isolation.  
 
Peptides  
 Cyclic peptides (cLAB-L and cIE-L) were designed as we have previously described 
(14), and purchased from American Peptide Company, Inc. (Sunnyvale, CA). Lyophilized 
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peptides were stored at -20°C in a dessicator.  Each peptide was resuspended in sterile saline at 1 
mg/ml and stored separately as aliquots at -70°C until used.  For intravenous injections, equal 
volumes of cLAB-L and cIE-L were mixed thoroughly immediate before use, and mice received 
100 µl solution containing 50 µg of each peptide by tail vein.  Amino acid sequences are 
DQPKLLGIET for cIE-L and ITDGEATDSG for cLAB-L. 
 
Intravenous injections of saline or peptides 
 Each mouse received 100 µl of either saline (saline or elastase control groups) or peptides 
(all peptide treatment groups) by tail vein for 5 consecutive days.  Peptide therapy began at 
different timepoints in the disease model with the day of intratracheal instillations marking day 0 
of this 21-day model (See Fig. 6.11 for model of experimental design).   
 
Tissue processing  
 Procedures were performed as described in Part I of this chapter.    
 
Morphometry and imaging 
Procedures were performed as described in Part I of this chapter.   
 
Antigen recall by proliferation or IFN-γ production 
Spleens from elastase control or saline control mice were harvested, minced and pressed 
through a sterile 70 µm nylon mesh cell strainer.  Splenocytes were incubated at room 
temperature for 5 minutes in ACK lysis buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM 
Na2EDTA, pH 7.2) to remove erythrocytes.  Remaining leukocytes (1.5x106 cells/ml) were 
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incubated in the presence or absence of murine elastin peptide (Elastin Products Co.), human 
elastin peptide (Elastin Products Co.), or homogenized lung tissue from 11 week old syngeneic 
mice (age matched for saline and elastase control mice at time of euthanasia).  Splenocytes were 
stimulated through anti-CD3+anti-CD28 (clone 500A2 at 0.5 µg/ml and clone 37.51 at 2.5 µg/ml 
as a positive control for proliferation and IFN-γ production.  For assessing antigen recall 
response by proliferation, splenocytes from elastase or saline control mice were stained with 2.5 
µM CFSE (from 5 mM CFSE stock in DMSO) in serum-free RPMI 1640 for 7 minutes at 37°C 
at the start of in vitro culture as described earlier (Chapter 2) and assessed for CFSE dilution at 3 
and 5 days.  IFN-γ production was determined by intracellular flow cytometry at days 3 and 5 by 
adding monensin at 1:1000 and stimulating cells with PDB and ionomycin for 5 hours prior to 
intracellular staining.   
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad Software Inc., La 
Jolla, CA).  Statistical tests and significance for individual figures are indicated in figure legends.  
Data are expressed as the mean value ± SEM. 
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Results 
Part I 
Emphysema induced in donor mice for either the NOD SCID or SCID mice was 
indistinguishable 
 Although studies have implicated autoimmunity in the cigarette smoke-induced model of 
emphysema (1, 2), autoimmunity in the elastase-induced model has not been investigated despite 
its widespread use.  To determine whether an autoimmune response may be involved in the 
elastase-induced model, T cells from the spleens of mice with elastase-induced emphysema were 
isolated and injected intravenously into either NOD SCID or SCID mice.  Lungs of recipient 
mice were harvested and assessed for indications of emphysema 21 days later (See Fig. 6.1 for 
model of experimental design).  To verify that emphysema was induced in donor mice used for 
the adoptive transfers, the degree of airspace enlargement and infiltration were compared 
between elastase and saline control mice (representative images in Fig. 6.2).  Lungs from 
elastase control mice exhibited marked enlargement and infiltration of airspaces (Lm: 69 ± 15 
µm) in comparison to saline control mice (Lm: 23 ± 1 µm) (Fig. 6.2-6.3).  The degree of alveolar 
destruction did not differ between the two groups of donor mice averaging 67 ± 15 µm and 73 ± 
37 µm for the donor mice used for the adoptive transfer into NOD SCID and SCID recipients, 
respectively.     
 
Peripheral CD8+ T cells were elevated in mice with elastase-induced emphysema 
 CD8+ T cells represent the major T cell population in the lungs of patients with COPD, 
and their numbers within the lung correlate with disease severity (5-8).  Pulmonary and 
peripheral CD4:CD8 ratios in patients with emphysema frequently is reduced (7, 21, 22)  
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Fig. 6.1 
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Figure 6.1, Model of adoptive transfer experimental design.  CD3+ T cells (5 x 106 cells/100 
µl saline) isolated from the spleens of donor mice (BALB/cByJ) with elastase-induced 
emphysema (21 days after intratracheal instillation of elastase) were injected intravenously into 
either NOD SCID or SCID mice.  21 days following adoptive transfer, recipient mice were 
euthanized and lungs harvested for histological analysis of alveolar destruction (by mean linear 
intercept) and leukocyte infiltration.  Evidence of airspace enlargement and infiltration will 
indicate that the elastase-induced model of emphysema can be driven by T cells.   
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Fig. 6.2 
                 Saline         Elastase 
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Figures 6.2-6.3. Elastase induced emphysema in donor mice.  Lungs were harvested from 
female BALB/cByJ mice 21 days after either elastase (donor mice) or saline (saline control) 
intratracheal instillations.  Airspace enlargement was measured by mean linear intercept (Lm).  
Infiltration scores were determined as described in Materials and Methods for all groups of mice.  
Representative of 2 separate experiments.  Fig. 6.2, Micrographs of lungs showing the degree of 
airspace enlargement and infiltration at 100X.  Fig. 6.3, Average leukocytes/field of view ± 
SEM.  Statistical significance was determined using a Mann-Whitney test. **p < 0.01 
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although in some individuals, the ratio in the periphery remains unchanged (23).  Furthermore, 
CD8+ T cell-deficient mice exposed to cigarette smoke do not develop emphysema (24), and 
MHC I-deficient mice are protected from emphysema induced by the adoptive transfer of CD3+ 
T cells from cigarette smoke-exposed mice (1).  Despite the contribution of CD8+ T cells to 
pathogenesis, the peripheral level of CD8+ T cells has not been established in the elastase-
induced model.  Therefore, we characterized the splenic T cells isolated from donor mice with 
elastase-induced emphysema (Fig. 6.4 and Fig. 6.5).  Splenic T cells were 97%, 55%, and 43% 
positive for CD3, CD4, and CD8 expression, respectively (Fig. 6.4).  The peripheral CD4:CD8 
ratio in mice with emphysema (1.34 ± 0.07) was significantly lower than their saline control 
counterparts (2.0 ± 0.04) (Fig. 6.5), demonstrating an elevated frequency of CD8+ T cells in the 
periphery of mice with elastase-induced emphysema supported by elevated numbers of CD8+ T 
cells but constant numbers of CD4+ T cells.  This implies that the CD8+ T cell population has 
activated and expanded in this model.   
 
 Adoptively transferred T cells induced alveolar destruction in NOD SCID but not SCID mice 
 The basic hypothesis under investigation was that T cells could transfer disease and thus, 
support a role for autoimmunity in an elastase-induced model of emphysema.  The degree of 
alveolar destruction and infiltration in the lungs of recipient mice (NOD SCID and SCID) was 
measured to address this question (Fig. 6.6-6.9).  SCID strains of mice lack functional T and B 
cells and readily accept allogeneic or xenogeneic grafts.  Therefore, these immunodeficient mice 
are often used for models of autoimmunity (25, 26).  To determine whether T cells can transfer 
emphysema, we measured the degree of airspace enlargement in the two strains of SCID mice.  
Alveolar destruction occurred in NOD SCID mice (Lm: 27.72 ± 0.56 µm) but not SCID mice  
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Fig. 6.4 
 
 
 
 
 
 
Fig. 6.5 
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Figures 6.4-6.5. Peripheral CD8+ T cells were elevated in mice with elastase-induced 
emphysema.  Spleens were harvested from female BALB/cByJ mice 21 days after either 
elastase (donor mice) or saline (saline control) intratracheal instillations.  T cells isolated from 
spleens were analyzed for CD3, CD4, and CD8 expression.  Representative of 2 separate 
experiments.  Fig. 6.4. Percentage ± SEM of CD3+, CD4+, or CD8+ T cells from donor mice.  
Fig. 6.5. Ratio of CD4:CD8 T cells ± SEM comparing saline control mice (open bar) to donor 
mice with elastase-induced emphysema (gray bar).  Statistical significance was determined using 
a Mann-Whitney test. **p < 0.01 
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Fig. 6.6 
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Fig. 6.7 
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Figures 6.6.-6.7.  T cells induced alveolar destruction in NOD SCID but not SCID mice.  
Lungs were harvested from BALB/cByJ mice 21 days after saline (saline control) intratracheal 
instillations.  Purified T cells from mice with elastase-induced emphysema were injected into 
either NOD SCID or SCID mice.  Lungs were harvested from the NOD SCID and SCID mice 21 
days after the adoptive transfer of T cells.  Airspace enlargement was determined by mean linear 
intercept (Lm).  Representative to 2 separate experiments. Fig. 6.6, Micrographs of lungs 
showing the degree of airspace enlargement at 100X.  Fig 6.7, Mean linear intercept ± SEM.  
Statistical significance was determined using a Mann-Whitney test. * p < 0.05, **p < 0.01 
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(Lm: 25.44 ± 0.71 µm) as determined by comparing mean linear intercept values to those of 
saline control mice, p < 0.01 and p = 0.16, respectively (representative images in Fig. 6.6 and 
summarized in Fig. 6.7).  Adoptive transfer of T cells into NOD SCID but not SCID mice causes 
destruction of the alveoli.    
 
Adoptively transferred T cells induced greater infiltration in the lungs of NOD SCID than in 
SCID mice  
 Next, we determined the degree of leukocyte infiltration induced by adoptive transfer of 
CD3+ T cells in each strain of SCID mice.  Infiltration was determined for saline control, 
elastase control, NOD SCID, and SCID mice by counting the number of leukocytes from three 
fields of view per mouse (Fig. 6.8).  Both types of immunodeficient strains exhibited signs of 
enhanced infiltration in comparison to the saline control (p < 0.001) (representative images in 
Fig. 6.8, summarized in Fig. 6.9).  However, the degree of infiltration was significantly greater 
in the NOD SCID mice averaging 95 ± 5 leukocytes/view compared to 71 ± 5 leukocytes/view in 
the SCID mice (p < 0.001) but less than 112 ± 5 leukocytes/view observed in the elastase control 
mice (p < 0.05).  Collectively, these data provide evidence that T cells can transfer emphysema 
from mice with elastase-induced emphysema, implicating autoimmunity in this widely used 
model.  
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Fig. 6.8 
	   
	   
 
 
 
 
 
 
 
Fig. 6.9 
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Figures 6.8-6.9.  T cells infiltrated the lungs of immunodeficient mice and promote 
inflammation.  Lungs were harvested from BALB/cByJ mice 21 days after either elastase 
(elastase control) or saline (saline control) intratracheal instillations.  Purified T cells from mice 
with elastase-induced emphysema were injected into either NOD SCID or SCID mice.  Lungs 
were harvested from the NOD SCID and SCID mice 21 days after the adoptive transfer of T 
cells.  Infiltration scores were determined as described in Materials and Methods for all groups of 
mice.  Representative of 2 separate experiments.  Fig. 6.8, Micrographs of lungs showing the 
degree of infiltration at 200X.  Fig. 6.9, Average leukocytes/field of view ± SEM.  Statistical 
significance was determined using a Mann-Whitney test. * p < 0.05, ***p < 0.001 
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Part II 
Peptide therapy protected mice from elastase-induced emphysema 
 The ability of CD3+ T cells to transfer emphysema in the elastase-induced model (Part I) 
suggests that autoimmunity is involved.  Cyclic peptides, cIE-L and cLAB-L, designed 
previously by our lab inhibit mixed lymphocyte reactions and homotypic adhesion of T cells 
through blockade of second signaling (stimulated through LFA-1 or ICAM-1 in T cells) (14, 27).  
We also recently demonstrated that these peptides suppress autoreactive T cells and delay onset 
of diabetes using the NOD mouse model (13).  Because these peptides can suppress T cell 
function in vitro and T cell-driven autoimmune disease in mice, we tested whether these peptides 
could protect mice from elastase-induced emphysema.  Intratracheal instillations of saline (saline 
control) or elastase (all other treatment groups) were given at the start (Day 0) of the 21-day 
model (See Fig. 6.10 for model of experimental design).  All mice were given 5 daily 
intravenous injections of either saline (saline and elastase control groups) or peptides (Day 0, 
Day 7, Day 10, and Day 14 peptide groups).  For the peptide treatment groups, the timing of 
when peptide therapy began differed, starting at day 0 (same day of intratracheal instillations), 
day 7 (7 days after intratracheal instillations and thus, a third of the way into the model), day 10 
(10 days after intratracheal instillations or the midpoint of the model) or day 14 (14 days after 
intratracheal instillations during the last third of the model) for Day 0, Day 7, Day 10 and Day 14 
mouse groups, respectively.  Lungs from all groups were harvested and assessed for alveolar 
destruction and leukocyte infiltration 21 days after intratracheal instillations.  Mice that began 
peptide therapy at either day 0 or day 7 were protected from emphysema (Fig. 6.11-6.13).   Mean 
linear intercept values from Day 0 or Day 7 groups were similar to the saline control mice (p =  
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Fig. 6.10 
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Figure 6.10.  Model of peptide experiment to test the therapeutic efficacy ICAM-1 and 
LFA-1 derived peptides in an elastase-induced model of emphysema.  Lungs were harvested 
from female BALB/cByJ mice 21 days after saline (saline control) or elastase (all other groups) 
intratracheal instillations.  Airspace enlargement was determined by mean linear intercept (Lm) 
and leukocyte infiltration as described in Materials and Methods.  Saline and elastase control 
mice received 5 daily intravenous injections of saline compared to the peptide treatment groups 
that were given peptide injections.  Day 0 treatment group began their first peptide injection the 
same day of intratracheal instillations and thus, received injections on days 0-4.  Day 7 treatment 
group began peptide injections 7 days after intratracheal instillations, receiving injections on 
days 7-11.  Day 10 treatment group began peptide injections 10 days after intratracheal 
instillations so on days 10-14.  Day 14 treatment group began peptide injections 14 days after 
intratracheal instillations and thus, received peptide treatment on days 14-18.   
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Fig. 6.11 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.12 
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Fig. 6.13 
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Figures 6.11-6.13.  Treatment with peptides attenuated disease severity in an elastase-
induced model of emphysema.  Lungs were harvested from BALB/cByJ mice 21 days after 
saline (saline control) or elastase (all other groups) intratracheal instillations. Airspace 
enlargement was determined by mean linear intercept (Lm).  Representative to 3 separate 
experiments.  Fig. 6.11, Micrographs of lungs showing the degree of airspace enlargement at 
100X.  Fig 6.12, Mean linear intercept ± SEM.  Fig. 6.13, The percentage of animals exhibiting 
no signs of emphysema (open bars), mild emphysema (striped bars: Lm = 30-50 µm) or severe 
emphysema (closed bars: Lm > 50 µm) was determined for each group of mice.   
Statistical significance was determined using a Mann-Whitney test. * p < 0.05, **p < 0.01, ***p 
< 0.001 
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or 14, peptide therapy was ineffective against airspace enlargement.  The percentage of mice 
exhibiting any indications of emphysema were 0% (saline), 72% (elastase), 12% (Day 0), 38% 
(Day 7), 66% (Day 10), and 56% (Day 14) (Fig. 6.13).  As peptide therapy began at later 
timepoints after disease initiation, the percentage of mice affected with severe emphysema (Lm: 
> 50 µm), increased from 0% (Day 0), 25% (Day 7), 44% (Day 10), to finally 56% (Day 14) 
(Fig. 6.13). 
 
Peptide therapy prevented a reduced CD4:CD8 ratio in the spleen and partially inhibited 
leukocyte infiltration  
 In our previous study (13), peptides significantly reduced the degree of infiltration in a 
mouse model of autoimmune diabetes.  Leukocyte infiltration particularly by neutrophils, 
macrophages and T cells is commonly observed in the elastase-induced model (12).  In part I, we 
observed that splenic T cells from mice with elastase-induced emphysema exhibited a skewed 
CD4:CD8 ratio with an elevated frequency of CD8+ T cells (Fig. 6.5).  We assessed the degree 
of infiltration for each treatment group and the CD4:CD8 ratio in the spleen (Fig. 6.14-6.16).  
The peptides significantly reduced leukocyte infiltration in the mice treated with peptides 
beginning on days 0 and 7 (Fig. 6.14-6.15) but only by 21%.  There was no therapeutic effect on 
leukocyte infiltration in the day 10 and 14 treatment groups, and all groups exhibited elevated 
infiltration compared to saline mice (Fig. 6.15).  Regardless of the time at which peptide 
treatment began, the mice treated with peptide therapy possessed a normal CD4:CD8 ratio in the 
periphery (2.0 ± 0.04) in contrast to the elastase control mice (1.6 ± 0.10) (Fig. 6.16).  The 
mechanism of protection by peptide therapy in the elastase-induced model of emphysema could 
not be entirely explained by inhibiting leukocyte infiltration.  We expect a  
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Fig. 6.14 
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Figures 6.14-6.15. Peptide therapy partially inhibited leukocyte infiltration. Lungs were 
harvested from BALB/cByJ mice 21 days after saline (saline control) or elastase (all other 
groups) intratracheal instillations.  Leukocyte infiltration was determined as described in 
Materials and Methods.  Representative to 3 separate experiments.  Fig. 6.14, Micrographs of 
lungs showing infiltration at 200X.  Fig. 6.15, Average leukocytes/field of view ± SEM.    
Statistical significance was determined using a Mann-Whitney test. * p < 0.05 
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Fig. 6.16 
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Figure 6.16.  Peptide therapy prevented the reversal of the CD4:CD8 ratio in the 
periphery. Splenic T cells were isolated on day 21 from elastase or peptide groups and analyzed 
by flow cytometry for CD4 and CD8 expression.  Representative of 1 experiment.  Average 
CD4:CD8 T cell ratio ± SEM comparing elastase control mice to all the peptide groups. 
Statistical significance was determined using a Mann-Whitney test. **p < 0.01, 
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direct inhibitory effect on T cells as we have previously observed (13) that results in either 
anergy or apoptosis due to blockade of second signaling by the peptides.  The partial inhibition 
of infiltration is not surprising because these peptides also function to suppress autoreactive T 
cells.   
 
Homogenized whole lung lysate and commercially prepared murine elastin peptides failed to 
induce an antigen-specific T cell response 
 In our previous work, peptide therapy inhibited antigen-specific responses of both CD4+ 
and CD8+ T cells in a murine model of autoimmune diabetes (13).  Although COPD has not 
been formally established as an autoimmune disease, there is growing evidence both in COPD 
patients and animal models of disease to support the hypothesis of autoimmune involvement (1, 
2, 10, 28-31).  Part I of this chapter also supported a role for autoimmunity in emphysema.  In 
many autoimmune diseases such as type I diabetes and multiple sclerosis, the autoantigens 
involved in the disease pathogenesis of have been clearly identified.  In the case of COPD, these 
are still being defined along with the contribution of autoimmunity.  One group has identified 
autoreactive CD4+ T cells in patients with COPD specific for elastin peptides, and elastin 
fragments induce monocyte recruitment to the lungs in a murine model of emphysema (30, 32).  
Therefore, we tested whether the peptide treatment would inhibit an antigen-specific response to 
either homogenized whole lung lysate or commercially prepared murine elastin peptides.  
However, two separate experiments comparing T cell proliferation (6 mice/group) or one 
experiment comparing the production of IFN-γ (3 mice/group, data not shown) between elastase 
and saline control groups failed to identify an antigen-specific response by either the CD4+ or 
CD8+ T cells from the elastase control group (Fig. 6.17-6.18).  Thus, we could not assess the  
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Figures 6.17-6.18.  T cells from mice with emphysema did not elicit an antigen-specific 
response to commercially prepared elastin peptides or homogenized lung lysate.  
Splenocytes were isolated from elastase treated (n = 6) or saline (n = 6) control mice 21 days 
after intratracheal instillations and stained with 2.5 µM CFSE.  Cells stimulated through anti-
CD3+anti-CD28 served as a positive control (left panels).  All other treatments were not 
stimulated using antibody but rather, murine elastin lung peptides (+ mELP), whole 
homogenized lung lysate (+ lung Ag) or saline ((-) Ag) were added to the wells at day 0.  5 days 
later, cells were analyzed for CFSE dilution and CD4 and CD8 expression by flow cytometry.  
Representative of 2 experiments.  Fig. 6.17, Percentage of CD4+ T cells that divided cells are 
indicated with cell numbers parenthetically.  Fig. 6.18, Percentage of CD8+ T cells that divided 
cells are indicated with cell numbers parenthetically. 
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ability of the peptides to inhibit antigen recall responses.  The non-specific proliferative 
responses by both CD4+ and CD8+ T cells stimulated through CD3+CD28 in the absence of 
antigen were routinely heightened in the elastase mice compared to saline mice (Fig. 6.17-6.18, 
CD3+CD28 panels).  This observation may indicate an overall elevated T cell activation state in 
the periphery of mice with emphysema. 
 
Mouse weight did not correlate with disease severity or differ among treatment groups 
 To test whether disease severity was associated with the weight of the mouse, we 
examined the weight of the mice at the start of the model in comparison to the mean linear 
intercept value (Fig. 6.19).  No correlation was found between the weight of the mouse and the 
degree of airspace enlargement.  We also compared the weights among the various treatment 
groups and found no significant differences (Fig. 6.20), indicating that the variances in mouse 
weight did not impact our results. 
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Fig. 6.19 
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Figures 6.19-6.20.  Mouse weight did not influence the severity of emphysema.  Mice from 
all treatment groups were weighed on day 0, immediately before intratracheal instillations of 
either saline (saline control) or elastase (all other groups).  Fig. 6.19, Plots of the weight of the 
mouse (g) versus its mean linear intercept value (µm).  Pearson correlation coefficients show no 
correlation between Lm and weight.  Fig. 6.20, Average weight ± SEM of mice for each group as 
indicated.  One-way ANOVA indicates no significant differences in the weights among the 
different treatment groups of mice. 
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Discussion 
Evidence for autoimmunity in COPD in human studies 
COPD predominantly affects current or past smokers.  Although smoking is the primary 
risk factor, only a fraction of smokers develop COPD (33), suggesting a complex pathogenesis 
involving the participation of genetic factors in addition to enviromental ones.  Several 
polymorphisms have been associated with COPD; some of these affect genes that encode 
important mediators of the immune response such as TNF-α, TGF-β and IL-13 (34).  
Furthermore, atopic individuals have a heightened risk for developing COPD, experience more 
severe respiratory symptoms, and represent 18-42% of COPD cases by some reports (35, 36).  
Pulmonary inflammation and subsequent destruction persists in COPD patients even after 
smoking cessation (28, 37, 38).  Additionally, CD4+ T cell responses to elastin peptides and the 
presence of anti-elastin antibodies correlate with disease severity; several CD4+ T cell clones 
from patients with emphysema have been characterized and produce elevated levels of IL-6 and 
IFN-γ in response to elastin fragments (31, 39, 40).  These observations and the various genetic 
risk factors associated with immune dysfunction suggest that autoimmunity is involved in the 
development and progression of emphysematous disease.   
 
Evidence of autoimmunity in the elastase-induced model of emphysema 
Evidence for autoimmunity in the pathogenesis of COPD is also supported by various 
studies in animal models of emphysema.  Mice deficient in either MHC I or CD8+ T cells are 
protected from emphysema (1, 24), and CD3+ T cells can transfer emphysema to naïve rodents 
(1, 2, 9).  Although both the cigarette smoke- and elastase-induced models are widely used to 
study emphysema in mice, the ability of T cells to transfer disease using the elastase-induced 
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model has not been investigated until now.  Additionally previous studies using other models 
have transferred (1, 2, 9) disease by injecting T cells intraperitoneally whereas we introduced T 
cells intravenously.  We demonstrate that CD3+ T cells from elastase induced emphysema can 
induce leukocyte infiltration and alveolar destruction in naïve immunodeficient mice and that the 
use of therapeutic peptides can inhibit pathogenesis.  The ability of these T cells to transfer 
disease suggests that they recognize autoantigen(s) within the lungs, home to the lungs or 
draining lymph nodes, and initiate disease, supporting a role for autoimmunity driven by T cells 
in the elastase-induced model.  Collectively, these observations suggest the involvement of an 
autoimmune response to pulmonary autoantigen released by the introduction of elastase to the 
lungs.  
 
Mechanism of action by peptide therapy in elastase-induced model  
 The peptide therapy attenuated the severity of alveolar destruction but not to the same 
degree that leukocyte infiltration was reduced, supporting the participation of more than one 
mechanism of action by the peptide therapy.  These peptides can suppress T cells by blocking the 
induction of second signals by the costimulatory molecules, LFA-1 and ICAM-1.  Therefore, it is 
likely that the peptides are also suppressing T cell responses in this model.  In support of this, we 
observed a normal CD4:CD8 ratio in the spleens of all peptide treatment groups in contrast to the 
elastase-treated mice that did not receive peptide therapy.  We were unable to identify an 
antigen-specific response to a murine elastin peptides or homogenized lung lysate.  However, 
this does not exclude the possibility of an antigen-specific response since we were able to 
effectively transfer emphysema driven by T cells into naïve mice.  Whether COPD is a form of 
autoimmunity is still an ongoing discussion, and although many candidate autoantigens have 
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been identified, no autoantigen has officially been established in contrast to other autoimmune 
diseases.  Recently, one group was able to identify elastin-reactive CD4+ T cells from patients 
with emphysema by synthesizing 78 overlapping peptide sequences (20 amino acids in length) 
encompassing the entire elastin sequence (40).  In this study, elastin-specific responses were 
confined to only 2 areas of the elastin molecule (786 amino acids).  Thus, it is possible that the 
lung homogenate and commercial elastin peptides did not include the correct amino acid 
sequence for an antigen-specific response.   
Alternatively, the commercial peptides and lung lysate may have included the correct 
autoantigen, but the levels of the autoantigen were too low within the two types of antigen 
preparations to be detected by a highly heterogeneous population of peripheral T cells.  The 
lungs or draining lymph nodes may contain oligoclonal expansions of autoreactive T cells 
specific to pulmonary antigens, which may provide a more robust response than splenic T cells.  
The presence of many other biological factors in the whole lung lysate may have interfered with 
the identification of an antigen-specific response.   
Therefore, we were unable to determine the other possible mechanisms of action of the 
peptide therapy in this model.  However, based on our other studies (13, 14), these peptides 
inhibit homotypic adhesion of T cells and antigen-specific T cell responses and most likely 
function to suppress T cell responses in the present model either by anergy induction or 
apoptosis.  The combined use of L-ABL and L-IEL peptides was able to reduce infiltration and 
destruction of pancreatic islets, delay onset of disease, and inhibit antigen-specific T cell 
responses to pancreatic lysate in an autoimmune model of diabetes (13).  In comparison, the 
peptide therapy in the emphysema model inhibited disease severity, reduced infiltration and 
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prevented an elevation of splenic CD8+ T cells in the peptide-treated mice compared to their 
elastase control counterparts.  
The timing of peptide treatment and efficacy is also consistent with T cell modulation 
since treatment was only effective if begun by 7 days after the start of inflammation within the 
lungs.  It is well understood that during a primary immune response, clonal expansion of T cells 
occurs during the first week, generating a large number of effector T cells that peaks around 7 
days followed by a significant reduction in cell number by the second week (41).  Peptide 
treatment that began 10 or 14 days after initiation of disease may have been too late to modulate 
the T cell response since T cells have already entered the contraction phase of the response.  It is 
likely that modulation of the T cell response such as inhibition of autoreactive cells by peptide 
therapy occurred in the day 10 and 14 treatment groups, but the timing of therapy was begun too 
late in the disease process to inhibit the destruction that already had ensued.  In future studies, 
adoptive transfer of T cells from peptide-treated mice at the various timepoints may determine 
whether the peptide therapy effectively inhibits the T cell response even after pulmonary 
inflammation and destruction have occurred.  The ability to suppress the driving factor of disease 
progression in COPD patients combined with a regenerative therapy to repair damaged lung 
epithelia may reverse disease and provide long-term protection in the future.  
 
NOD SCID mice were more susceptible to development of emphysema 
Although we observed enhanced leukocyte infiltration in both strains of immunodeficient 
mice, airspace enlargement was only evident in the NOD SCID mice 21 days after the adoptive 
transfer.  Additional mutations in the NOD SCID compared to the SCID mice may account for 
variation in disease susceptibility.  In comparison to other SCID strains, the NOD SCID mouse 
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accepts spleen engraftments donor cells at a four-fold increased frequency (42).  In the present 
study, leukocyte infiltration of the lungs in the NOD SCID mice was approximately three-fold 
higher than the SCID mice, demonstrating a similar degree of enhanced engraftment in the NOD 
SCID mouse.  The SCID deficiency in the NOD SCID mouse is approximately 10 fold less leaky 
than the SCID mouse (42), which may also influence disease susceptibility.  The increased 
leakiness of the SCID mouse (as defined by serum Ig levels > 1 µg/ml) (42), may result in 
sufficient T and B cell populations to interfere with the establishment of donor T cells.  
Additionally, the degree of emphysematous disease can vary among immunocompetent strains of 
mice (43).  In a smoke-induced model of emphysema, T cells were able to transfer disease to 
naïve immunocompetent mice (1).  Whether T cells from the elastase-induced model can transfer 
disease to immunocompetent mice remains to be determined.   
 
Summary 
The controversy over whether an autoimmune response is involved in the pathogenesis of 
COPD may be attributed to the complexity of mechanisms involved in this disease, significant 
variables among COPD patients including the use of corticosteroids and differences in 
susceptibility to disease among mouse strains.  Overall, combined observations from patients 
with COPD and animal models of smoke-induced emphysema have led to the hypothesis that 
COPD may involve an autoimmune component and led us to investigate this in an elastase-
induced model of emphysema.  We demonstrate for the first time the ability of T cells from mice 
with elastase-induced emphysema to transfer disease to naïve immunodeficient mice, supporting 
the utility of this model in future studies of autoimmunity in emphysema.  We also show that 
blocking ICAM-1:LFA-1 interactions by peptide therapy attenuates disease severity by inhibiting 
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leukocyte infiltration and suppressing a skewed CD4:CD8 ratio.  As evidence for autoimmunity 
in COPD continues to grow, inevitably more studies will be needed to establish the mechanisms 
by which T cells contribute to pathogenesis and develop therapeutic strategies to inhibit these 
responses.   
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Chapter 7: Summary of Dissertation 
 
This dissertation addresses how costimulatory proteins such as CTLA4, and other 
biological factors such as biologically relevant lipoproteins LDL and HDL can tune the 
differentiation of human naïve CD4+ T cells to various T cell subsets.  In this way, the work 
contributes to the overall work by the Benedict lab in establishing the differential influence of 
costimulatory proteins on cell fate (See Table 7.1 for a summary of our collective data in support 
of this) Costimulation through CTLA-4 in the absence of exogenous cytokines activated 
proliferation and differentiation of naïve CD4+ T cells to effector, memory, and regulatory T 
cells.  CTLA-4 favored differentiation to Treg cells more aggressively than any of the stimuli 
studied thus far, supporting its other known roles as an overall negative regulator of the immune 
response.  As a an additional stimulus to either costimulation through ICAM-1 or CD28, CTLA-
4 augmented differentiation to Treg cells induced by ICAM-1 and shifted differentiation induced 
by CD28 in favor of memory T cells.  
Th17 cells represent an important T helper subset that had not been evaluated using our 
in vitro system of differentiation until now.  Costimulation through CD28, ICAM-1, LFA-1, or 
CTLA-4, did not induce differentiation to Th17 in the absence of exogenous cytokines (also 
summarized in Table 7.1). 
The function of CD23, the low affinity receptor for IgE, was evaluated in naïve and 
mature T cells in healthy subjects.  I found that the addition of CD23 to costimulation through 
CD28 opposed Th2 functions by inhibiting differentiation of naïve T cells to Th2 cells and by 
activating Th1 cells in mature T cells.  
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The influence of other biological factors potentially present in the microenvironment 
during naïve T cell activation also was addressed.  I found that similar to their opposing roles in 
atherosclerosis, LDL and HDL exerted opposing effects on naïve T cell differentiation and 
proliferation.  LDL enhanced the generation of effector T cells with a Th1-phenotype, the T cell 
type most predominant in atherosclerotic plaque, supporting a novel hypothetical role by which 
LDL regulates T cell differentiation to Th1 to exacerbate atherosclerosis.  HDL, in contrast, 
inhibited proliferation and cell survival and this hypothetically would slow the progression of 
atherosclerosis by limiting the number of Th1 cells in plaque.   
Finally, I investigated whether autoimmunity plays a role in a murine model of 
emphysema.  I determined that purified T cells transferred from a mouse in which emphysema 
had been induced by an enzyme treatment, carried the disease emphysema to naïve mice when 
injected intravenously.  I also demonstrated the ability of a peptide therapy to attenuate disease 
severity in this murine model of emphysema.   
It is well studied and well accepted that regulation of naïve T cell differentiation is 
guided by cytokines located in the intercellular microenvironment. Collectively, my data support 
our ongoing hypothesis that costimulatory proteins and other relevant factors within the T cell 
microenvironment also can influence the outcome of cell differentiation.  The implications of 
these findings may support the development of future therapies in which specific T cell 
responses are targeted for inhibition or activation depending on the disease.   
 
 
 
 
	   379	  
Table 7.1 
 CD3+CD28 CD3+ICAM-1 CD3+LFA-1 CD3+CTLA-4 
Proliferation 
 ✔ ✔ ✔ ✔ 
Protection from 
apoptosis 
 
✔ ✔ ✕  ✔ 
Memory T cell  
Differentiation 
 
✔ ✔ ✕ ✔ 
Effector T cell  
Differentiation 
 
✔ ✔ ✔ ✔ 
Differentiation 
 to Th1 cells 
 
✔ ✔ ✔ ✕ 
Differentiation 
to Th2 cells 
 
✔ ✕ ✕ ? 
Differentiation 
to Tregs 
 
✕ ✔ ✕ ✔ 
Differentiation 
to Th17 cells 
 
✕ ✕ ✕ ✕ 
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Table 7.1.  Summary of the differential effects of costimulatory proteins on T cell 
differentiation and function.  Black text reflects our published work determined by previous 
lab members: Drs. Jacob Kohlmeier, Scott Tibbetts, Chintana Chirathaworn, Kelli Williams, and 
Abby Dotson.  Orange text reflects my contribution to this ongoing study of how specific 
resident T cell surface proteins can participate in regulating T cell fate during differentiation 
(Chapters 2 and 3 of this dissertation). 
 
